EP0240890B1 - Prostacyclin (PGI2) analogues - Google Patents
Prostacyclin (PGI2) analogues Download PDFInfo
- Publication number
- EP0240890B1 EP0240890B1 EP87104669A EP87104669A EP0240890B1 EP 0240890 B1 EP0240890 B1 EP 0240890B1 EP 87104669 A EP87104669 A EP 87104669A EP 87104669 A EP87104669 A EP 87104669A EP 0240890 B1 EP0240890 B1 EP 0240890B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hydroxy
- preparing
- compound according
- azabicyclo
- oct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960001123 epoprostenol Drugs 0.000 title abstract description 5
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 title abstract 2
- 150000003174 prostaglandin I2 derivatives Chemical class 0.000 title abstract 2
- -1 arythio Chemical group 0.000 claims abstract description 121
- 239000000203 mixture Substances 0.000 claims abstract description 118
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 239000001257 hydrogen Substances 0.000 claims abstract description 17
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 99
- 238000006243 chemical reaction Methods 0.000 claims description 50
- 239000002904 solvent Substances 0.000 claims description 38
- 150000002148 esters Chemical class 0.000 claims description 21
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 10
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 9
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 9
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 claims description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 6
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 claims description 5
- 150000001350 alkyl halides Chemical class 0.000 claims description 5
- NDJYIGJHHQHCLR-UHFFFAOYSA-N 4-[6a-ethenyl-5-hydroxy-4-(3-hydroxy-4-methyloct-1-enyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound N1=C(CCCC(O)=S)CC2C(C=CC(O)C(C)CCCC)C(O)CC21C=C NDJYIGJHHQHCLR-UHFFFAOYSA-N 0.000 claims description 3
- ZXIKDSQMGRKLCV-UHFFFAOYSA-N 4-[4-(3-cyclohexyl-3-hydroxyprop-1-enyl)-6a-ethenyl-5-hydroxy-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound OC1CC2(C=C)N=C(CCCC(O)=S)CC2C1C=CC(O)C1CCCCC1 ZXIKDSQMGRKLCV-UHFFFAOYSA-N 0.000 claims description 2
- SCMSDJDGOKGEBX-UHFFFAOYSA-N 4-[4-(3-cyclohexyl-3-hydroxyprop-1-enyl)-6a-ethynyl-5-hydroxy-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound OC1CC2(C#C)N=C(CCCC(O)=S)CC2C1C=CC(O)C1CCCCC1 SCMSDJDGOKGEBX-UHFFFAOYSA-N 0.000 claims description 2
- SGXRELSMHMJTRM-UHFFFAOYSA-N 4-[4-(3-cyclopentyl-3-hydroxyprop-1-enyl)-6a-ethenyl-5-hydroxy-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound OC1CC2(C=C)N=C(CCCC(O)=S)CC2C1C=CC(O)C1CCCC1 SGXRELSMHMJTRM-UHFFFAOYSA-N 0.000 claims description 2
- XGYYGGULLJFTNX-UHFFFAOYSA-N 4-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-6a-methyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound N1=C(CCCC(O)=S)CC2C(C=CC(O)CCCCC)C(O)CC21C XGYYGGULLJFTNX-UHFFFAOYSA-N 0.000 claims description 2
- JCKPSZWNQKALPJ-UHFFFAOYSA-N 4-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-6a-prop-1-ynyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound N1=C(CCCC(O)=S)CC2C(C=CC(O)CCCCC)C(O)CC21C#CC JCKPSZWNQKALPJ-UHFFFAOYSA-N 0.000 claims description 2
- UGMNAUPEPGBPHN-UHFFFAOYSA-N 4-[6a-buta-1,3-diynyl-5-hydroxy-4-(3-hydroxyoct-1-enyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound N1=C(CCCC(O)=S)CC2C(C=CC(O)CCCCC)C(O)CC21C#CC#C UGMNAUPEPGBPHN-UHFFFAOYSA-N 0.000 claims description 2
- KRQDIHJSDYYSMM-UHFFFAOYSA-N 4-[6a-cyano-5-hydroxy-4-(3-hydroxyoct-1-enyl)-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-2-yl]butanethioic s-acid Chemical compound N1=C(CCCC(O)=S)CC2C(C=CC(O)CCCCC)C(O)CC21C#N KRQDIHJSDYYSMM-UHFFFAOYSA-N 0.000 claims description 2
- IVUGYZCWYLFMMB-UHFFFAOYSA-N 4-[6a-ethenyl-5-hydroxy-4-(3-hydroxyoct-1-enyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound N1=C(CCCC(O)=S)CC2C(C=CC(O)CCCCC)C(O)CC21C=C IVUGYZCWYLFMMB-UHFFFAOYSA-N 0.000 claims description 2
- WPOMURSFEDDCDZ-UHFFFAOYSA-N 4-[6a-ethynyl-4-[5-(furan-2-yl)-3-hydroxypent-1-enyl]-5-hydroxy-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound C(#C)C12N=C(CC2C(C(C1)O)C=CC(CCC=1OC=CC1)O)CCCC(=S)O WPOMURSFEDDCDZ-UHFFFAOYSA-N 0.000 claims description 2
- QWMCOJSQOSMBQS-UHFFFAOYSA-N 4-[6a-ethynyl-5-hydroxy-4-(3-hydroxyoct-1-enyl)-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-2-yl]butanethioic s-acid Chemical compound N1=C(CCCC(O)=S)CC2C(C=CC(O)CCCCC)C(O)CC21C#C QWMCOJSQOSMBQS-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 26
- DWKHRXUCIYYARQ-UHFFFAOYSA-N 4-[4-(3-cyclopentyl-3-hydroxyprop-1-enyl)-6a-ethynyl-5-hydroxy-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-2-yl]butanethioic s-acid Chemical compound OC1CC2(C#C)N=C(CCCC(O)=S)CC2C1C=CC(O)C1CCCC1 DWKHRXUCIYYARQ-UHFFFAOYSA-N 0.000 claims 1
- XBYLGKMUJUARQB-UHFFFAOYSA-N 4-[5-hydroxy-4-(3-hydroxy-4-methyloct-1-en-6-ynyl)-6a-prop-1-ynyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound OC1C(C2CC(=NC2(C1)C#CC)CCCC(=S)O)C=CC(C(CC#CC)C)O XBYLGKMUJUARQB-UHFFFAOYSA-N 0.000 claims 1
- KKSJVGCOARUGSV-UHFFFAOYSA-N 4-[6a-ethenyl-5-hydroxy-4-(3-hydroxy-4-methyloct-1-en-6-ynyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound C(=C)C12N=C(CC2C(C(C1)O)C=CC(C(CC#CC)C)O)CCCC(=S)O KKSJVGCOARUGSV-UHFFFAOYSA-N 0.000 claims 1
- SPHQPOGEYLWCHO-UHFFFAOYSA-N 4-[6a-ethynyl-5-hydroxy-4-(3-hydroxy-4,4-dimethyloct-1-enyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound C(#C)C12N=C(CC2C(C(C1)O)C=CC(C(CCCC)(C)C)O)CCCC(=S)O SPHQPOGEYLWCHO-UHFFFAOYSA-N 0.000 claims 1
- YFMBHIFCHUQVLO-UHFFFAOYSA-N 4-[6a-ethynyl-5-hydroxy-4-(3-hydroxy-4-methyloct-1-en-6-ynyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound N1=C(CCCC(O)=S)CC2C(C=CC(O)C(C)CC#CC)C(O)CC21C#C YFMBHIFCHUQVLO-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 125000004650 C1-C8 alkynyl group Chemical group 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 abstract description 11
- 239000003699 antiulcer agent Substances 0.000 abstract description 4
- 230000002785 anti-thrombosis Effects 0.000 abstract description 2
- 239000003146 anticoagulant agent Substances 0.000 abstract description 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 274
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 216
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 173
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 155
- 239000000243 solution Substances 0.000 description 95
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 92
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 74
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 68
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 68
- 238000002360 preparation method Methods 0.000 description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 61
- 239000011541 reaction mixture Substances 0.000 description 59
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 58
- 238000004440 column chromatography Methods 0.000 description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 57
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 50
- 239000007864 aqueous solution Substances 0.000 description 50
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 46
- 229910052799 carbon Inorganic materials 0.000 description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 41
- 239000012298 atmosphere Substances 0.000 description 41
- 239000000463 material Substances 0.000 description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 34
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 229920006395 saturated elastomer Polymers 0.000 description 33
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 30
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
- 229910052757 nitrogen Inorganic materials 0.000 description 29
- 239000000741 silica gel Substances 0.000 description 29
- 229910002027 silica gel Inorganic materials 0.000 description 29
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 238000001816 cooling Methods 0.000 description 21
- 239000011780 sodium chloride Substances 0.000 description 21
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 19
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical class SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 230000004520 agglutination Effects 0.000 description 18
- 0 *CCCSC(C1)=N[C@@](*)(CC2)[C@@]1C2C=C[*@@](*)O* Chemical compound *CCCSC(C1)=N[C@@](*)(CC2)[C@@]1C2C=C[*@@](*)O* 0.000 description 17
- 229940125773 compound 10 Drugs 0.000 description 17
- 239000005457 ice water Substances 0.000 description 17
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 17
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
- FZRKAZHKEDOPNN-UHFFFAOYSA-N Nitric oxide anion Chemical compound O=[N-] FZRKAZHKEDOPNN-UHFFFAOYSA-N 0.000 description 16
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 14
- 235000019270 ammonium chloride Nutrition 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 239000012043 crude product Substances 0.000 description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
- 239000008096 xylene Substances 0.000 description 14
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 12
- 208000007536 Thrombosis Diseases 0.000 description 11
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 229940125758 compound 15 Drugs 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 11
- 150000003951 lactams Chemical class 0.000 description 11
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 11
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 150000003180 prostaglandins Chemical class 0.000 description 10
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 10
- 150000003571 thiolactams Chemical class 0.000 description 10
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 9
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 229940126657 Compound 17 Drugs 0.000 description 9
- 239000003849 aromatic solvent Substances 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 8
- XDLDASNSMGOEMX-UHFFFAOYSA-N benzene benzene Chemical compound C1=CC=CC=C1.C1=CC=CC=C1 XDLDASNSMGOEMX-UHFFFAOYSA-N 0.000 description 8
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 8
- 150000002596 lactones Chemical class 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 7
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 7
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 210000004623 platelet-rich plasma Anatomy 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 239000011592 zinc chloride Substances 0.000 description 6
- 235000005074 zinc chloride Nutrition 0.000 description 6
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 5
- 239000003377 acid catalyst Substances 0.000 description 5
- ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 description 5
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 125000004494 ethyl ester group Chemical group 0.000 description 5
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 5
- 239000007800 oxidant agent Substances 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 150000008065 acid anhydrides Chemical class 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Inorganic materials [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 239000002198 insoluble material Substances 0.000 description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- 208000033386 Buerger disease Diseases 0.000 description 3
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- FAMGJMYDHOESPR-UHFFFAOYSA-M dilithium;carbanide;bromide Chemical compound [Li+].[Li+].[CH3-].[Br-] FAMGJMYDHOESPR-UHFFFAOYSA-M 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- DLLJVQNYBYOKGS-UHFFFAOYSA-N ethoxyethane;pentane Chemical compound CCCCC.CCOCC DLLJVQNYBYOKGS-UHFFFAOYSA-N 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 2
- LQZCYXCHWNQBKX-UHFFFAOYSA-N 1-dimethoxyphosphorylheptan-2-one Chemical compound CCCCCC(=O)CP(=O)(OC)OC LQZCYXCHWNQBKX-UHFFFAOYSA-N 0.000 description 2
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- HCLQARMRCPEALF-DNQXCXABSA-N 3-[[(2r)-2-[(1r)-2-[[1-(1-benzothiophen-2-yl)-2-methylpropan-2-yl]amino]-1-hydroxyethyl]pyrrolidin-1-yl]methyl]benzonitrile Chemical compound C([C@@H]1[C@H](O)CNC(C)(CC=2SC3=CC=CC=C3C=2)C)CCN1CC1=CC=CC(C#N)=C1 HCLQARMRCPEALF-DNQXCXABSA-N 0.000 description 2
- TYQJZTFALLGUOZ-SYBHYAAWSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-methoxy-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrol-2-one Chemical compound COC12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O TYQJZTFALLGUOZ-SYBHYAAWSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- KSQVGVMZECCPAT-AEFFLSMTSA-N [(1R)-4-phenyl-1-[[(2R)-2-(pyrazine-2-carbonylamino)pentanoyl]amino]butyl]boronic acid Chemical compound B([C@H](CCCC1=CC=CC=C1)NC(=O)[C@@H](CCC)NC(=O)C2=NC=CN=C2)(O)O KSQVGVMZECCPAT-AEFFLSMTSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004523 agglutinating effect Effects 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- PCCNIENXBRUYFK-UHFFFAOYSA-O azanium;cerium(4+);pentanitrate Chemical compound [NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O PCCNIENXBRUYFK-UHFFFAOYSA-O 0.000 description 2
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
- VYLVYHXQOHJDJL-UHFFFAOYSA-K cerium trichloride Chemical compound Cl[Ce](Cl)Cl VYLVYHXQOHJDJL-UHFFFAOYSA-K 0.000 description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
- FIMJSWFMQJGVAM-UHFFFAOYSA-N chloroform;hydrate Chemical compound O.ClC(Cl)Cl FIMJSWFMQJGVAM-UHFFFAOYSA-N 0.000 description 2
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 2
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 2
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 150000003008 phosphonic acid esters Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 150000003815 prostacyclins Chemical class 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- NPRDHMWYZHSAHR-UHFFFAOYSA-N pyridine;trioxochromium Chemical compound O=[Cr](=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 NPRDHMWYZHSAHR-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006884 silylation reaction Methods 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- 210000005167 vascular cell Anatomy 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- DGSRAILDFBJNQI-UHFFFAOYSA-N (2,4,6-trimethylphenyl)methanamine Chemical compound CC1=CC(C)=C(CN)C(C)=C1 DGSRAILDFBJNQI-UHFFFAOYSA-N 0.000 description 1
- KDDNKZCVYQDGKE-UHFFFAOYSA-N (2-chlorophenyl)methanamine Chemical compound NCC1=CC=CC=C1Cl KDDNKZCVYQDGKE-UHFFFAOYSA-N 0.000 description 1
- PXJACNDVRNAFHD-UHFFFAOYSA-N (2-methoxyphenyl)methanamine Chemical compound COC1=CC=CC=C1CN PXJACNDVRNAFHD-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- DIVNUTGTTIRPQA-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1OC DIVNUTGTTIRPQA-UHFFFAOYSA-N 0.000 description 1
- DKLGLHQHLFISGJ-YLBFUXKPSA-N (5e)-5-[(3as,4r,5r,6as)-4-[(e,3s)-3-cyclopentyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]pentanoic acid Chemical compound C1([C@@H](\C=C\[C@@H]2[C@H]3CC(/C[C@H]3C[C@H]2O)=C/CCCC(O)=O)O)CCCC1 DKLGLHQHLFISGJ-YLBFUXKPSA-N 0.000 description 1
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 1
- BKHZLTKQOBJPLB-UHFFFAOYSA-N 1,3-thiazole-4,5-dicarbaldehyde Chemical compound O=CC=1N=CSC=1C=O BKHZLTKQOBJPLB-UHFFFAOYSA-N 0.000 description 1
- VORMYBVXEYNQBI-UHFFFAOYSA-N 1-[(2,4-dimethoxyphenyl)methyl]-6a-ethynyl-5-hydroxy-4-(hydroxymethyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)CO)O)C#C)C=CC(=C1)OC VORMYBVXEYNQBI-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- FTZNMXSYERMMBC-UHFFFAOYSA-N 1-cyclohexyl-2-dimethoxyphosphorylethanone Chemical compound COP(=O)(OC)CC(=O)C1CCCCC1 FTZNMXSYERMMBC-UHFFFAOYSA-N 0.000 description 1
- WIYMDOCSCMPUJI-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3,3-dimethylheptan-2-one Chemical compound CCCCC(C)(C)C(=O)CP(=O)(OC)OC WIYMDOCSCMPUJI-UHFFFAOYSA-N 0.000 description 1
- QAQKMSOVMMCNSE-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-methylhept-5-yn-2-one Chemical compound COP(=O)(OC)CC(=O)C(C)CC#CC QAQKMSOVMMCNSE-UHFFFAOYSA-N 0.000 description 1
- RYCSYYMZXSIBJI-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3-methylheptan-2-one Chemical compound CCCCC(C)C(=O)CP(=O)(OC)OC RYCSYYMZXSIBJI-UHFFFAOYSA-N 0.000 description 1
- IVBKIMUBUJLMJA-UHFFFAOYSA-N 1-dimethoxyphosphoryl-4-(furan-2-yl)butan-2-one Chemical compound COP(=O)(OC)CC(=O)CCC1=CC=CO1 IVBKIMUBUJLMJA-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- NDKJATAIMQKTPM-UHFFFAOYSA-N 2,3-dimethylbenzenethiol Chemical compound CC1=CC=CC(S)=C1C NDKJATAIMQKTPM-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- YLSSVFGTKZXLPA-UHFFFAOYSA-N 2-(1-benzyl-2-ethyl-3-oxamoylbenzo[g]indol-4-yl)oxyacetic acid Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)C=C3C=CC=CC3=C2N1CC1=CC=CC=C1 YLSSVFGTKZXLPA-UHFFFAOYSA-N 0.000 description 1
- HJFGULDHUDIPDA-UHFFFAOYSA-N 2-(2-formylphenyl)benzaldehyde Chemical compound O=CC1=CC=CC=C1C1=CC=CC=C1C=O HJFGULDHUDIPDA-UHFFFAOYSA-N 0.000 description 1
- ABROBCBIIWHVNS-UHFFFAOYSA-N 2-Ethylbenzenethiol Chemical compound CCC1=CC=CC=C1S ABROBCBIIWHVNS-UHFFFAOYSA-N 0.000 description 1
- DSCJETUEDFKYGN-UHFFFAOYSA-N 2-Methoxybenzenethiol Chemical compound COC1=CC=CC=C1S DSCJETUEDFKYGN-UHFFFAOYSA-N 0.000 description 1
- LXUNZSDDXMPKLP-UHFFFAOYSA-N 2-Methylbenzenethiol Chemical compound CC1=CC=CC=C1S LXUNZSDDXMPKLP-UHFFFAOYSA-N 0.000 description 1
- NQOZPTYIJQUKTJ-UHFFFAOYSA-N 2-[2-(3-methoxyphenyl)-4-oxo-6-(3-piperidin-1-ylpropoxy)quinazolin-3-yl]-n-propan-2-ylacetamide Chemical compound COC1=CC=CC(C=2N(C(=O)C3=CC(OCCCN4CCCCC4)=CC=C3N=2)CC(=O)NC(C)C)=C1 NQOZPTYIJQUKTJ-UHFFFAOYSA-N 0.000 description 1
- LISGGSJOYDXQHJ-VNEKAHSKSA-N 2-[3-[tert-butyl(diphenyl)silyl]oxy-2-[(3s)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-5-hydroxycyclopentyl]-n-[(2,4-dimethoxyphenyl)methyl]acetamide Chemical compound O([C@@H](CCCCC)C=CC1C(C(O)CC1O[Si](C=1C=CC=CC=1)(C=1C=CC=CC=1)C(C)(C)C)CC(=O)NCC=1C(=CC(OC)=CC=1)OC)[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 LISGGSJOYDXQHJ-VNEKAHSKSA-N 0.000 description 1
- RIWRTRRUHUQQLV-XBGZWIEASA-N 2-[3-[tert-butyl(diphenyl)silyl]oxy-2-[(3s)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-5-hydroxycyclopentyl]acetamide Chemical compound O([C@@H](CCCCC)C=CC1C(C(O)CC1O[Si](C=1C=CC=CC=1)(C=1C=CC=CC=1)C(C)(C)C)CC(N)=O)[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 RIWRTRRUHUQQLV-XBGZWIEASA-N 0.000 description 1
- AMWQHGVDJNXLNC-OEKZNHOFSA-N 2-[3-[tert-butyl(diphenyl)silyl]oxy-2-[(3s)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-5-oxocyclopentyl]-n-[(2,4-dimethoxyphenyl)methyl]acetamide Chemical compound O([C@@H](CCCCC)C=CC1C(C(=O)CC1O[Si](C=1C=CC=CC=1)(C=1C=CC=CC=1)C(C)(C)C)CC(=O)NCC=1C(=CC(OC)=CC=1)OC)[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 AMWQHGVDJNXLNC-OEKZNHOFSA-N 0.000 description 1
- UWXWTYWMOUQMOH-WICNXUKUSA-N 2-[3-[tert-butyl(diphenyl)silyl]oxy-2-[(3s)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-5-oxocyclopentyl]acetamide Chemical compound O([C@@H](CCCCC)C=CC1C(C(=O)CC1O[Si](C=1C=CC=CC=1)(C=1C=CC=CC=1)C(C)(C)C)CC(N)=O)[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 UWXWTYWMOUQMOH-WICNXUKUSA-N 0.000 description 1
- AWHOZLLOCDARHR-UHFFFAOYSA-N 2-[3-[tert-butyl(diphenyl)silyl]oxy-2-[[tert-butyl(diphenyl)silyl]oxymethyl]-5-hydroxycyclopentyl]-n-[(2,4-dimethoxyphenyl)methyl]acetamide Chemical compound COC1=CC(OC)=CC=C1CNC(=O)CC1C(CO[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)C(O[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)CC1O AWHOZLLOCDARHR-UHFFFAOYSA-N 0.000 description 1
- MZLOZJQZJVTULR-UHFFFAOYSA-N 2-[3-[tert-butyl(diphenyl)silyl]oxy-2-[[tert-butyl(diphenyl)silyl]oxymethyl]-5-oxocyclopentyl]-n-[(2,4-dimethoxyphenyl)methyl]acetamide Chemical compound COC1=CC(OC)=CC=C1CNC(=O)CC1C(=O)CC(O[Si](C=2C=CC=CC=2)(C=2C=CC=CC=2)C(C)(C)C)C1CO[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 MZLOZJQZJVTULR-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- JKIFPWHZEZQCQA-UHFFFAOYSA-N 2-nitrobenzenethiol Chemical compound [O-][N+](=O)C1=CC=CC=C1S JKIFPWHZEZQCQA-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- YQGBBEPRAOWIOF-UHFFFAOYSA-N 4-[4-(3-cyclohexyl-3-hydroxyprop-1-enyl)-5-hydroxy-6a-prop-1-ynyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound C1(CCCCC1)C(C=CC1C2CC(=NC2(CC1O)C#CC)CCCC(=S)O)O YQGBBEPRAOWIOF-UHFFFAOYSA-N 0.000 description 1
- QQQYAEKVACQHCI-UHFFFAOYSA-N 4-[5-hydroxy-4-(3-hydroxy-4,4-dimethyloct-1-enyl)-6a-prop-1-ynyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound OC1C(C2CC(=NC2(C1)C#CC)CCCC(=S)O)C=CC(C(CCCC)(C)C)O QQQYAEKVACQHCI-UHFFFAOYSA-N 0.000 description 1
- PFQNROIJCNYOHW-UHFFFAOYSA-N 4-[5-hydroxy-4-(3-hydroxy-4-methyloct-1-enyl)-6a-prop-1-ynyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound OC1C(C2CC(=NC2(C1)C#CC)CCCC(=S)O)C=CC(C(CCCC)C)O PFQNROIJCNYOHW-UHFFFAOYSA-N 0.000 description 1
- GBKVDQOLWBSPOG-UHFFFAOYSA-N 4-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-6a-(2-phenylethynyl)-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-2-yl]butanethioic s-acid Chemical compound N1=C(CCCC(O)=S)CC2C(C=CC(O)CCCCC)C(O)CC21C#CC1=CC=CC=C1 GBKVDQOLWBSPOG-UHFFFAOYSA-N 0.000 description 1
- ZHWVUPYKKIZBDE-UHFFFAOYSA-N 4-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-6a-methoxy-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound N1=C(CCCC(O)=S)CC2C(C=CC(O)CCCCC)C(O)CC21OC ZHWVUPYKKIZBDE-UHFFFAOYSA-N 0.000 description 1
- YIOMZXGCMZMWHA-UHFFFAOYSA-N 4-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-6a-phenylsulfanyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound N1=C(CCCC(O)=S)CC2C(C=CC(O)CCCCC)C(O)CC21SC1=CC=CC=C1 YIOMZXGCMZMWHA-UHFFFAOYSA-N 0.000 description 1
- RNTDYEWHHFVSTB-UHFFFAOYSA-N 4-[6a-cyano-4-(3-cyclohexyl-3-hydroxyprop-1-enyl)-5-hydroxy-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound OC1CC2(C#N)N=C(CCCC(O)=S)CC2C1C=CC(O)C1CCCCC1 RNTDYEWHHFVSTB-UHFFFAOYSA-N 0.000 description 1
- CFNDHESAUDMSBJ-UHFFFAOYSA-N 4-[6a-cyano-4-(3-cyclopentyl-3-hydroxyprop-1-enyl)-5-hydroxy-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound C(#N)C12N=C(CC2C(C(C1)O)C=CC(O)C1CCCC1)CCCC(=S)O CFNDHESAUDMSBJ-UHFFFAOYSA-N 0.000 description 1
- CMQORBBJVJYRCT-UHFFFAOYSA-N 4-[6a-cyano-5-hydroxy-4-(3-hydroxy-4,4-dimethyloct-1-enyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound C(#N)C12N=C(CC2C(C(C1)O)C=CC(C(CCCC)(C)C)O)CCCC(=S)O CMQORBBJVJYRCT-UHFFFAOYSA-N 0.000 description 1
- ADGQXBWHISLXCO-UHFFFAOYSA-N 4-[6a-cyano-5-hydroxy-4-(3-hydroxy-4-methyloct-1-enyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound C(#N)C12N=C(CC2C(C(C1)O)C=CC(C(CCCC)C)O)CCCC(=S)O ADGQXBWHISLXCO-UHFFFAOYSA-N 0.000 description 1
- GAPWPLRYOBKBDM-UHFFFAOYSA-N 4-[6a-ethyl-5-hydroxy-4-(3-hydroxyoct-1-enyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioic S-acid Chemical compound N1=C(CCCC(O)=S)CC2C(C=CC(O)CCCCC)C(O)CC21CC GAPWPLRYOBKBDM-UHFFFAOYSA-N 0.000 description 1
- DAEBGUKDZLFVFF-UHFFFAOYSA-N 4-[6a-ethynyl-5-hydroxy-4-(3-hydroxy-4-methyloct-1-enyl)-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-2-yl]butanethioic s-acid Chemical compound N1=C(CCCC(O)=S)CC2C(C=CC(O)C(C)CCCC)C(O)CC21C#C DAEBGUKDZLFVFF-UHFFFAOYSA-N 0.000 description 1
- BHWUTOCNTWPATQ-UHFFFAOYSA-N 4-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-[(2,4-dimethoxyphenyl)methyl]-5-hydroxy-6a-prop-1-ynyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)CO[Si](C)(C)C(C)(C)C)O)C#CC)C=CC(=C1)OC BHWUTOCNTWPATQ-UHFFFAOYSA-N 0.000 description 1
- FHDNCIGDIHNVPR-UHFFFAOYSA-N 4-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-ethynyl-5-hydroxy-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)CO[Si](C)(C)C(C)(C)C)O)C#C)C=CC(=C1)OC FHDNCIGDIHNVPR-UHFFFAOYSA-N 0.000 description 1
- TZKBVRDEOITLRB-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2C=C3C=NNC3=NC=2)=C1 TZKBVRDEOITLRB-UHFFFAOYSA-N 0.000 description 1
- JPVUWCPKMYXOKW-UHFFFAOYSA-N 4-phenylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1C1=CC=CC=C1 JPVUWCPKMYXOKW-UHFFFAOYSA-N 0.000 description 1
- SRSGVKWWVXWSJT-ATVHPVEESA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide Chemical compound CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCCN1CCCC1 SRSGVKWWVXWSJT-ATVHPVEESA-N 0.000 description 1
- MKDOMLJGXKRLGH-ORQBHYTNSA-N 5-[[5-tert-butyl-1-[(2,4-dimethoxyphenyl)methyl]-2,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrol-6a-yl]oxysilyl]-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-5-hydroxycyclohex-3-en-1-one Chemical compound COC1=C(CN2C3(CC(CC3CC2)C(C)(C)C)O[SiH2]C2(CC(CC=C2C=C[C@H](CCCCC)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)=O)O)C=CC(=C1)OC MKDOMLJGXKRLGH-ORQBHYTNSA-N 0.000 description 1
- OFBCJDYPBWJMCS-VNEKAHSKSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-1-[(2,4-dimethoxyphenyl)methyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3CC(C(C3CC2=O)C=C[C@H](CCCCC)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)C=CC(=C1)OC OFBCJDYPBWJMCS-VNEKAHSKSA-N 0.000 description 1
- ZQKQIHDWGORARN-FINQOHIRSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-(2-phenylethynyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)C=C[C@H](CCCCC)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)C#CC2=CC=CC=C2)C=CC(=C1)OC ZQKQIHDWGORARN-FINQOHIRSA-N 0.000 description 1
- LOTGPXZQKQYZOL-REPIPVHZSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-(2-trimethylsilylethynyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)C=C[C@H](CCCCC)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)C#C[Si](C)(C)C)C=CC(=C1)OC LOTGPXZQKQYZOL-REPIPVHZSA-N 0.000 description 1
- IGIIKFCJOKFFSD-BAYMZMLYSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-(4-trimethylsilylbuta-1,3-diynyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)C=C[C@H](CCCCC)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)C#CC#C[Si](C)(C)C)C=CC(=C1)OC IGIIKFCJOKFFSD-BAYMZMLYSA-N 0.000 description 1
- YVLKYRWVSVVBAT-MMBCXZTRSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-ethyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)C=C[C@H](CCCCC)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)CC)C=CC(=C1)OC YVLKYRWVSVVBAT-MMBCXZTRSA-N 0.000 description 1
- UREHJIIZADOIBQ-VWUYWKSRSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-methyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)C=C[C@H](CCCCC)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)C)C=CC(=C1)OC UREHJIIZADOIBQ-VWUYWKSRSA-N 0.000 description 1
- IANFBJJTFQSXAW-XJWLSCIMSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-phenylsulfanyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)C=C[C@H](CCCCC)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)SC2=CC=CC=C2)C=CC(=C1)OC IANFBJJTFQSXAW-XJWLSCIMSA-N 0.000 description 1
- JGSWBDKEZAQGLM-NOBDXFPDSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-prop-1-ynyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)C=C[C@H](CCCCC)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)C#CC)C=CC(=C1)OC JGSWBDKEZAQGLM-NOBDXFPDSA-N 0.000 description 1
- JTSFAIFDKGVVNH-NOBDXFPDSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-trimethylsilyloxy-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)C=C[C@H](CCCCC)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C)(C)C)C=CC(=C1)OC JTSFAIFDKGVVNH-NOBDXFPDSA-N 0.000 description 1
- WSFRYIGIQDHDHF-SYBHYAAWSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-2-sulfanylidene-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrole-6a-carbonitrile Chemical compound C(#N)C12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=S WSFRYIGIQDHDHF-SYBHYAAWSA-N 0.000 description 1
- LMWPHBUWVQDGNV-XBGZWIEASA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[b]pyrrol-2-one Chemical compound O=C1NC2CC(C(C2C1)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C LMWPHBUWVQDGNV-XBGZWIEASA-N 0.000 description 1
- AVKFLPWHYDFWTH-UZFSLQNCSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-(2-trimethylsilylethynyl)-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrol-2-one Chemical compound C[Si](C#CC12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O)(C)C AVKFLPWHYDFWTH-UZFSLQNCSA-N 0.000 description 1
- RKLODWQWOXVNMY-VBJPGOGMSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-(4-trimethylsilylbuta-1,3-diynyl)-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrol-2-one Chemical compound C[Si](C#CC#CC12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O)(C)C RKLODWQWOXVNMY-VBJPGOGMSA-N 0.000 description 1
- CXMUBTPHDSUXLR-VBJPGOGMSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-(4-trimethylsilylbuta-1,3-diynyl)-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrole-2-thione Chemical compound C[Si](C#CC#CC12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=S)(C)C CXMUBTPHDSUXLR-VBJPGOGMSA-N 0.000 description 1
- TXILBNQTQWYOGC-ANOHPWOVSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-ethenyl-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrole-2-thione Chemical compound C(=C)C12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=S TXILBNQTQWYOGC-ANOHPWOVSA-N 0.000 description 1
- NEXUHJMBFFOAHY-ANOHPWOVSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-ethynyl-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrol-2-one Chemical compound C(#C)C12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O NEXUHJMBFFOAHY-ANOHPWOVSA-N 0.000 description 1
- HAWDDABZEBQSBR-SYBHYAAWSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-methoxy-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrole-2-thione Chemical compound COC12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=S HAWDDABZEBQSBR-SYBHYAAWSA-N 0.000 description 1
- PTFVQJPQWFBTEZ-SLLLNJJJSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-phenylsulfanyl-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrol-2-one Chemical compound C1(=CC=CC=C1)SC12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O PTFVQJPQWFBTEZ-SLLLNJJJSA-N 0.000 description 1
- VINUWLLOVUDBKX-SLLLNJJJSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-phenylsulfanyl-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrole-2-thione Chemical compound C1(=CC=CC=C1)SC12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=S VINUWLLOVUDBKX-SLLLNJJJSA-N 0.000 description 1
- XLQPGAUJSVDRAM-GTNCXAEDSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-sulfanyl-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrole-2-thione Chemical compound SC12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=S XLQPGAUJSVDRAM-GTNCXAEDSA-N 0.000 description 1
- AVKFLPWHYDFWTH-UHFFFAOYSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-(2-trimethylsilylethynyl)-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrol-2-one Chemical compound C[Si](C#CC12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=CC(CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O)(C)C AVKFLPWHYDFWTH-UHFFFAOYSA-N 0.000 description 1
- BWTLIYBFEGXXPO-UHFFFAOYSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[[tert-butyl(diphenyl)silyl]oxymethyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-(2-trimethylsilylethynyl)-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)CO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)C#C[Si](C)(C)C)C=CC(=C1)OC BWTLIYBFEGXXPO-UHFFFAOYSA-N 0.000 description 1
- ACKVJVUZLLWCNH-UHFFFAOYSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[[tert-butyl(diphenyl)silyl]oxymethyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-phenylsulfanyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)CO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)SC2=CC=CC=C2)C=CC(=C1)OC ACKVJVUZLLWCNH-UHFFFAOYSA-N 0.000 description 1
- KTTZEHWHNMLJKQ-UHFFFAOYSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[[tert-butyl(diphenyl)silyl]oxymethyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-prop-1-ynyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)CO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)C#CC)C=CC(=C1)OC KTTZEHWHNMLJKQ-UHFFFAOYSA-N 0.000 description 1
- OFIHEQAOYAFOPU-UHFFFAOYSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[[tert-butyl(diphenyl)silyl]oxymethyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-trimethylsilyloxy-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-one Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)CO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[Si](C)(C)C)C=CC(=C1)OC OFIHEQAOYAFOPU-UHFFFAOYSA-N 0.000 description 1
- HVISUHJEGYWDFU-UHFFFAOYSA-N 5-[tert-butyl(diphenyl)silyl]oxy-4-[[tert-butyl(diphenyl)silyl]oxymethyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OCC(C1CC(=O)OC1C1)C1O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 HVISUHJEGYWDFU-UHFFFAOYSA-N 0.000 description 1
- FCBOUJYKAGWYQM-DEOSSOPVSA-N 6-[[(2s)-1-hydroxy-3-phenylpropan-2-yl]amino]-n-(2-phenoxyethyl)-2-(3,4,5-trimethoxyphenyl)pyridine-3-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=C(N[C@H](CO)CC=3C=CC=CC=3)N=2)C(=O)NCCOC=2C=CC=CC=2)=C1 FCBOUJYKAGWYQM-DEOSSOPVSA-N 0.000 description 1
- LTUZPODERZUPRD-UHFFFAOYSA-N 6-chloro-2-(1h-indol-3-yl)-4-phenylquinoline Chemical compound C12=CC(Cl)=CC=C2N=C(C=2C3=CC=CC=C3NC=2)C=C1C1=CC=CC=C1 LTUZPODERZUPRD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- UJHRPQKUPKHGAI-SYBHYAAWSA-N C(#N)C12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O Chemical compound C(#N)C12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O UJHRPQKUPKHGAI-SYBHYAAWSA-N 0.000 description 1
- OFIRDEUJDDUOKU-ANOHPWOVSA-N C(=C)C12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O Chemical compound C(=C)C12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O OFIRDEUJDDUOKU-ANOHPWOVSA-N 0.000 description 1
- NZZHHJRRLVXFCR-ANOHPWOVSA-N C(C)C12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O Chemical compound C(C)C12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O NZZHHJRRLVXFCR-ANOHPWOVSA-N 0.000 description 1
- YBJPKOOYXZMTKK-UHFFFAOYSA-N C1=CC=NC=C1.S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 Chemical compound C1=CC=NC=C1.S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 YBJPKOOYXZMTKK-UHFFFAOYSA-N 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- NTBMJZLEYYRDTN-UHFFFAOYSA-N CC1C2(C)NCC12 Chemical compound CC1C2(C)NCC12 NTBMJZLEYYRDTN-UHFFFAOYSA-N 0.000 description 1
- IMPDZUQVMLZQFB-OTNBPSNESA-N CCCCC[C@@H](/C=C/[C@@H](CC1)C[C@@]1(C#C)/N=C(\C)/CSCCCC)O Chemical compound CCCCC[C@@H](/C=C/[C@@H](CC1)C[C@@]1(C#C)/N=C(\C)/CSCCCC)O IMPDZUQVMLZQFB-OTNBPSNESA-N 0.000 description 1
- BVSYISXLTSWCOD-UHFFFAOYSA-N C[NH+]=[N-]c1ccccc1 Chemical compound C[NH+]=[N-]c1ccccc1 BVSYISXLTSWCOD-UHFFFAOYSA-N 0.000 description 1
- UJLCANZTYGSFMW-KVTFRISMSA-N C[Si](OC12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O)(C)C Chemical compound C[Si](OC12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O)(C)C UJLCANZTYGSFMW-KVTFRISMSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- XZFRIPGNUQRGPI-WLPVIMDJSA-N Carbacyclin Chemical class C1\C(=C\CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 XZFRIPGNUQRGPI-WLPVIMDJSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 229910004664 Cerium(III) chloride Inorganic materials 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000635799 Homo sapiens Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- QWMCOJSQOSMBQS-PDRSHUBSSA-N N1=C(CCCC(O)=S)CC2C(C=C[C@@H](O)CCCCC)C(O)CC21C#C Chemical compound N1=C(CCCC(O)=S)CC2C(C=C[C@@H](O)CCCCC)C(O)CC21C#C QWMCOJSQOSMBQS-PDRSHUBSSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- LGPZNXMTNPLPPJ-VBJPGOGMSA-N O-ethyl 4-[5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-cyano-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioate Chemical compound C(#N)C12N=C(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)CCCC(=S)OCC LGPZNXMTNPLPPJ-VBJPGOGMSA-N 0.000 description 1
- YPQHQAXGEINFDR-QAPXZPTISA-N O-ethyl 4-[5-[tert-butyl(diphenyl)silyl]oxy-4-[(3S)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-ethenyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioate Chemical compound C(=C)C12N=C(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)CCCC(=S)OCC YPQHQAXGEINFDR-QAPXZPTISA-N 0.000 description 1
- VUWUDHHRZMLLMI-XBGZWIEASA-N O=C1OC2CC(C(C2C1)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C Chemical compound O=C1OC2CC(C(C2C1)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C VUWUDHHRZMLLMI-XBGZWIEASA-N 0.000 description 1
- HCGFDYMJTKCLMC-GTNCXAEDSA-N OC12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O Chemical compound OC12NC(CC2C(C(C1)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)C=C[C@H](CCCCC)O[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)=O HCGFDYMJTKCLMC-GTNCXAEDSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- ACIAHEMYLLBZOI-ZZXKWVIFSA-N Unsaturated alcohol Chemical compound CC\C(CO)=C/C ACIAHEMYLLBZOI-ZZXKWVIFSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- BFSDICJGHFFYLJ-UHFFFAOYSA-N [4-(hydroxymethyl)-2-oxo-6a-prop-1-ynyl-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrol-5-yl] 4-phenylbenzoate Chemical compound C(#CC)C12NC(CC2C(C(C1)OC(C1=CC=C(C=C1)C1=CC=CC=C1)=O)CO)=O BFSDICJGHFFYLJ-UHFFFAOYSA-N 0.000 description 1
- QWHBLSGSTHQVKH-UHFFFAOYSA-N [4-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-[(2,4-dimethoxyphenyl)methyl]-2-oxo-6a-prop-1-ynyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-5-yl] 4-phenylbenzoate Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)CO[Si](C)(C)C(C)(C)C)OC(C2=CC=C(C=C2)C2=CC=CC=C2)=O)C#CC)C=CC(=C1)OC QWHBLSGSTHQVKH-UHFFFAOYSA-N 0.000 description 1
- CJEDKKSJLQSVER-UHFFFAOYSA-N [4-[[tert-butyl(dimethyl)silyl]oxymethyl]-1-[(2,4-dimethoxyphenyl)methyl]-6a-ethynyl-2-oxo-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-5-yl] 4-phenylbenzoate Chemical compound COC1=C(CN2C3(CC(C(C3CC2=O)CO[Si](C)(C)C(C)(C)C)OC(C2=CC=C(C=C2)C2=CC=CC=C2)=O)C#C)C=CC(=C1)OC CJEDKKSJLQSVER-UHFFFAOYSA-N 0.000 description 1
- KACQKOADVBUFQN-UHFFFAOYSA-N [6a-ethenyl-4-(hydroxymethyl)-2-oxo-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrol-5-yl] 4-phenylbenzoate Chemical compound C(=C)C12NC(CC2C(C(C1)OC(C1=CC=C(C=C1)C1=CC=CC=C1)=O)CO)=O KACQKOADVBUFQN-UHFFFAOYSA-N 0.000 description 1
- LJNXXZFQESPGRQ-UHFFFAOYSA-N [6a-ethynyl-4-(hydroxymethyl)-2-oxo-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrol-5-yl] 4-phenylbenzoate Chemical compound C(#C)C12NC(CC2C(C(C1)OC(C1=CC=C(C=C1)C1=CC=CC=C1)=O)CO)=O LJNXXZFQESPGRQ-UHFFFAOYSA-N 0.000 description 1
- DYUPOHIBCADMOV-ABMDCBBXSA-N [6a-ethynyl-4-[(3R)-3-hydroxyoct-1-enyl]-2-oxo-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrol-5-yl] 4-phenylbenzoate Chemical compound C(#C)C12NC(CC2C(C(C1)OC(C1=CC=C(C=C1)C1=CC=CC=C1)=O)C=C[C@@H](CCCCC)O)=O DYUPOHIBCADMOV-ABMDCBBXSA-N 0.000 description 1
- DYUPOHIBCADMOV-JSKKQJDMSA-N [6a-ethynyl-4-[(3S)-3-hydroxyoct-1-enyl]-2-oxo-1,3,3a,4,5,6-hexahydrocyclopenta[b]pyrrol-5-yl] 4-phenylbenzoate Chemical compound C(#C)C12NC(CC2C(C(C1)OC(C1=CC=C(C=C1)C1=CC=CC=C1)=O)C=C[C@H](CCCCC)O)=O DYUPOHIBCADMOV-JSKKQJDMSA-N 0.000 description 1
- PKTCETKLEASGFQ-OJZQKMKLSA-M [Na+].N1=C(CCCC([O-])=S)CC2C(C=C[C@@H](O)CCCCC)C(O)CC21C#C Chemical compound [Na+].N1=C(CCCC([O-])=S)CC2C(C=C[C@@H](O)CCCCC)C(O)CC21C#C PKTCETKLEASGFQ-OJZQKMKLSA-M 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 238000005905 alkynylation reaction Methods 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- JKOSHCYVZPCHSJ-UHFFFAOYSA-N benzene;toluene Chemical compound C1=CC=CC=C1.C1=CC=CC=C1.CC1=CC=CC=C1 JKOSHCYVZPCHSJ-UHFFFAOYSA-N 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- UCKORWKZRPKRQE-UHFFFAOYSA-N bromo(triethyl)silane Chemical compound CC[Si](Br)(CC)CC UCKORWKZRPKRQE-UHFFFAOYSA-N 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- JUPMBRMEHSUGLE-UHFFFAOYSA-N butenyl Chemical compound CCC=[CH] JUPMBRMEHSUGLE-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125800 compound 12j Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- AXAZMDOAUQTMOW-UHFFFAOYSA-N dimethylzinc Chemical compound C[Zn]C AXAZMDOAUQTMOW-UHFFFAOYSA-N 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- ZCRPOGJQHIXCOD-FGGZNOQHSA-N ethyl 4-[5-[tert-butyl(diphenyl)silyl]oxy-4-[(3s)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-methoxy-2-sulfanylidene-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-1-yl]butanoate Chemical compound O([C@@H](CCCCC)C=CC1C2C(N(C(=S)C2)CCCC(=O)OCC)(OC)CC1O[Si](C=1C=CC=CC=1)(C=1C=CC=CC=1)C(C)(C)C)[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 ZCRPOGJQHIXCOD-FGGZNOQHSA-N 0.000 description 1
- RLZFVPPGVAHZPE-UHFFFAOYSA-N ethyl 4-iodobutanoate Chemical compound CCOC(=O)CCCI RLZFVPPGVAHZPE-UHFFFAOYSA-N 0.000 description 1
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- UWNADWZGEHDQAB-UHFFFAOYSA-N i-Pr2C2H4i-Pr2 Natural products CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 1
- HIFJCPQKFCZDDL-ACWOEMLNSA-N iloprost Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)C(C)CC#CC)[C@H](O)C[C@@H]21 HIFJCPQKFCZDDL-ACWOEMLNSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 150000004797 ketoamides Chemical class 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- TUOQTRVLPKMMDB-KNAQOGQBSA-N methyl 4-[[(3ar,4r,5r,6as)-5-hydroxy-4-[(e,3s)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]pyrrol-2-yl]sulfanyl]butanoate Chemical compound N1=C(SCCCC(=O)OC)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 TUOQTRVLPKMMDB-KNAQOGQBSA-N 0.000 description 1
- QAWFLJGZSZIZHO-UHFFFAOYSA-N methyl 4-bromobutanoate Chemical compound COC(=O)CCCBr QAWFLJGZSZIZHO-UHFFFAOYSA-N 0.000 description 1
- ZZUYIRISBMWFMV-UHFFFAOYSA-N methyl 4-chlorobutanoate Chemical compound COC(=O)CCCCl ZZUYIRISBMWFMV-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- BODLESUVCQEUII-UHFFFAOYSA-N n-[4-[2-(hydroxyamino)-2-oxoethyl]piperidin-4-yl]-4-[(2-methylquinolin-4-yl)methoxy]benzamide Chemical compound C=12C=CC=CC2=NC(C)=CC=1COC(C=C1)=CC=C1C(=O)NC1(CC(=O)NO)CCNCC1 BODLESUVCQEUII-UHFFFAOYSA-N 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- LSCYTCMNCWMCQE-UHFFFAOYSA-N n-methylpyridin-4-amine Chemical compound CNC1=CC=NC=C1 LSCYTCMNCWMCQE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- UDVQXZQSUAHJKK-VBJPGOGMSA-N o-ethyl 4-[5-[tert-butyl(diphenyl)silyl]oxy-4-[(3s)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-methoxy-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-2-yl]butanethioate Chemical compound O([C@@H](CCCCC)C=CC1C2CC(CCCC(=S)OCC)=NC2(OC)CC1O[Si](C=1C=CC=CC=1)(C=1C=CC=CC=1)C(C)(C)C)[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 UDVQXZQSUAHJKK-VBJPGOGMSA-N 0.000 description 1
- RYRWBKBYPIGLAO-WUCQRGFYSA-N o-ethyl 4-[5-[tert-butyl(diphenyl)silyl]oxy-4-[(3s)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-6a-phenylsulfanyl-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-2-yl]butanethioate Chemical compound O([C@@H](CCCCC)C=CC1C2CC(CCCC(=S)OCC)=NC2(SC=2C=CC=CC=2)CC1O[Si](C=1C=CC=CC=1)(C=1C=CC=CC=1)C(C)(C)C)[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 RYRWBKBYPIGLAO-WUCQRGFYSA-N 0.000 description 1
- IMJRLWFMMSFXQQ-WIFUHMOSSA-N o-ethyl 4-[5-hydroxy-4-[(3s)-3-hydroxyoct-1-enyl]-6a-phenylsulfanyl-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-2-yl]butanethioate Chemical compound N1=C(CCCC(=S)OCC)CC2C(C=C[C@@H](O)CCCCC)C(O)CC21SC1=CC=CC=C1 IMJRLWFMMSFXQQ-WIFUHMOSSA-N 0.000 description 1
- FMTHUEMIFADXQW-LVTGDIRUSA-N o-ethyl 4-[6a-buta-1,3-diynyl-5-[tert-butyl(diphenyl)silyl]oxy-4-[(3s)-3-[tert-butyl(diphenyl)silyl]oxyoct-1-enyl]-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-2-yl]butanethioate Chemical compound O([C@@H](CCCCC)C=CC1C2CC(CCCC(=S)OCC)=NC2(CC1O[Si](C=1C=CC=CC=1)(C=1C=CC=CC=1)C(C)(C)C)C#CC#C)[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 FMTHUEMIFADXQW-LVTGDIRUSA-N 0.000 description 1
- BCESJNRUZTZJEL-WEWRAIFCSA-N o-ethyl 4-[6a-cyano-5-hydroxy-4-[(3s)-3-hydroxyoct-1-enyl]-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-2-yl]butanethioate Chemical compound N1=C(CCCC(=S)OCC)CC2C(C=C[C@@H](O)CCCCC)C(O)CC21C#N BCESJNRUZTZJEL-WEWRAIFCSA-N 0.000 description 1
- HWAHMMUAWKJBAR-OBHCEDRKSA-N o-ethyl 4-[6a-ethenyl-5-hydroxy-4-[(3s)-3-hydroxyoct-1-enyl]-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-2-yl]butanethioate Chemical compound N1=C(CCCC(=S)OCC)CC2C(C=C[C@@H](O)CCCCC)C(O)CC21C=C HWAHMMUAWKJBAR-OBHCEDRKSA-N 0.000 description 1
- BLVDAFVQRIMTQM-OBHCEDRKSA-N o-ethyl 4-[6a-ethynyl-5-hydroxy-4-[(3s)-3-hydroxyoct-1-enyl]-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-2-yl]butanethioate Chemical compound N1=C(CCCC(=S)OCC)CC2C(C=C[C@@H](O)CCCCC)C(O)CC21C#C BLVDAFVQRIMTQM-OBHCEDRKSA-N 0.000 description 1
- BJPDYDKPEQYWSF-WEWRAIFCSA-N o-methyl 4-[6a-ethynyl-5-hydroxy-4-[(3s)-3-hydroxyoct-1-enyl]-3a,4,5,6-tetrahydro-3h-cyclopenta[b]pyrrol-2-yl]butanethioate Chemical compound N1=C(CCCC(=S)OC)CC2C(C=C[C@@H](O)CCCCC)C(O)CC21C#C BJPDYDKPEQYWSF-WEWRAIFCSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- FZPPRDIJOYTGRS-UHFFFAOYSA-N propyl 4-bromobutanoate Chemical compound CCCOC(=O)CCCBr FZPPRDIJOYTGRS-UHFFFAOYSA-N 0.000 description 1
- RGFHUYWGQUDWDL-UHFFFAOYSA-N propyl 4-chlorobutanoate Chemical compound CCCOC(=O)CCCCl RGFHUYWGQUDWDL-UHFFFAOYSA-N 0.000 description 1
- ASDNBJRMSYCUAE-UHFFFAOYSA-N propyl 4-iodobutanoate Chemical compound CCCOC(=O)CCCI ASDNBJRMSYCUAE-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- VXBAJLGYBMTJCY-NSCUHMNNSA-N sb1317 Chemical compound N=1C2=CC=NC=1NC(C=1)=CC=CC=1CN(C)C\C=C\CCOC1=CC=CC2=C1 VXBAJLGYBMTJCY-NSCUHMNNSA-N 0.000 description 1
- BHRZNVHARXXAHW-UHFFFAOYSA-N sec-butylamine Chemical compound CCC(C)N BHRZNVHARXXAHW-UHFFFAOYSA-N 0.000 description 1
- JFMUOXDGGBVQHP-BYFHNKFLSA-M sodium 4-[5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-6a-prop-1-ynyl-3a,4,5,6-tetrahydro-3H-cyclopenta[b]pyrrol-2-yl]butanethioate Chemical compound OC1C(C2CC(=NC2(C1)C#CC)CCCC(=S)[O-])C=C[C@H](CCCCC)O.[Na+] JFMUOXDGGBVQHP-BYFHNKFLSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- DCGLONGLPGISNX-UHFFFAOYSA-N trimethyl(prop-1-ynyl)silane Chemical compound CC#C[Si](C)(C)C DCGLONGLPGISNX-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- This invention relates to prostacyclin (PGl 2 ) analogues which are used as antithromboic and anti-ulcer drugs in the field of medicine.
- this invention relates to the compounds represented by the general formula (I) or their salts, which have prostacyclin (PG1 2 )-like inhibitory activity against platelet agglutination and anti- ulcer activity, wherein R 1 is hydrogen or C 1 -C 6 alkyl; R 2 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkynyl substituted with unsubstituted or C 1 -C 8 alkyl-, C 1 -C 8 alkyloxy- or nitro-substituted phenyl, naphthyl or polycyclic aromatic hydrocarbon at optional position, C 1 -C 6 alkyloxy, unsubstituted or C 1 -C 8 alkyl-, C 1 -C
- PG1 2 is produced mainly in vascular cells or leukocytes as follows. Phospholipase A 2 activated by chemical or physical stimulation of vascular cells, promotes release of arachidonic acid which is converted into PG1 2 by the action of cyclooxygenase and PG1 2 synthetase. PG1 2 has a potent inhibitory activity against platelet agglutination and vasodilative activity and is used as an antiplatelet agent for patients who have been treated with artificial dialysis or pump-oxygenator.
- thrombotic diseases such as peripheral circulatory insufficiency, e.g., vibration disease, collagen diseases, Buerger disease, and arteriosclerosis obliterans; ischemic heart diseases, e.g., angina pectoris and myocardial infarction; and disturbance of cerebral circulation, e.g., cerebral thrombosis, cerebral embolis and cerebral infarction, are expected.
- peripheral circulatory insufficiency e.g., vibration disease, collagen diseases, Buerger disease, and arteriosclerosis obliterans
- ischemic heart diseases e.g., angina pectoris and myocardial infarction
- cerebral circulation e.g., cerebral thrombosis, cerebral embolis and cerebral infarction
- PG1 2 also has several drawbacks; for example, it is chemically unstable and has hypotensive activity, which is undesirable for antithromboic drugs.
- Thrombosis is induced with occurrence of hemangioendothelium injury or inflammation, alteration of blood flow volume, or raise of blood coagulation ability.
- a white thrombus often induced by Buerger disease, arteriosclerosis obliterans and so on, is also known as conglutination thrombus which is generated by gathering of platelets, leukocytes, fibrin, or erythrocytes on the injury, ulcer or rough surface of the intima, obliterates or strangulates the lumen, readily adheres to the wall of an artery and causes the organic diseases.
- alteration of the blood flow volume and congestion of the blood flow which are provoked by many causes generate intravascular coagulation to form a red thrombus.
- the red thrombus adheres to the surface of the white thrombus to gradually induce the obliteration extending over a wide area.
- a strong disturbance of peripheral circulation is caused accompanied by the necrosis of tissue.
- the agglutination activity of platelets is an important factor in vascular diseases such as thrombosis and arterial sclerosis. Therefore, it has been recognized that the administration of antithromboic drugs, especially drugs which possess inhibitory activity against platelet agglutination will be efficacious for the prevention or treatment of those vascular diseases.
- PG prostaglandins
- PG analogues which act as agonists of the receptor of PG E 1 and 1 2 , having potent inhibitory activity against platelet agglutination and vasodilating activity, have been developed as well as, inhibitors which inhibit synthesis of thromboxane A 2 adversely acting to PG1 2 .
- PG1 2 analogues Hoe-892 [B. A.
- EP-A-0 034 778 relates to analogues of PG1 2 which are useful in the therapy and prophylaxis of thromboses and infarcts.
- the subject matter of the invention are prostacyclin (PG1 2 ) analogues represented by the general formula: wherein R 1 is hydrogen or C 1 -C 6 alkyl; R 2 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkynyl substituted with unsubstituted or C 1 -C 8 alkyl-, C 1 -C 8 alkyloxy- or nitro-substituted phenyl, naphthyl or polycyclic aromatic hydrocarbon at optional position, C 1 -C 6 alkyloxy, unsubstituted or C 1 -C 8 alkyl-, C 1 -C 8 alkyloxy- or nitro-substituted phenylthio, naphthylthio or polycyclic aromatic thiohydrocarbon, or cyano; R 3 and R 4 are each hydrogen, tetrahydropyranyl, trimethyl
- Said compounds are used as antithrombotic and antiulcer drugs.
- the compounds of the present invention represented by the general formula (I) may be prepared from (1S,5R,6R,7R)-2-oxa-3-oxo-6-[(3S)-3-hydroxyoct-1-enyl]-7-hydroxybicyclo[3.3.0]octane [E. J. Corey et.al., J.Am.Chem.Soc., 92, 397, (1970)] or (1 S,5R,6S, 7R)-2-oxa-3-oxo-6-hydroxymethyl-7-hydroxybicyclo[3.3.0]-octane [E. J. Corey et.al., J.Am.Chem.Soc., 93, 1490, (1971)] according to the following process.
- a tetrahydropyranyl, trimethylsilyl, dimethyl-tert-butylsilyl or diphenyl-tert-butylsilyl is introduced into hydroxy groups of the compound 1 in order to protect them in the succeeding reaction steps.
- the reaction may be carried out with tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride, trimethylsilyl chloride, or the like in the presence of a base such as triethylamine, pyridine, or 4-dimethylaminopyridine at room temperature or under warming for a period of several hours to several days.
- a solvent used in this reaction an aromatic hydrocarbon.
- benzene toluene
- a chlorinated hydrocarbon e.g., chloroform, dichloromethane
- dimethylformamide e.g., benzene, toluene
- the hydroxy-protection may also be achieved by treating the compound 1 with dihydropyrane in the presence of an acid catalyst such as p-toluenesulfonic acid, pyridinium p-toluenesulfonate, Amberlyst 15 (Rohm & Haas Co.) at room temperature.
- an acid catalyst such as p-toluenesulfonic acid, pyridinium p-toluenesulfonate, Amberlyst 15 (Rohm & Haas Co.) at room temperature.
- a solvent an ethereal solvent.
- a hydrocarbon e.g., hexane: an aromatic hydrocarbon. e.g., bezene or toluene; or a chlorinated hydrocarbon, e.g., chloroform, dichloromethane is exemplified.
- the lactone 2 is allowed to react with an amine to give the hydroxyamide 3.
- the reaction is carried out with an amine such as an alkylamine, e.g., methylamine, ethylamine, n-propylamine, 2-propylamine, n-butylamine or 2-butylamine; an cycloalkylamine, e.g., cyclopentylamine or cyclohexylamine; benzylamine; or a substituted benzylamine, e.g., 2-chlorobenzylamine.
- an alkylamine e.g., methylamine, ethylamine, n-propylamine, 2-propylamine, n-butylamine or 2-butylamine
- an cycloalkylamine e.g., cyclopentylamine or cyclohexylamine
- benzylamine or a substituted benzylamine, e.g.,
- a base such as 2-hydroxypyridine or sodium methoxide may be added as a catalyst.
- the lactone 2 is allowed to react gradually with ammonia to give the hydroxylactone 4.
- This step may be carried out, for example, by reacting the lactone 2 with ammonia in an alcohol solvent, e.g., methanol or ethanol, under heating for a period of several tens of hours. This reaction may be carried out preferably in an autoclave. If required, sodium methoxide may be used as a catalyst.
- the compound 3 is oxidized into the keto-amide 5 and the hydroxy-lactam 6.
- the reaction is carried out in the following manners: (1) using a chromic acid derived oxidizing agent, e.g., Jones' reagent, Collins' reagent, pyridinium chlorochromate or pyridinium dichromate; or (2) using dimethylsulfoxide combined with oxalyl chloride, sulfuryl chloride or the like, or pyridinium sulfur trioxide combined with a base such as triethylamine, 4-dimethylaminopyridine as an oxidizing agent.
- a chromic acid derived oxidizing agent e.g., Jones' reagent, Collins' reagent, pyridinium chlorochromate or pyridinium dichromate
- dimethylsulfoxide combined with oxalyl chloride, sulfuryl chloride or the like, or pyridinium sulfur trioxide combined with a base such as trieth
- reaction is achieved in a solvent, e.g., acetone, benzene, chloroform, dichloromethane or ether, which may be chosen according to the property of the agent used under cooling or warming within a period of several tens of minutes to several hours.
- a solvent e.g., acetone, benzene, chloroform, dichloromethane or ether, which may be chosen according to the property of the agent used under cooling or warming within a period of several tens of minutes to several hours.
- the substituent R 6 of the N-substituted keto-amide 5 is removed oxidatively to give the keto-amide 7 and hydroxy-lactam 8.
- an oxidizing agent used in this reaction 2, 3-dichloro-5,6-dicyano-1,4-benzoquinone, potassium persulfate, cerium ammonium nitrate, or the like is exemplified.
- an aromatic solvent e.g., benzene or xylene
- a chlorinated hydrocarbon e.g., chloroform or dichloromethane
- an ethereal solvent e.g., ethyl ether, tetrahydrofuran or dioxane
- an alcohol e.g., methanol or ethanol
- the reaction is achieved at room temperature or under heating within a period of several tens of minutes to several hours.
- the hydroxyamide 4 is oxidized into the keto-amide 7.
- the reaction is carried out by the use of an oxidizing agent such as chromic acid derived one, e.g., Jones' reagent. Collins' reagent, pyridinium chlorochromate, pyridinium dichromate, in a solvent such as a chlorinated hydrocarbon, e.g., chloroform or dichloromethane; an ethereal solvent, e.g., ethyl ether or tetrahydrofuran; acetone; or benzene under cooling or at room temperature for a period of several hours.
- an oxidizing agent such as chromic acid derived one, e.g., Jones' reagent. Collins' reagent, pyridinium chlorochromate, pyridinium dichromate, in a solvent such as a chlorinated hydrocarbon, e.g., chloroform or dichloromethane; an ethereal solvent, e
- the keto-amide 7 and/or hydroxy-lactam 8 is silylated to give the compound 9.
- the reaction may be carried out by the use of an alkylsilylating agent such as trimethylsilyl chloride, trimethylsilyl bromide, triethylsilyl chloride, triethylsilyl bromide, hexamethyldisilazane, tert-butyldimethyisilyl chloride or tert-butyldiphenylsilyl chloride, in the presence of a base such as triethylamine, pyridine, or 4-dimethylaminopyridine in a dry solvent such as chlorinated hydrocarbon, e.g., chloroform or dichloromethane; ethereal solvent, e.g., ethyl ether or tetrahydrofuran; aromatic solvent, e.g., benzene, toluene, xylene or pyridine; dimethyl
- the compound 9 is allowed to react with a substituted or unsubstituted benzenethiol or an alcohol in the presence of an acid catalyst to give the compound 10.
- an acid catalyst p-toluenesulfonic acid, formic acid, hydrochloric acid, sulfuric acid, baron trifluoride etherate or the like is exemplified.
- a substituted benzenethiol having the preferable substituent methoxybenzenethiol, nitrobenzenethiol, toluenethiol, ethylbenzenethiol, or dimethylbenzenethiol is exemplified.
- methanol, ethanol, propanol, isopropanol, butanol, or isobutanol is exemplified.
- the reaction is carried out in a solvent such as an ethereal solvent, e.g., ethyl ether or tetrahydrofuran; acetonitrile; dimethylsulfoxide; dimethylformamide; acetone, at room temperature for several tens of minutes to several hours.
- a solvent such as an ethereal solvent, e.g., ethyl ether or tetrahydrofuran; acetonitrile; dimethylsulfoxide; dimethylformamide; acetone, at room temperature for several tens of minutes to several hours.
- the aforementioned alcohol also works as solvent.
- the hydroxy-lactam 8 is allowed to react with an alcohol to give the compound 10.
- the reaction is achieved in the same manner as in Step 8.
- the compound 11 is allowed to react with a benzenethiol derivative in the presence of an acid catalyst to give the compound 12a.
- the reaction is achieved in the same manner as in Step 8.
- the desired alkyl group or alkynyl group is introduced into the compound 12a.
- the alkylation is carried out with an alkylating agent such as dialkyl zinc.
- the alkynylation is carried out with an alkynylating agent such as a mixture of dialkynyl zinc and alkynyl zinc halogenide.
- Both reactions are carried out in a solvent such as chlorinated hydrocarbon, e.g., chloroform or dichloromethane; aromatic solvent, e.g., benzene; toluene or xylene; or dioxane, under heating for a period of several tens of minutes to several tens of hours.
- the alkyl of the alkylating agent used includes Cl-C5 straight or branched alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl or isopentyl, and the like.
- the alkynyl of the alkynylating agent includes ethynyl or substituted ethynyi, e.g., 2-trimethylsilylethynyl, 1-propynyl, 1-butynyl, 1-pentynyl, 3-buten-1-ynyl, 3-penten-1-ynyl, 4-penten-1-ynyl, 1,3-butadiynyl, 4-trimethylsilyl-1,3-butadiynyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 2-phenylethynyl, methoxyphenylethynyl, nitrophenylethynyl, tolylethynyl or dimethylphenylethynyl, and the like.
- 2-trimethylsilylethynyl 1-propynyl
- 1-butynyl 1-pentynyl
- the substituent R 6 of the N-substituted lactam 12 is removed oxidatively to give the lactam 10.
- an oxidizing agent used in this reuction 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, potassium persulfate, cerium ammonium nitrate, or the like is exemplified.
- an aromatic solvent e.g., benzene or xylene
- a chlorinated hydrocarbon e.g., chloroform or dichloromethane
- an ethereal solvent e.g., ethyl ether, tetrahydrofuran or dioxane
- an alcohol e.g., methanol or ethanol
- acetonitrile is used with a proper amount of water and they are used singly or in a combination according to the property of the agent used.
- the reaction is achieved at room temperature or under heating within several tens of minutes to several hours.
- the phenylthio group of the compound 10a is displaced with a desired alkyl or alkynyl.
- the reaction is achieved in the same manner as in Step 12.
- the lactam 10 is converted into the thiolactam 13.
- This step is carried out in the following manners: (1) heating in an aromatic solvent such as benzene, toluene or xylene containing 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetan-2, 4-disulfide (Lawesson's Reagent), if required, with a base such as triethylamine, pyridine, or 4-methylaminopyridine; or (2) reacting with phosphorus pentasulfide, phosphorus pentasulfide-pyridine complex, or the like in a solvent such as toluene, dimethoxyethane or pyridine.
- compounds having a mercapto group at the 1-position may sometimes be produced as by-product.
- the thiolactam 13 is alkylated with an alkyl halide to give the thiolactim ether 15.
- the reaction is carried out in a solvent such as a chlorinated hydrocarbon, e.g., chloroform or dichloromethane; an ethereal solvent, e.g., tetrahydrofuran, dioxane or dimethoxyethane; aromatic solvent, e.g., benzene, toluene or xylene; dimethylsulfoxide; or dimethylformamide, in the precence of a base such as potassium carbonate or sodium hydride under cooling or heating for a period of several tens of minutes to several hours.
- a solvent such as a chlorinated hydrocarbon, e.g., chloroform or dichloromethane
- an ethereal solvent e.g., tetrahydrofuran, dioxane or dimethoxyethane
- aromatic solvent e.
- methyl 4-iodobutyrate, ethyl 4-iodobutyrate, propyl 4-iodobutyrate, methyl 4-bromobutyrate, ethyl 4-bromobutyrate, propyl 4-bromobutyrate, methyl 4-chlorobutyrate, ethyl 4-chlorobutyrate or propyl 4-chlorobutyrate is exemplified.
- the thiolactim the compound of the present invention is prepared.
- N-alkylated compounds may sometimes be produced as by-product.
- silyl groups of the compound 15 are removed to give the compound 17.
- the reaction is carried out in a solvent such as alcohol, e.g., methanol or ethanol; ether, e.g., ethyl ether or tetrahydrofuran; acetonitrile; or water, if necessary, using an agent such as acetic acid, hydrochloric acid, p-toluenesulfonic acid, hydrofluoric acid and pyridine or tetrabutylammonium fluoride at room temperature or under heating for a period of several tens of minutes to several hours.
- a solvent such as alcohol, e.g., methanol or ethanol
- ether e.g., ethyl ether or tetrahydrofuran
- acetonitrile e.g., acetonitrile
- water if necessary, using an agent such as acetic acid, hydrochloric acid, p-toluen
- the ester 17 is applied to an ester-exchange reaction or hydrolyzed with a proper base catalyst to give the compound of the present invention; the ester having a desired ester group or the carboxylate salt 18, respectively.
- the ester exchange reaction is easily achieved by the usual method, that is, the ester may be allowed to react with an alcohol having a desired alkly in the presence of a base such as sodium methoxide at room temperature.
- the nydrolysis may also be carried out in a usual manner.
- the carboxylate salt 18 may be converted into the free carboxylic acid 19, the compound of the present invention, by the use of a proper acid such as hydrochloric acid, acctic acid, phosphoric acid, citric acid or boric acid, or a buffer solution such as acetic acid/sodium acetate, citric acid/disodium hydrogenphosphate, citric acid/sodium hydroxide, phosphoric acid/sodium hydroxide, boric acid/sodium hydroxide or acetic acid/sodium hydroxide.
- a proper acid such as hydrochloric acid, acctic acid, phosphoric acid, citric acid or boric acid
- a buffer solution such as acetic acid/sodium acetate, citric acid/disodium hydrogenphosphate, citric acid/sodium hydroxide, phosphoric acid/sodium hydroxide, boric acid/sodium hydroxide or acetic acid/sodium hydroxide.
- the 1-methoxy group of the compound 10b is displaced with a cyano group.
- This step may be carried out by reacting cyanotrimethylsilane in the presence of a Lewis acid such as boron trifluoride etherate. The reaction is achieved at room temperature within a period of several hours.
- the lactam 10k is converted into the thiolactam 13. This step may be carried out in the same manner as in Step 15.
- the trimethylsilyl group of the compound 10f is selectively removed.
- This step may be carried out by using a base, e.g., potassium carbonate or sodium carbonate, as a catalyst in an alcohol, e.g., methanol or ethanol.
- a base e.g., potassium carbonate or sodium carbonate
- an alcohol e.g., methanol or ethanol.
- the reaction is achieved at room temperature within a period of several hours.
- the ethynyl group is reduced to an ethenyl group.
- a catalyst Lindler catalyst, palladium - barium sulfate with quinoline, or Raney Nickel may be used.
- a solvent an alcohol, e.g., methanol or ethanol or an aromatic solvent, e.g., benzene is used. The reaction is carried out at ordinary temperature and atmospheric pressure in an atmosphere of hydrogen for several hours.
- an ammonia solution of alkali metal e.g., lithium or sodium, may be used.
- the lactam 101 is converted into the thiolactam 13. This step may be carried out in the same manner as in Step 15.
- the thiolactam 13 is alkylated with an alkyl halide to give the thiolactim ether 15.
- This step may be carried out in the same manner as in Step 16.
- the thiolactim compounds of the present invention are prepared.
- tetrahydropyranyl, trimethylsilyl, dimethyl-tert-butylsilyl or diphenyl-tert-butylsilyl are introduced into the hydroxy groups of the compound 21.
- This step may be carried out in the same manner as in Step 1.
- the lactone 22 is allowed to react with an amine to give the hydroxyamide 23.
- This step may be carried out in the same manner as in Step 2.
- the compound 23 is oxidized into the keto-amide 24.
- This step may be carried out in the same as in Step 4.
- the keto-amide 24 is silylated to give the compound 25.
- This step may be carried out in the same manner as in Step 7.
- the compound 25 is allowed to react with a substituted or unsubstituted benzenethiol in the presence of an acid catalyst to give the compound 26a.
- This step may be carried out in the same manner as in Step 8.
- the desired substituent is introduced into the compound 26a.
- This step may be carried out in the same manner as in Step 12.
- silyl groups of the compound 26' are removed to give the compound 27.
- This step may be carried out in the same manner as in Step 17. In this reaction, when the 1-substituent is trimethylsilylethynyl, it is converted into ethynyl.
- the hydroxy group of the 6-side chain of the compound 27 is selectively protected.
- the reaction is carried out using trimethylsilyl chloride, tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride or the like in the presence of a base such as triethylamine, pyridine, or 4-dimethylaminopyridine at room temperature or under warming for a period of several hours to several days.
- a solvent an aromatic solvent, e.g., benzene or xylene; a chlorinated hydrocarbon, e.g., chloroform or dichloromethane; or dimethylformamide is exemplified.
- the alcohol 28 is protected with a protecting group which is relatively stable in acidic condition.
- the reaction is carried out by reacting the alcohol 28 with an acid anhydride or acid chloride.
- an acyl group forming an acid anhydride or acid chloride acetyl, propionyl, benzoyl or a substituted benzoyl, e.g., 3-methylbenzoyl, 4-phenylbenzoyl or 2-nitrobenzoyl; or 1-naphthoyl or 2-naphthoyl; is exemplified.
- the alcohol 28 is allowed to react with an acid anhydride or acid chloride in the presence of a base such as pyridine, triethylamine, or 4-dimethylaminopyridine in a solvent such as a chlorinated hydrocar- bone, e.g., chloroform, dichloromethane or carbon tetrachloride; or dioxane at room temperature for a period of several hours.
- a base such as pyridine, triethylamine, or 4-dimethylaminopyridine
- a solvent such as a chlorinated hydrocar- bone, e.g., chloroform, dichloromethane or carbon tetrachloride; or dioxane
- the substituent R 6 of the N-substituted lactam 29 is removed oxidatively to give the lactam 30.
- This step may be carried out in the same manner as in Step 13. Depending on the condition, protecting group, and agent used, the silyl group may be removed.
- the silyl group When the silyl group remains, it may be removed by further acid treatment.
- the 1-substituent of the compound 30 is ethynyl, it may be reduced to prepare the 1-ethenyl compound in the same manner as in Step 22, if necessary.
- the alcohol 30 is oxidized into the aldehyde, which is further allowed to react with a phosphonic acid ester to give the enone 31.
- the oxidation may be carried out in the same manner as in Step 4.
- the reaction to prepare the enone 31 may be carried out by the Horner-Wadsworth-Emmons Reaction using a base such as sodium hydride or sodium amide in a solvent such as 1,2-dimethoxyethane or tetrahydrofuran.
- a base such as sodium hydride or sodium amide
- a solvent such as 1,2-dimethoxyethane or tetrahydrofuran.
- the phosphonic acid esters used in this reaction are those having a desired side chain to be condensed, namely, dimethyl 2-oxoheptylphosphonate, dimethyl 2-oxo-3-methylheptylphosphonate, dimethyl 2-oxo-3,3-dimethylheptylphosphonate, dimethyl 2-oxo-3-methyl-5-heptynylphosphonate, dimethyl 2-oxo-2-cyclohexylethylphosphonate, dimethyl 2-oxo-2-cyclopentyl ethylphosphonate, dimethyl 4-(2-furyl)-2-oxo-butylphosphonate, or the like.
- the enone 31 is reduced into the unsaturated alcohol 32.
- a reducing agent aluminium isopropoxide, diisobornylaluminium isopropoxide, sodium cyanoborohydride, potassium tri-sec-butyl borohydride, zinc borohydride, sodium borohydride, a combination of sodium borohydride and cerium (III) chloride, diisobutyl aluminium 2,6-di-tert-butyl-4-methylphenoxide, lithium hexyllimonyl borohydride, BINAL-H or the like may be used.
- an etheral solvent e.g., diethyl ether or tetrahydrofuran
- an alcohol e.g., methanol or ethanol
- an aromatic solvent e.g., benzene or toluene
- a chlorinated hydrocarbon e.g., dichloromethane or chloroform
- the reaction is carried out under cooling or at room temperature for a period of several tens of minutes.
- the alcohol prepared in this step is a mixture of the epimers.
- the 7-hydroxy-protecting group is removed.
- the reaction is carried out using a base such as sodium methoxide, sodium hydroxide, sodium carbonate, or calcium carbonate in an alcohol solvent such as methanol or ethanol at room temperature for a period of several hours.
- Step 2 the hydroxy group of the compound 34 or 35 is protected. This step may be carried out in the same manner as in Step 1.
- the lactam 10 is converted into the thio-lactam 13. This step may be carried out in the same manner as in Step 15.
- the ethenyl compound may be prepared by reduction carried out in the same manner as in Step 22, if necessary.
- the thiolactam 13 is alkylated with an alkyl halide to give the thiolactim ether 15.
- This step may be carried out in the same manner as in Step 16.
- the thiolactim ether compounds of the present invention are prepared.
- silyl groups of the compound 15 are removed to give the compound 17.
- This step may be carried out in the same manner as in Step 17.
- the ester 17 is applied to an ester-exchange reaction or hydrolyzed with a proper base catalyst to give the compound of the present invention.
- This step may be carried out in the same manner as in Step 18.
- Ri, R 2 , R 3 , R 4 and R 5 each is the same as defined in the general formula (I).
- R 6 is straight or branched C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, substituted or unsubstituted benzyl (e.g., benzyl, 2-chlorobenzyl, 2,4,6-trimethylbenzyl, 2-methoxybenzyl, 2,4-dimethoxybenzyl, 3,4-dimethoxybenzyl), or the like.
- R 7 is alkanoyl, e.g., acetyl, propionyl, benzoyl, substituted benzoyl ( e.g., 3-methylbenzoyl, 4-phenylbenzoyl, 2,4-dihydrobenzoyl, 2-nitrobenzoyl), 1-naphthoyl, 2-naphthoyl, or the like.
- alkanoyl e.g., acetyl, propionyl, benzoyl, substituted benzoyl (e.g., 3-methylbenzoyl, 4-phenylbenzoyl, 2,4-dihydrobenzoyl, 2-nitrobenzoyl), 1-naphthoyl, 2-naphthoyl, or the like.
- phenyl is Ph
- methyl is Me
- ethyl is Et
- tert-butyl is t Bu or But.
- the extract is washed with water, dried over anhydrous magnesium sulfate and evaporated to give 7.52 g of residue, which is crystallized from a mixture of ethyl ether and n-pentane to give 4.87 g of the compound 5 (67 % yield).
- the crude product 5 is recrystallized from a mixture of ethyl ether and n-pentane to give the compound 5 as crystals, mp. 97-98 ° C.
- the crude product 6 is recrystallized from a mixture of ethyl ether and n-pentane to give the compound 6 as crystals, mp. 123-125 ° C.
- 185 mg (0.185 mmol) of the phenylthio-lactam 12a (Example 1-10) is dissolved in 7 ml of dry chloroform and 1 ml (2 mmol) of 2M n-hexane solution of diethyl zinc is added thereto, and then the mixture is stirred in a tightly closed vessel on an oil bath at 80 ° C for 2 hours. After cooling, the reaction mixture is poured into iced water and a saturated aqueous solution of ammonium chloride is added.
- reaction mixture is stirred in a tightly closed state on an oil bath at 60 ° C for about 1 hour.
- the solvent is evaporated and to the residue is added a solution of 100 mg (0.10 mmol) of the compound 12a (Example I-10) in 5 ml of dry xylene.
- the mixture is stirred in a tightly closed vessel on an oil bath at 140 °C for 30 minutes.
- the compound 10 (S)c can also be prepared from the compound 12(S)c (Example I-11 ) on the reaction with 2, 3-dichloro-5, 6-dicyano-1, 4-benzoquinon in chloroform -water (19 : 1) mixture by refluxing under heating.
- Example 1-24 To a solution of 507 mg (Example 1-24) of the ethynyl-lactam 10(S)g in 50 ml of benzene are added 0.5 ml of quinoline and 25 mg of 5 % palladium-barium sulfate and the mixture is stirred in an atmosphere of hydrogen at ordinary temperature and atmospheric pressure for 55 minutes. The insoluble material is removed by filtration and the filtrate is evaporated.
- Example 1-25 419 mg of the ethenyllactam 10(S)I (Example 1-25) is allowed to react to give 423 mg of the compound 13(S)I as a foamy material (99 % yield).
- the extract is washed with saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and evaporated to give 31.22 g of residue, which is dissolved in ethyl acetate.
- the solution is washed with dilute aqueous solution of sodium hydrogencarbonate and then with saturated aqueous solution of sodium chloride.
- the aqueous layer is extracted with ethyl acetate twice and the extract is washed with saturated aqueous solution of sodium chloride.
- Example 1-40 150 mg of the benzyl-lactam 29h (Example 1-40) is allowed to react to give 50 mg of the compound 30h, mp. 159 -160 ° C (63 % yield).
- the compound 10(S)g prepared in this example is comfirmed to be identical with the compound prepared in Example 1-24 by MS, [ ⁇ ] D , IR and proton NMR.
- Example F-2-(1) 254 mg of the methoxy-thiolactam 13(S)b (Example F-2-(1)) is alkylated to give 262 mg of the compound 15(S)b as an oil (90 % yield) and 19 mg of ethyl 4-[7-tert-butyldiphenylsilyloxy-6-[(3S)-3-tert-butyldiphenylsilyloxy-1-octenyl]-1-methoxy-3-thioxo-2-azabicyclo[3.3.0]-oct-2-yl]butanoate 16(S)b as an oil (6.5 % yield).
- the compound 15(S)f may be converted into the compound 17(S)g in the same manner as in the desilylation reaction as mentioned above.
- ethyl acetate is suspended the sodium salt of carboxylic acid 19(S)g (Fxample F-16-(1)) prepared from 29.3 mg (0.0695 mmol) of the ethyl ester 17(S)g (Example F-12) and then a buffer of about pH 4.5 [which is prepared by mixing an aqueous solution of disodium citrate (prepared from 21 g of citric acid (C 6 H 8 O 7 ⁇ H20) and 200 ml of aqueous solution of sodium hydroxide) and 1/10 N hydrochloric acid in the ratio 5.65 : 4.35] and an aqueous solution of sodium chloride are added to the suspension. After the mixture is shaken, the ethyl acetate layer is separated.
- a buffer of about pH 4.5 which is prepared by mixing an aqueous solution of disodium citrate (prepared from 21 g of citric acid (C 6 H 8 O 7 ⁇ H20) and 200 ml of aqueous solution of sodium hydro
- Example F-17-(1) The alkylation of 402 mg of the 4-trimethylsilyl-1,3-butadiynyl-thiolactam 13(S)j (Example F-17-(1)) is carried out in the same manner as in Example F-1-(2) to afford 403 mg of the compound 15(S)k as an oil (95.5 % yield).
- Example F-17-(2) Removal of silyl groups carried out in the same manner as in Example F-8 using 346 mg the silyl ether 15(S)k (Example F-17-(2)) affords 136 mg of the compound 17(S)k as an oil (81.5 % yield)
- Example 1-27 383 mg of the ethenyl-thiolactam 13(S)I (Example 1-27) is alkylated to give 402 mg of the compound 15(S)I as an oil (91.5 % yield).
- Example F-21 Removal of silyl groups carried out in the same manner as in Example F-21 affords 145 mg of the oily compound 17(S)I (85.5 % yield) from 360 mg of the silyl ether 15(S)I (Example F-20).
- Example F-13 The ethyl ester 17(S)h (64 mg; Example F-13) is allowed to react in the same manner as in Example F-67 to give 50 mg of the compound 19(S)h as a foamy material.
- the compounds of the present invention are chemically stable analogues of prostacyclin (PG1 2 ) which act as agonists to PG1 2 receptors.
- PG1 2 prostacyclin
- the compounds of the present invention strongly inhibit platelet agglutination as does PG1 2 so that they are expected to be useful as antithrombotic drugs for the improvement of peripheral circulatory insufficiency, extracorporeal circulation such as artificial dialysis or ischemic disease, and the like.
- the compounds of the present invention may be used as antiulcer drugs.
- PRP was diluted with PPP to prepare a blood sample whose platelet number was 50 - 55 x 10 4 / ⁇ l. The sample was then subjected to a platelet agglutination test.
- the platelet agglutination was examined by the method of Born [Born, G.V.R., Nature, 194, 927-929 (1962)], using a Type AUTO RAM-61 aggregometer, (Rika Denki Co., Ltd., Tokyo). A volume of 400 ⁇ l of PRP, whose platelet number was adjusted to 50 - 55x10 4 / ⁇ l, was placed in a measuring cuvette and set in the aggregometer.
- PRP was warmed at 37 ° C for 1 minute with stirring at 1,200 rpm, and then a solution of the test compound [dimethylsulfoxide solution (2 ⁇ l) of the compound + saline (48ul); in case of prostaglandin 1 2 (PG1 2 ) and prostagladin E 1 (PG E 1 ), a solution of each compound (50 ⁇ l) in Tris buffer] was added thereto.
- the light transmissions of PRP and PPP were taken as 0 % and 100 % agglutination, respectively, and the maximum light transmission after addition of an agglutinating agent was made to the maximum agglutination.
- the inhibition rate of the platelet agglutination was expressed as the percentage of the maximum agglutination by a test compound to that by a control (Vehicle added group).
- Prostaglandin (PG) 1 2 and E 1 and test compound 18c, disclosed in EP-A-0 034 778 serve as standard substances.
- the compounds of the present invention strongly inhibit the platelet agglutination induced by arachidonic acid, collagen and ADP.
- the compounds of the present invention act as agonist to PG1 2 receptors and strongly inhibit the platelet agglutination or aggregation.
- the compounds having such pharmacological action can be used for extracorporeal circulation, e.g., artificial dialysis, pump-oxygenator; prevention of thrombosis caused after operation; or treatment or prevention of peripheral circulatory insufficiency or ischemic disease, e.g., vibration disease, Buerger disease, arteriosclerosis obliteration, plumonary embolism, plumonary hypertension, angina pectoris, acute myocardial infarction, cerebral thrombosis, cerebral embolism or cerebral infarction.
- the compounds are formulated into dosage forms such as tablets, capsules, pills, granules, fine subtilaes, solutions, or emulsions and for parenteral administration, such as suppositories or injections, e.g., intravenous, intramusucular or subcutaneous injection.
- parenteral administration such as suppositories or injections, e.g., intravenous, intramusucular or subcutaneous injection.
- adequated carriers and fillers are selected from conventionally used carriers and fillers.
- the compounds of the present invention may be orally administered to the adult in a daily dose of about 0.1 mg - 500mg.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Paper (AREA)
- Vending Machines For Individual Products (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
- This invention relates to prostacyclin (PGl2) analogues which are used as antithromboic and anti-ulcer drugs in the field of medicine. In more detail, this invention relates to the compounds represented by the general formula (I)
or their salts, which have prostacyclin (PG12)-like inhibitory activity against platelet agglutination and anti- ulcer activity, wherein R1 is hydrogen or C1-C6 alkyl; R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C6 alkynyl substituted with unsubstituted or C1-C8 alkyl-, C1-C8 alkyloxy- or nitro-substituted phenyl, naphthyl or polycyclic aromatic hydrocarbon at optional position, C1-C6 alkyloxy, unsubstituted or C1-C8 alkyl-, C1-C8 alkyloxy- or nitro-substituted phenylthio, naphthylthio or polycyclic aromatic thiohydrocarbon, or cyano; R3 and R4 are each hydrogen, tetrahydropyranyl, trimethylsilyl, dimethyl-tert-butylsilyl or diphenyl-tert-butylsilyl; R5 is straight or branched C1-C8 alkyl which may be substituted with a N-, O- or S-containing 5- membered ring, straight or branched C2-Cg alkynyl, or C3-C8 cycloalkyl; the navy line indicates R- or S-configuration, or their mixture, or a salt thereof, except for compounds of the formula: wherein R2 is CH3O-, CH3CH2-, CH3-, or CH2 = CH-; and the compound of the formula: wherein R2 is CH2 = CH-and R5 is and compounds of the formula: wherein R2 is CH≡C-and R5 is or or wherein R2 is CH2 = CH-and R5 is - PG12 is produced mainly in vascular cells or leukocytes as follows. Phospholipase A2 activated by chemical or physical stimulation of vascular cells, promotes release of arachidonic acid which is converted into PG12 by the action of cyclooxygenase and PG12 synthetase. PG12 has a potent inhibitory activity against platelet agglutination and vasodilative activity and is used as an antiplatelet agent for patients who have been treated with artificial dialysis or pump-oxygenator. As further clinical applications of PG12, the application to thrombotic diseases such as peripheral circulatory insufficiency, e.g., vibration disease, collagen diseases, Buerger disease, and arteriosclerosis obliterans; ischemic heart diseases, e.g., angina pectoris and myocardial infarction; and disturbance of cerebral circulation, e.g., cerebral thrombosis, cerebral embolis and cerebral infarction, are expected. However, PG12 also has several drawbacks; for example, it is chemically unstable and has hypotensive activity, which is undesirable for antithromboic drugs.
- Therefore, it is an object of the present application to develop chemically stable PG12 analogues having more potent platelet agglutination inhibitory activity and higher selectivity of action.
- This object has been solved by the prostacyclin analogues represented by the general formula (I), which have been found to show a potent activity as PG12 receptor agonists and are chemically stable.
- Thrombosis is induced with occurrence of hemangioendothelium injury or inflammation, alteration of blood flow volume, or raise of blood coagulation ability. A white thrombus, often induced by Buerger disease, arteriosclerosis obliterans and so on, is also known as conglutination thrombus which is generated by gathering of platelets, leukocytes, fibrin, or erythrocytes on the injury, ulcer or rough surface of the intima, obliterates or strangulates the lumen, readily adheres to the wall of an artery and causes the organic diseases. In the vein, alteration of the blood flow volume and congestion of the blood flow which are provoked by many causes generate intravascular coagulation to form a red thrombus. Usually, the red thrombus adheres to the surface of the white thrombus to gradually induce the obliteration extending over a wide area. When the main artery is rapidly blocked by a thrombus, a strong disturbance of peripheral circulation is caused accompanied by the necrosis of tissue. Thus, it is thought that the agglutination activity of platelets is an important factor in vascular diseases such as thrombosis and arterial sclerosis. Therefore, it has been recognized that the administration of antithromboic drugs, especially drugs which possess inhibitory activity against platelet agglutination will be efficacious for the prevention or treatment of those vascular diseases. In addition to the conventional antithromboic drugs such as heparin and coumarin compounds, a certain type of prostaglandins (hereinafter abbreviated to PG) are known to have a potent inhibitory activity against platelet agglutination. From these facts, prostaglandin derivatives have attached public attention as antithromboic drugs. For example, PG analogues which act as agonists of the receptor of PG E1 and 12, having potent inhibitory activity against platelet agglutination and vasodilating activity, have been developed as well as, inhibitors which inhibit synthesis of thromboxane A2 adversely acting to PG12. As the PG12 analogues, Hoe-892 [B. A. Schölkens et.al., Prostaglandins Leukotrienes. Med., 10, 231-256, (1983)], OP-41483 [P. G. Adaikan et.al., Prostaglandins Leukotrienes. Med., 10, 53-64, (1983)], ZK-36374 [J. J. F. Belch et.al., Prostaglandins, 28, 67-77, (1984)] Nitrilo-PG12 [R. R. German et.al , Prostaglandins, 19, 2-14, (1980)], and 9-substituted carbacyclin analogue [P. A. Aristoff et al., J. Org. Chem., 48, 5341-5348, (1983)] can be exemplified.
- EP-A-0 034 778 relates to analogues of PG12 which are useful in the therapy and prophylaxis of thromboses and infarcts.
- The subject matter of the invention are prostacyclin (PG12) analogues represented by the general formula:
wherein R1 is hydrogen or C1-C6 alkyl; R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C6 alkynyl substituted with unsubstituted or C1-C8 alkyl-, C1-C8 alkyloxy- or nitro-substituted phenyl, naphthyl or polycyclic aromatic hydrocarbon at optional position, C1-C6 alkyloxy, unsubstituted or C1-C8 alkyl-, C1-C8 alkyloxy- or nitro-substituted phenylthio, naphthylthio or polycyclic aromatic thiohydrocarbon, or cyano; R3 and R4 are each hydrogen, tetrahydropyranyl, trimethylsilyl, dimethyl-tert-butylsilyl or diphenyl-tert-butylsilyl; R5 is straight or branched C1-C8 alkyl which may be substituted with a N-, O- or S-containing 5- membered ring, straight or branched C2-Cg alkynyl, or C3-C8 cycloalkyl; the wavy line indicates R- or S-configuration, or their mixture, or a salt thereof, except for compounds of the formula: wherein R2 is CH3O-, CH3CH2-, CH3-, or CH2 = CH-; and the compound of the formula: wherein R2 is CH2 = CH-and R5 is and compounds of the formula: wherein R2 is CH≡C-and R5 is or or wherein R2 is CH2 = CH-and R5 is - Said compounds are used as antithrombotic and antiulcer drugs.
- The following are examples given for various terms used throughout this specification.
- Examples of straight or branched C1 -C6 alkyls are methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl and pentyl. Examples of straight or branched C1 -C8 alkyls are methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-methylpentyl, 1,1-dimethylpentyl, hexyl, heptyl and octyl.
- Examples of C2-C6 alkenyls are alkyls having one or more double bonds in the chain like ethenyl, 1-propenyl, 2-propenyl, butenyl, isobutenyl, pentenyl and isopentenyl.
- Examples of C2-C6 alkynyls are alkyls having one or more triple bonds in the chain like ethynyl, 1-propynyl, 1-butynyl, 1,3-butadiynyl, 1-pentynyl, 1,3-pentadiynyl, 1-hexynyl and 1,3-hexadiynyl.
- Examples of C2-C8 alkynyls are alkyls having one or more triple bonds in the alkyl chain like ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 1-methyl-3-butynyl, 1,1-dimethyl-3-butynyl, 1,3-butadiynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-3-pentynyl, 1,1-dimethyl-3-pentynyl, 1-hexynyl, 3- hexynyl, 1-methyl-3-hexynyl and 1,1-dimethylhexynyl.
- Examples of C3-C8 cycloalkyls are cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Examples of C1-C6 alkyloxys are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentoxy and isopentoxy.
- Examples of nitrogen-, oxygen- or sulfur-containing 5-membered rings are 2-pyrrolyl, 3-pyrrolyl, 2-thienyl, 3-thienyl, 2-furyl and 3-furyl. Examples of C2-C6 alkynyls substituted with unsubstituted or C1-C8 alkyl-, C1-C8 alkyloxy- or nitro-substituted phenyl, naphthyl or polycyclic aromatic hydrocarbon at optional position are phenylethynyl, 2-naphthylethynyl and 3-phenyl-1-propynyl.
- The salts of the compounds represented by the general formula (I) may include, for example, salts with an alkali metal such as lithium, sodium, and potassium, salts with an alkaline earth metal such as calcium, ammonium salts, salts with an organic base such as triethylamine, N-methylmorpholine and pyridine, and salts with an amino acid such as glycine, valine and alanine.
- In the above definition, preferably R1 is hydrogen or C1 -C6 alkyl; and more preferably R1 is hydrogen, methyl, or ethyl. Preferably R2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C6 alkynyl substituted with unsubstituted or C1 -C8 alkyl-, C1-C8 alkyloxy- or nitro-substituted phenyl, naphthyl or polycyclic aromatic hydrocarbon at optional position, cyano, C1-C6 alkyloxy, unsubstituted or C1 -C8 alkyl-, C1 -C8 alkyloxy- or nitro-substituted phenyl-thio, naphthylthio or polycyclic aromatic thiohydrocarbon, and more preferably R2 is methyl, ethyl, ethenyl, ethynyl, 1-propynyl, 1,3-butadiynyl, phenylethynyl, methoxy, or phenylthio. Preferably R3 and R4 are each hydrogen or tetrahydropyranyl, trimethylsilyl, dimethyl-tert-butylsilyl or diphenyl-tert-butylsilyl; and more preferably R3 and R4 are each hydrogen, diphenyl-tert-butylsilyl, or dimethyl-tert-butylsilyl. Preferably R5 is straight or branched C1 -C8 alkyl which may be substituted with a N-, O- or S-containing 5-membered ring, straight or branched C2-Cg alkynyl, or C3-C8 cycloalkyl; and more preferably R5 is pentyl, 1-methylpentyl, 1,1-dimethylpentyl, 2-(2-furyl)ethyl, 1-methyl-3-pentynyl, cyclopentyl or cyclohexyl.
- Illustrative of the compounds (I) of present invention are the following:
- 4-[7-hydroxy-6-(3-hydroxy-1-octenyl)-1-methoxy-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid.
- 4-[7-hydroxy-6-(3-hydroxy-1-octenyl)-1-phenylthio-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid. 4-[1-ethyl-7-hydroxy-6-(3-hydroxy-1-octenyl)-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[1-ethynyl-7-hydroxy-6-(3-hydroxy-1-octenyl)-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[7-hydroxy-6-(3-hydroxy-1-octenyl)-1-(1-propynyl)-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[1-(1,3-butadiynyl)-7-hydroxy-6-(3-hydroxy-1-octenyl)-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[7-hydroxy-6-(3-hydroxy-1-octenyl)-1-phenylethynyl-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[1-cyano-7-hydroxy-6-(3-hydroxy-1-octenyl)-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[1-ethenyl-7-hydroxy-6-(3-hydroxy-4-methyl-1-octenyl)-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[1-ethynyl-7-hydroxy-6-(3-hydroxy-4-methyl-1-octenyl)-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[7-hydroxy-6-(3-hydroxy-4-methyl-1-octenyl)-1-(1-propynyl)-2-azabicyclo[3.3.0]oct-2-en-3-yl]-thiobutanoic acid,
- 4-[1-cyano-7-hydroxy-6-(3-hydroxy-4-methyl-1-octenyl)-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[1-ethenyl-7-hydroxy-6-(3-hydroxy-4,4-dimethyl-1-octenyl)]-2-azabicylo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[1-ethynyl-7-hydroxy-6-(3-hydroxy-4,4-dimethyl-1-octenyl)]-2-azabicylo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[7-hydroxy-6-(3-hydroxy-4,4-dimethyl-1-octenyl)-1-(1-propynyl)-2-azabicyclo[3.3.0]oct-2-en-3-yl]-thiobutanoic acid,
- 4-[1-cyano-7-hydroxy-6-(3-hydroxy-4,4-dimethyl-1-octenyl)-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[1-ethenyl-7-hydroxy-6-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2-azabicylo[3.3.0]oct-2-en-3-yl]-thiobutanoic acid,
- 4-[1-ethynyl-7-hydroxy-6-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2-azabicylo[3.3.0]oct-2-en-3-yl]-thiobutanoic acid,
- 4-[7-hydroxy-6-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1-(1-propynyl-2-azabicylo[3.3.0]oct-2-en-3-yl]-thiobutanoic acid,
- 4-[1-cyano-7-hydroxy-6-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2-azabicylo[3.3.0]occ-2-en-3-yl]thiobutanoic acid,
- 4-[6-(3-cyclopentyl-3-hydroxy-1-propenyl)-1-ethynyl-7-hydroxy)-2-azabicyclo[3.3.0]oct-2-en-3-yl]-thiobutanoic acid,
- 4-[6-(3-cyclopentyl-3-hydroxy-1-propenyl)-1-(1-propynyl)-7-hydroxy)-2-azabicyclo[3.3.0]oct-2-en-3-yl]-thiobutanoic acid,
- 4-[1-cyano-6-(3-cyclopentyl-3-hydroxy-1-propenyl)-7-hydroxy-2-azabicyclo[3.3.0]oct-2-en-3-yl]-thiobutanoic acid,
- 4-[6-(3-cyclohexyl-3-hydroxy-1-propenyl)-1-ethenyl-7-hydroxy-2-azabicyclo[3.3.0]oct-2-en-3-yl]-thiobutanoic acid,
- 4-[6-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-hydroxy-1-(1-propynyl)-2-azabicyclo[3.3.0]oct-2-en-3-yl]-thiobutanoic acid,
- 4-[1-cyano-6-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-hydroxy-2-azabicyclo[3.3.0]oct-2-en-3-yl]-thiobutanoic acid,
- 4-[1-ethynyl-6-[5-(2-furyl)-3-hydroxy-1-pentenyl]-7-hydroxy-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid.
- The above compounds can be converted into esters or salts which also form part of the invention.
- Further illustrative of the compounds (I) of present invention are the following:
- 4-[7-hydroxy-6-(3-hydroxy-1-octenyl)-1-methyl-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[1-ethenyl-7-hydroxy-6-(3-hydroxy-1-octenyl)-2-azabicyclo[3.3.0]oct-2-en-3-yl]thiobutanoic acid,
- 4-[6-(3-cyclopentyl-3-hydroxy-1-propenyl)-1-ethenyl-7-hydroxy-2-azabicyclo[3.3.0]oct-2-en-3-yl]-thiobutanoic acid,
- 4-[6-(3-cyclohexyl-3-hydroxy-1-propenyl)-1-ethynyl-7-hydroxy-2-azabicyclo[3.3.0]oct-2-en-3-yl]-thiobutanoic acid.
- The above compounds can be converted into salts which also form part of the invention.
- The compounds of the present invention represented by the general formula (I) may be prepared from (1S,5R,6R,7R)-2-oxa-3-oxo-6-[(3S)-3-hydroxyoct-1-enyl]-7-hydroxybicyclo[3.3.0]octane [E. J. Corey et.al., J.Am.Chem.Soc., 92, 397, (1970)] or (1 S,5R,6S, 7R)-2-oxa-3-oxo-6-hydroxymethyl-7-hydroxybicyclo[3.3.0]-octane [E. J. Corey et.al., J.Am.Chem.Soc., 93, 1490, (1971)] according to the following process.
-
- In this step, a tetrahydropyranyl, trimethylsilyl, dimethyl-tert-butylsilyl or diphenyl-tert-butylsilyl is introduced into hydroxy groups of the compound 1 in order to protect them in the succeeding reaction steps. The reaction may be carried out with tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride, trimethylsilyl chloride, or the like in the presence of a base such as triethylamine, pyridine, or 4-dimethylaminopyridine at room temperature or under warming for a period of several hours to several days. As a solvent used in this reaction, an aromatic hydrocarbon. e.g., benzene, toluene; a chlorinated hydrocarbon, e.g., chloroform, dichloromethane; or dimethylformamide, is exemplified. The hydroxy-protection may also be achieved by treating the compound 1 with dihydropyrane in the presence of an acid catalyst such as p-toluenesulfonic acid, pyridinium p-toluenesulfonate, Amberlyst 15 (Rohm & Haas Co.) at room temperature. As a solvent, an ethereal solvent. e.g., diethyl ether, tetrahydrofuran; a hydrocarbon, e.g., hexane: an aromatic hydrocarbon. e.g., bezene or toluene; or a chlorinated hydrocarbon, e.g., chloroform, dichloromethane is exemplified.
- In this step. the lactone 2 is allowed to react with an amine to give the hydroxyamide 3. The reaction is carried out with an amine such as an alkylamine, e.g., methylamine, ethylamine, n-propylamine, 2-propylamine, n-butylamine or 2-butylamine; an cycloalkylamine, e.g., cyclopentylamine or cyclohexylamine; benzylamine; or a substituted benzylamine, e.g., 2-chlorobenzylamine. 2,4,6-trimethylbenzylamine, 2-methoxybenzylamine, 2,4-dimethoxybenzylamine or 3,4-dimethoxybenzylamine, in a solvent, (when the aforementioned amine is liquid, it also works as solvent), or water; an alcohol, e.g., methanol or ethanol; an ethereal solvent, e.g. ethyl ether, tetrahydrofuran or dioxane; or an aromatic hydrocarbon solvent, e.g., benzene, toluene or xylene, at room temperature or under warming for a period of several tens of hours. In order to accelerate the reaction, a base such as 2-hydroxypyridine or sodium methoxide may be added as a catalyst.
- In this step, the lactone 2 is allowed to react gradually with ammonia to give the hydroxylactone 4. This step may be carried out, for example, by reacting the lactone 2 with ammonia in an alcohol solvent, e.g., methanol or ethanol, under heating for a period of several tens of hours. This reaction may be carried out preferably in an autoclave. If required, sodium methoxide may be used as a catalyst.
- In this step, the compound 3 is oxidized into the keto-amide 5 and the hydroxy-lactam 6. The reaction is carried out in the following manners: (1) using a chromic acid derived oxidizing agent, e.g., Jones' reagent, Collins' reagent, pyridinium chlorochromate or pyridinium dichromate; or (2) using dimethylsulfoxide combined with oxalyl chloride, sulfuryl chloride or the like, or pyridinium sulfur trioxide combined with a base such as triethylamine, 4-dimethylaminopyridine as an oxidizing agent. The reaction is achieved in a solvent, e.g., acetone, benzene, chloroform, dichloromethane or ether, which may be chosen according to the property of the agent used under cooling or warming within a period of several tens of minutes to several hours.
- In this step, the substituent R6 of the N-substituted keto-amide 5 is removed oxidatively to give the keto-amide 7 and hydroxy-lactam 8. As an oxidizing agent used in this reaction, 2, 3-dichloro-5,6-dicyano-1,4-benzoquinone, potassium persulfate, cerium ammonium nitrate, or the like is exemplified. As a solvent, an aromatic solvent, e.g., benzene or xylene; a chlorinated hydrocarbon, e.g., chloroform or dichloromethane; an ethereal solvent, e.g., ethyl ether, tetrahydrofuran or dioxane; or an alcohol, e.g., methanol or ethanol is used with a proper amount of water, and they may be used singly or in a combination according to the property of the agent. The reaction is achieved at room temperature or under heating within a period of several tens of minutes to several hours.
- In this step, the hydroxyamide 4 is oxidized into the keto-amide 7. The reaction is carried out by the use of an oxidizing agent such as chromic acid derived one, e.g., Jones' reagent. Collins' reagent, pyridinium chlorochromate, pyridinium dichromate, in a solvent such as a chlorinated hydrocarbon, e.g., chloroform or dichloromethane; an ethereal solvent, e.g., ethyl ether or tetrahydrofuran; acetone; or benzene under cooling or at room temperature for a period of several hours.
- In this step, the keto-amide 7 and/or hydroxy-lactam 8 is silylated to give the compound 9. The reaction may be carried out by the use of an alkylsilylating agent such as trimethylsilyl chloride, trimethylsilyl bromide, triethylsilyl chloride, triethylsilyl bromide, hexamethyldisilazane, tert-butyldimethyisilyl chloride or tert-butyldiphenylsilyl chloride, in the presence of a base such as triethylamine, pyridine, or 4-dimethylaminopyridine in a dry solvent such as chlorinated hydrocarbon, e.g., chloroform or dichloromethane; ethereal solvent, e.g., ethyl ether or tetrahydrofuran; aromatic solvent, e.g., benzene, toluene, xylene or pyridine; dimethylsulfoxide; or dimethylformamide, or in a mixture of two or more solvents at room temperature or under heating for a period of several hours.
- In this step, the compound 9 is allowed to react with a substituted or unsubstituted benzenethiol or an alcohol in the presence of an acid catalyst to give the compound 10. As an acid catalyst, p-toluenesulfonic acid, formic acid, hydrochloric acid, sulfuric acid, baron trifluoride etherate or the like is exemplified. As a substituted benzenethiol having the preferable substituent, methoxybenzenethiol, nitrobenzenethiol, toluenethiol, ethylbenzenethiol, or dimethylbenzenethiol is exemplified. As an alcohol, methanol, ethanol, propanol, isopropanol, butanol, or isobutanol is exemplified. The reaction is carried out in a solvent such as an ethereal solvent, e.g., ethyl ether or tetrahydrofuran; acetonitrile; dimethylsulfoxide; dimethylformamide; acetone, at room temperature for several tens of minutes to several hours. The aforementioned alcohol also works as solvent.
- In this step, the hydroxy-lactam 8 is allowed to react with an alcohol to give the compound 10. The reaction is achieved in the same manner as in Step 8.
- In this step, the keto-amide 5 and hydroxy-lactam 6 is silylated to give the compound 11. The reaction is achieved in the same manner as in Step 7.
- In this step, the compound 11 is allowed to react with a benzenethiol derivative in the presence of an acid catalyst to give the compound 12a. The reaction is achieved in the same manner as in Step 8.
- In this step, the desired alkyl group or alkynyl group is introduced into the compound 12a. The alkylation is carried out with an alkylating agent such as dialkyl zinc. The alkynylation is carried out with an alkynylating agent such as a mixture of dialkynyl zinc and alkynyl zinc halogenide. Both reactions are carried out in a solvent such as chlorinated hydrocarbon, e.g., chloroform or dichloromethane; aromatic solvent, e.g., benzene; toluene or xylene; or dioxane, under heating for a period of several tens of minutes to several tens of hours. The alkyl of the alkylating agent used includes Cl-C5 straight or branched alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl or isopentyl, and the like. The alkynyl of the alkynylating agent includes ethynyl or substituted ethynyi, e.g., 2-trimethylsilylethynyl, 1-propynyl, 1-butynyl, 1-pentynyl, 3-buten-1-ynyl, 3-penten-1-ynyl, 4-penten-1-ynyl, 1,3-butadiynyl, 4-trimethylsilyl-1,3-butadiynyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 2-phenylethynyl, methoxyphenylethynyl, nitrophenylethynyl, tolylethynyl or dimethylphenylethynyl, and the like.
- In this step, the substituent R6 of the N-substituted lactam 12 is removed oxidatively to give the lactam 10. As an oxidizing agent used in this reuction, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, potassium persulfate, cerium ammonium nitrate, or the like is exemplified.
- As a solvent, an aromatic solvent, e.g., benzene or xylene; a chlorinated hydrocarbon, e.g., chloroform or dichloromethane; an ethereal solvent, e.g., ethyl ether, tetrahydrofuran or dioxane; an alcohol, e.g., methanol or ethanol; or acetonitrile; is used with a proper amount of water and they are used singly or in a combination according to the property of the agent used. The reaction is achieved at room temperature or under heating within several tens of minutes to several hours.
- In this step, the phenylthio group of the compound 10a is displaced with a desired alkyl or alkynyl. The reaction is achieved in the same manner as in Step 12.
- In this step, the lactam 10 is converted into the thiolactam 13. This step is carried out in the following manners: (1) heating in an aromatic solvent such as benzene, toluene or xylene containing 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetan-2, 4-disulfide (Lawesson's Reagent), if required, with a base such as triethylamine, pyridine, or 4-methylaminopyridine; or (2) reacting with phosphorus pentasulfide, phosphorus pentasulfide-pyridine complex, or the like in a solvent such as toluene, dimethoxyethane or pyridine. In this step, compounds having a mercapto group at the 1-position may sometimes be produced as by-product.
- In this step, the thiolactam 13 is alkylated with an alkyl halide to give the thiolactim ether 15. The reaction is carried out in a solvent such as a chlorinated hydrocarbon, e.g., chloroform or dichloromethane; an ethereal solvent, e.g., tetrahydrofuran, dioxane or dimethoxyethane; aromatic solvent, e.g., benzene, toluene or xylene; dimethylsulfoxide; or dimethylformamide, in the precence of a base such as potassium carbonate or sodium hydride under cooling or heating for a period of several tens of minutes to several hours. As an alkyl halide, methyl 4-iodobutyrate, ethyl 4-iodobutyrate, propyl 4-iodobutyrate, methyl 4-bromobutyrate, ethyl 4-bromobutyrate, propyl 4-bromobutyrate, methyl 4-chlorobutyrate, ethyl 4-chlorobutyrate or propyl 4-chlorobutyrate is exemplified. In this step, the thiolactim, the compound of the present invention is prepared. In this step, N-alkylated compounds may sometimes be produced as by-product.
- In this step, silyl groups of the compound 15 are removed to give the compound 17. The reaction is carried out in a solvent such as alcohol, e.g., methanol or ethanol; ether, e.g., ethyl ether or tetrahydrofuran; acetonitrile; or water, if necessary, using an agent such as acetic acid, hydrochloric acid, p-toluenesulfonic acid, hydrofluoric acid and pyridine or tetrabutylammonium fluoride at room temperature or under heating for a period of several tens of minutes to several hours. In this step, the compounds of the present invention, the hydroxy groups of which are not protected are prepared.
- In this step, the ester 17 is applied to an ester-exchange reaction or hydrolyzed with a proper base catalyst to give the compound of the present invention; the ester having a desired ester group or the carboxylate salt 18, respectively. The ester exchange reaction is easily achieved by the usual method, that is, the ester may be allowed to react with an alcohol having a desired alkly in the presence of a base such as sodium methoxide at room temperature. The nydrolysis may also be carried out in a usual manner. If necessary, the carboxylate salt 18 may be converted into the free carboxylic acid 19, the compound of the present invention, by the use of a proper acid such as hydrochloric acid, acctic acid, phosphoric acid, citric acid or boric acid, or a buffer solution such as acetic acid/sodium acetate, citric acid/disodium hydrogenphosphate, citric acid/sodium hydroxide, phosphoric acid/sodium hydroxide, boric acid/sodium hydroxide or acetic acid/sodium hydroxide.
Process 2 - In this step, the 1-methoxy group of the compound 10b is displaced with a cyano group. This step may be carried out by reacting cyanotrimethylsilane in the presence of a Lewis acid such as boron trifluoride etherate. The reaction is achieved at room temperature within a period of several hours.
- In this step, the lactam 10k is converted into the thiolactam 13. This step may be carried out in the same manner as in Step 15.
- In this step, the trimethylsilyl group of the compound 10f is selectively removed. This step may be carried out by using a base, e.g., potassium carbonate or sodium carbonate, as a catalyst in an alcohol, e.g., methanol or ethanol. The reaction is achieved at room temperature within a period of several hours.
- In this step, the ethynyl group is reduced to an ethenyl group. As a catalyst, Lindler catalyst, palladium - barium sulfate with quinoline, or Raney Nickel may be used. As a solvent, an alcohol, e.g., methanol or ethanol or an aromatic solvent, e.g., benzene is used. The reaction is carried out at ordinary temperature and atmospheric pressure in an atmosphere of hydrogen for several hours. As an alternative manner, an ammonia solution of alkali metal, e.g., lithium or sodium, may be used.
- In this step, the lactam 101 is converted into the thiolactam 13. This step may be carried out in the same manner as in Step 15.
- In this step, the thiolactam 13 is alkylated with an alkyl halide to give the thiolactim ether 15. This step may be carried out in the same manner as in Step 16.
- In this step, the thiolactim compounds of the present invention are prepared.
- In this step, silyl groups of the compound 15 are removed to give the compound 17. The reaction may be carried out in the same manner as in Step 1T
-
- In this step, tetrahydropyranyl, trimethylsilyl, dimethyl-tert-butylsilyl or diphenyl-tert-butylsilyl are introduced into the hydroxy groups of the compound 21. This step may be carried out in the same manner as in Step 1.
- In this step, the lactone 22 is allowed to react with an amine to give the hydroxyamide 23. This step may be carried out in the same manner as in Step 2.
- In this step, the compound 23 is oxidized into the keto-amide 24. This step may be carried out in the same as in Step 4.
- In this step, the keto-amide 24 is silylated to give the compound 25. This step may be carried out in the same manner as in Step 7.
- In this step, the compound 25 is allowed to react with a substituted or unsubstituted benzenethiol in the presence of an acid catalyst to give the compound 26a. This step may be carried out in the same manner as in Step 8.
- In this step, the desired substituent is introduced into the compound 26a. This step may be carried out in the same manner as in Step 12.
- In this step, silyl groups of the compound 26' are removed to give the compound 27. This step may be carried out in the same manner as in Step 17. In this reaction, when the 1-substituent is trimethylsilylethynyl, it is converted into ethynyl.
- In this step, the hydroxy group of the 6-side chain of the compound 27 is selectively protected. The reaction is carried out using trimethylsilyl chloride, tert-butyldimethylsilyl chloride, tert-butyldiphenylsilyl chloride or the like in the presence of a base such as triethylamine, pyridine, or 4-dimethylaminopyridine at room temperature or under warming for a period of several hours to several days. As a solvent, an aromatic solvent, e.g., benzene or xylene; a chlorinated hydrocarbon, e.g., chloroform or dichloromethane; or dimethylformamide is exemplified.
- In this step, the alcohol 28 is protected with a protecting group which is relatively stable in acidic condition. The reaction is carried out by reacting the alcohol 28 with an acid anhydride or acid chloride. As an acyl group forming an acid anhydride or acid chloride, acetyl, propionyl, benzoyl or a substituted benzoyl, e.g., 3-methylbenzoyl, 4-phenylbenzoyl or 2-nitrobenzoyl; or 1-naphthoyl or 2-naphthoyl; is exemplified.
- The alcohol 28 is allowed to react with an acid anhydride or acid chloride in the presence of a base such as pyridine, triethylamine, or 4-dimethylaminopyridine in a solvent such as a chlorinated hydrocar- bone, e.g., chloroform, dichloromethane or carbon tetrachloride; or dioxane at room temperature for a period of several hours. When the alcohol 28 is allowed to react with an acid anhydride, the reaction may be carried out without any solvent.
- In this step, the substituent R6 of the N-substituted lactam 29 is removed oxidatively to give the lactam 30. This step may be carried out in the same manner as in Step 13. Depending on the condition, protecting group, and agent used, the silyl group may be removed.
- When the silyl group remains, it may be removed by further acid treatment.
- When the 1-substituent of the compound 30 is ethynyl, it may be reduced to prepare the 1-ethenyl compound in the same manner as in Step 22, if necessary.
- In this step, the alcohol 30 is oxidized into the aldehyde, which is further allowed to react with a phosphonic acid ester to give the enone 31. The oxidation may be carried out in the same manner as in Step 4.
- The reaction to prepare the enone 31 may be carried out by the Horner-Wadsworth-Emmons Reaction using a base such as sodium hydride or sodium amide in a solvent such as 1,2-dimethoxyethane or tetrahydrofuran.
- The phosphonic acid esters used in this reaction are those having a desired side chain to be condensed, namely, dimethyl 2-oxoheptylphosphonate, dimethyl 2-oxo-3-methylheptylphosphonate, dimethyl 2-oxo-3,3-dimethylheptylphosphonate, dimethyl 2-oxo-3-methyl-5-heptynylphosphonate, dimethyl 2-oxo-2-cyclohexylethylphosphonate, dimethyl 2-oxo-2-cyclopentyl ethylphosphonate, dimethyl 4-(2-furyl)-2-oxo-butylphosphonate, or the like.
- In this step, the enone 31 is reduced into the unsaturated alcohol 32. As a reducing agent, aluminium isopropoxide, diisobornylaluminium isopropoxide, sodium cyanoborohydride, potassium tri-sec-butyl borohydride, zinc borohydride, sodium borohydride, a combination of sodium borohydride and cerium (III) chloride, diisobutyl aluminium 2,6-di-tert-butyl-4-methylphenoxide, lithium hexyllimonyl borohydride, BINAL-H or the like may be used. As a solvent, an etheral solvent, e.g., diethyl ether or tetrahydrofuran, an alcohol, e.g., methanol or ethanol, an aromatic solvent, e.g., benzene or toluene, or a chlorinated hydrocarbon, e.g., dichloromethane or chloroform may be used singly or combined according to the property of the agent. The reaction is carried out under cooling or at room temperature for a period of several tens of minutes. The alcohol prepared in this step is a mixture of the epimers.
- In this step, the 7-hydroxy-protecting group is removed. The reaction is carried out using a base such as sodium methoxide, sodium hydroxide, sodium carbonate, or calcium carbonate in an alcohol solvent such as methanol or ethanol at room temperature for a period of several hours.
- In this step, the hydroxy group of the compound 34 or 35 is protected. This step may be carried out in the same manner as in Step 1.
- In this step, the lactam 10 is converted into the thio-lactam 13. This step may be carried out in the same manner as in Step 15.
- When the 1-substituent of the compound 13 is ethynyl, the ethenyl compound may be prepared by reduction carried out in the same manner as in Step 22, if necessary.
- In this step, the thiolactam 13 is alkylated with an alkyl halide to give the thiolactim ether 15. This step may be carried out in the same manner as in Step 16.
- In this step, the thiolactim ether compounds of the present invention are prepared.
- In this step, silyl groups of the compound 15 are removed to give the compound 17. This step may be carried out in the same manner as in Step 17.
- In this step, the compounds of the present invention, the hydroxy groups of which are not protected are prepared.
- In this step, the ester 17 is applied to an ester-exchange reaction or hydrolyzed with a proper base catalyst to give the compound of the present invention. This step may be carried out in the same manner as in Step 18.
- In the reaction scheme, Ri, R2, R3, R4 and R5 each is the same as defined in the general formula (I). R6 is straight or branched C1-C6 alkyl, C3-C8 cycloalkyl, substituted or unsubstituted benzyl ( e.g., benzyl, 2-chlorobenzyl, 2,4,6-trimethylbenzyl, 2-methoxybenzyl, 2,4-dimethoxybenzyl, 3,4-dimethoxybenzyl), or the like. R7 is alkanoyl, e.g., acetyl, propionyl, benzoyl, substituted benzoyl ( e.g., 3-methylbenzoyl, 4-phenylbenzoyl, 2,4-dihydrobenzoyl, 2-nitrobenzoyl), 1-naphthoyl, 2-naphthoyl, or the like.
- The following Examples are included to explain the embodiments of the present invention in more detail.
- All the compounds described in the following Examples are optically active substances which have the absolute configuration defined in the reaction formulae. The absolute configuration of the starting material is designated by the R and S denotations, which, however, are omitted in the subsequent intermediates and final products in the Examples, since the original configuration is retained to the final product.
- The abbreviation for phenyl is Ph, methyl is Me, ethyl is Et, and tert-butyl is tBu or But.
-
- In an atmosphere of nitrogen, 5.52 g (45.24 mmol) of 4-dimethylaminopyridine and 9.51 g (34.72 mmol) of tert-butyldiphenylsilyl chloride are added to a solution of 3.03 g (11.30 mmol) of (1 S,5R,6R,7R)-2-oxa-3-oxo-6-[(3S)-3-hydroxyoct-1-enyl]-7-hydroxybicyclo[3.3.0]octane 1 in 90 ml of dry N,N-dimethylformamide, and the mixture is allowed to stand at room temperature for 3 days. The reaction mixture is poured into ice water, then extracted with ethyl acetate three times. The extract is washed with water and dried over anhydrous magnesium sulfate and evaporated to give 13.73 g of a residue, which is purified by column- chromatography (300 g of silica gel, eluted with benzene - benzene/ethyl acetate = 20/1 ) to give 8.40 g of the compound 2 as an oil (quantitative yield).
- MS : m/z 744(M+), m/z 687(M+-tBu).
- [α]D - 25.2±1.3 ° (23.5 ° C, c = 0.511, CHCl3).
- IR: v max(CHCl3) 3080, 1768, 1592, 1112, 1082 cm-1.
- NMR: δ ppm(CDCl3) 0.80(3H), 1.01(18H, s), 3.75-4.15(2H, m), 4.75 (1H, m), 4.8-5.35(2H, m), 7.1-7.8(20H, m).
-
- In an atmosphere of nitrogen, a mixture of 6.365 g (8.55 mmol) of the lactone 2 (prepared in Example I-1), 844 mg (8.77 mmol) of 2-hydroxypyridine, and 15 g (89.8 mmol) of 2, 4-dimethoxybenzylamine is stirred on an oil bath at 100 °C for 2 hours and 10 minutes, and then allowed to stand at room temperature overnight. The reaction mixture is poured into a saturated aqueous solution of sodium chloride and extracted with ethyl acetate twice. The extract is washed successively with 1N hydrochloric acid, a saturated aqueous solution of sodium chloride, a dilute aqueous solution of sodium hydrogencarbonate, and a saturated aqueous solution of sodium chloride, dried over anliydrous magnesium sulfate and evaporated to give 12.65 g of residue, which is purified by column chromatography (260 g of silica gel, benzene : ethyl acetate = 50 : 1 - 5 : 1) to give 7.32 g of the compound 3 as an oil (94 % yield).
- MS: m/z 912(MH+), m/z 854(M+-tBu).
- [α]D + 1.5±0.8 ° (23.5 ° C, c = 0.500, CHCl3
- IR: v max(CHCl3) 3450, 3075, 3005, 1650, 1616, 1590, 1508, 1111, 1036 cm-1.
- NMR: δ ppm(CDCl3) 0.79(3H), 1.02(18H, s), 3.78(6H, s), 3.7-4.3 (2H, m), 4.32(2H, d, J=6Hz), 5.25(2H, m), 5.98(1 H, t, J = 6Hz), 6.45(2H, m), 7.1-7.8(21 H, m).
-
- To 1.79 g (2.40 mmol) of the lactone 2 (prepared in Example 1-1) are added 10 ml of methanol and 55 ml of saturated methanol solution of ammonia, and the mixture is heated in an autoclave at 100 °C for 27 hours. After cooling, the reaction mixture is evaporated to give 2.80 g of residue, which is purified by column chromatography (20 g of silica gel; eluted with benzene - benzene:ethyl acetate = 1:1) to give 530 mg of the starting material lactone 2 (30 % yield) and 1.12 g of the oily compound 4 (61 % yield).
- MS: m/z 704(M+-tBu).
- [α]D + 2.2±0.5 ° (25 ° C, C = 0.820, CHCl3).
- IR: v max(CHCl3) 3535, 3510, 3425, 3082, 3005, 1675, 1593, 1113 cm-1.
- NMR: δ ppm(CDCl3) 0.80(3H), 1.02(18H, s), 3.8 -4.25(3H, m), 5.23 (2H, m), 5.78(2H, br.s), 7.15-7.75(20H, m).
- Preparation of N-(2,4-dimethoxybenzyl)-[3-((3S)-3-tert-butyldiphenylsilyloxyoct-1-enyl)-4-tert-butyldiphenylsilyloxycyclopentan-1-on-2-yl]-acetoamide 5 and N-(2, 4-dimethoxybenzyl)-1-hydroxy-2-aza-3-oxo-6-[(3S)-3-tert-butyldiphenylsilyloxyoct-1-enyl]-7-tert-butylphenylsilyloxybicyclo[3.3.0]octane 6.
- In an atmosphere of nitrogen, a solution of 2.47 g (19.49 mmol) of oxalyl chloride in 100 ml of dry dichloromethane is cooled to -60 ° C, then a solution of 3.19 g (40.83 mmol) of dimethylsulfoxide in 11 ml of dry dichloromethane is dropwise added thereto under Stirring over a 6 minute period, and the mixture is stirred at the same temperature for 30 minutes. A solution of 7.32 g (8.03 mmol) of the alcohol (prepared in Example 1-2) and 4.21 g (41.62 mmol) of triethylamine in 150 ml of dry dichloromethane is added dropwise to the above mixture over a 50 minute period, and the resulting mixture is stirred at the same temperature for additional 1 hour. After the reaction mixture is brought to room temperature, water is added and the reaction mixture is acidified with 1 N hydrochloric acid, and extracted with dichloromethane three times. The extract is washed with water, dried over anhydrous magnesium sulfate and evaporated to give 7.52 g of residue, which is crystallized from a mixture of ethyl ether and n-pentane to give 4.87 g of the compound 5 (67 % yield). The mother liquor (2.53 g) is applied to column chromatography (Merck; Lober column size C; eluted with benzene; ethyl acetate = 9:1-3:1) to give further 1.97 g of the compound 5 (27 % yield) and 143 mg of the compound 6 (2 % yield). The crude product 5 is recrystallized from a mixture of ethyl ether and n-pentane to give the compound 5 as crystals, mp. 97-98 ° C.
- MS: m/z 852(M+-tBu).
- [α]D-23.1±1.2° (23.5°C, C=0.510, CHCl3).
- IR: v max(CHCl3) 3450, 3075, 3005, 1741, 1670, 1617, 1592, 1509, 1112 cm-1.
- NMR: δ ppm(CDCl3) 0.81 (3H), 1.02(18H, s), 3.75(3H, s), 3.76(3H, s), 4.0(2H, m), 4.30(2H, d, J = 6Hz), 5.35-(2H, m), 5.82(1 H, t, J = 6Hz), 6.42(2H, m), 7.05-7.8(21 H, m).
-
- [α]D - 5.2±0.9 ° (24 ° C, c = 0.517, CHCl3).
- IR: v max(CHCl3) 3460, 3075, 3005, 1678, 1616, 1591, 1508, 1112, 1042 cm-1.
- NMR: δ ppm(CDCl3) 0.80(3H), 0.98(9H, s), 1.04 (9H, s), 3.68(3H, s), 3.73(3H, s), 4.07(2H, m), 4.19(1 H, d, J =15Hz), 4.47(1 H, d, J =15Hz), 5.41 (2 H, m), 6.41 (2H, m), 7.2-7.75(21 H, m).
- Preparation of [3-((3S)-3-tert-butyldiphenylsilyloxyoct-1-enyl)-4-tert-butyldiphenylsilyloxycyclopentan-1-on-2-yl]-acetoamide 7 and 1-hydroxy-2-aza-3-oxo-6-[(3S)-3-tert-butyldiphenylsilyloxyoct-1-enyl]-7-tert-butyl- diphenylsilyloxybicyclo[3.3.0]octane 8
-
- To a solution of 1.583 g (1.74 mmol) of N-benzylamide 5 (prepared in Example 1-4) in 60 ml of dichloromethane/ water (19:1) mixture is added 595 mg (2.62 mmol) of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone and the mixture is stirred at room temperature for four and half hours. The reaction mixture is poured into water and extracted with dichloromethane three times. The extract is successively washed with 1 N sodium thiosulfate and water, dried over anhydrous magnesium sulfate and evaporated to give 1.92 g of residue, which is applied to column chromatography (45 g of silica gel; eluted with benzene : ethyl acetate = 20:1 - ethyl acetate) to give 1.152 g of a mixture of keto-amide 7 and hydroxy-lactam 8. (This mixture may he applied to the following reaction without further purification.) Further, this mixture is purified by column chromatography (Lober column size B; eluted with benzene : ethyl acetate = 3:1 - ethyl acetate) to give 751 mg of the compound 7 as a foamy material (57 % yield) and 322 mg of the compound 8 as a foamy material (24 % yield).
-
- A solution of 317 mg (0.416 mmol) of the hydroxy-amide 4 (prepared in Example 1-3) in 10 ml of acetone is cooled to -20 ° C, then 0.52 ml (0.624 mmol) of 1.2 M Jones' reagent is added thereto under stirring over a 5 minute period, and the mixture is stirred at the same temperature for 5 hours and 45 minutes. Then, 0.5 ml of isopropanol is added, and further, the mixture is stirred at room temperature for 30 minutes. The reaction mixture is brought to room temperature and water is added, and then the mixture is neutralized with a dilute aqueous solution of sodium hydrogencarbonate and extracted with ethyl acetate three times. The extract is washed with water, dried over anhydrous magnesium sulfate and evaporated to give 327 mg of the residue, which is purified by column chromatography (Lober column size B; eluted with benzene : ethyl acetate = 4:1) to give 253 mg of the compound 7 as a foamy material (80 % yield).
- Keto-amide 7:
- MS: m/z 759(M+), 702(M+-tBu).
- [α]D - 30.8±0.7 ° (22 ° C, c = 1.007, CHCl3).
- IR: v max(CHCl3) 3530, 3415, 3075, 3005, 1741, 1688, 1590, 1111 cm-1.
- NMR: 6 ppm(CDCl3) 0.81(3H), 1.02(9H, s), 1.04 (9H, s), 4.07(2H, m), 5.46(4H, m), 7.0-7.8(20H, m).
- Hydroxy-lactam 8:
- MS: m/z 741(M+-H20), 702(M+-tBu).
- [α]D - 4.4±0.6 ° (22.5 ° C, c = 0.726, CHCl3).
- IR: v max(CHCl3) 3590, 3430, 3080, 3010, 1693, 1591, 1112 cm-1.
- NMR: δ ppm(CDCl3) 0.80(3H), 1.00(9H, s), 1.03(9H, s), 4.03(2H, m), 5.30(2H, m), 6.75(1 H, m), 7.0-7.8(20H, m).
- Preparation of 1-trimethylsilyloxy-2-aza-3-oxo-6-[(3S)-3-tert-butyldiphenylsilyloxyoct-1-enyl]-7-tert-butyl- diphenylsilyloxybicyclo[3.3.0]octane 9
- (1) From the keto- amide 7.
- To a solution of 649mg (0.855mmol) of the keto-amide 7 (Example 1-5) dissolved in 14ml of a mixture of dried dichloromethane and dried pyridine (1:1) under a nitrogen atmosphere are added 1.05g (8.60 mmol) of 4-dimethylaminopyridine and 470mg (4.33 mmol) of trimethylsilyl chloride and the mixture is stirred for 3 hrs on an oil bath at 70 ° C. After cooling, the reaction mixture is concentrated, poured into ice water, and extracted 3 times with ethyl acetate. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 1.20g of residue.
- The residue is refined by column chromatography (silica gel 40g, benzene : ethyl acetate (15:1) - ethyl acetate) to provide 560mg (79% yield) of the compound 9 and 83mg (13% yield) the hydroxylactam 8.
-
- To a solution of 2.63g (3.465 mmol) of a mixture of the keto-amide 7 and the hydroxy-lactam 8 - (Example 1-5) dissolved in 60ml of a mixture of dry dichloromethane and dry pyridine (1:1) in a nitrogen atmosphere are added 4.24g (34.70 mmol) of 4-dimethylaminopyridine and 1.88g (17.41 mmol) of trimethylsilyl chloride and the mixture is stirred for 5 hrs on an oil bath at 70 ° C. After cooling, the reaction mixture is concentrated, poured into ice water, and extracted 3 times with ethyl acetate. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 3.77g of residue. The residue is refined by column chromatography (silica gel 120g, benzene : ethyl acetate (15:1)) to provide 2.61 g of compound 9 as a foamy material (90% yield).
- MS : m/z 831 (M+), m/z 774 (M+-tBu).
- [α]D -11.1 ± 0.9 ° (22.5 ° C, C = 0.591, CHCl3).
- IR : v max (CHCl3) 3430, 3075, 3005, 1703, 1591, 1111, 843 cm-1.
- NMR : 6 ppm (CDCl3) 0.0(9H, s), 0.80(3H), 1.01 (9H, s), 1.04(9H, s), 4.04(2H, m), 5.34(2H, m), 6.83(1 H, s), 7.1-7.8 (20H, m).
-
- In a nitrogen atmosphere, 1.80 g (16.3 mmol) of thiophenol and 0.3 ml of 3N ethyl ether solution of hydrogen chloride are added to a solution of 2.676 g (3.22 mmol) of the trimethylsilyloxy-lactam 9 (Example 1-6) in 30 ml dry ethyl ether and the mixture is stirred at room temperature for 2 hours. The reaction mixture is neutralized with powder sodium hydrogencarbonate and evaporated. The residue is purified by column chromatography (50 g of silica gel; eluted with benzene-benzene : ethyl acetate = 2 : 1) to give 2.721 g of the compound 10(S)a as a foamy material (99 % yield).
- MS : m/z 794 (M+-tBu), m/z 742 (M+-PhS).
- [α]D + 24.8 ± 0.6 ° (23.5 ° C, c = 1.015, CHCl3).
- IR : v max (CHCl3) 3435, 3090, 3020, 1704, 1594, 1115 cm-1.
- NMR : δ ppm (CDCl3) 0.80(3H), 1.00(9H, s), 1.05(9H, s), 4.10(2H, m), 5.38(2H, m), 6.60(1 H, s), 7.1-7.8(25H, m).
- Preparation of 1-methoxy-2-aza-3-oxo-6-[(3S)-3-tert-butyldiphenylsilyloxyoct-1-enyl]-7-tert-butyldiphenylsilyloxybicyclo[3.3.0]octane 10(S)b
- (1) From hydroxy-lactam 8
- In 7 ml of methanol solution of hydrochloric acid (1 N hydrochloric acid (1 ml) is dissolved in 50 ml of methanol) is dissolved 260 mg of the hydroxy-lactam 8 (Example 1-5) and the mixture is stirred at room temperature for 1 hour and 40 minutes. The reaction mixture is neutralized with dilute aqueous solution of sodium hydrogencarbonate and then methanol is evaporated. The residue is poured into water and extracted 3 times with dichloromethane, and the extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 260 mg of residue, which is purified by column chromatography (10 g of silica gel, benzene : ethyl acetate = 15 : 1-4 : 1) to give 230 mg of the compound 10(S)b (87 % yield).
-
- (2) From trimethylsilyloxy-lactam 9.
- In 10 ml of methanol solution of hydrochloric acid (1 N hydrochloric acid (1 ml) is dissolved in 50 ml of methanol.) is dissolved 435 mg of the trimethylsilyloxy-lactam 9 (Example 1-6) and the mixture is stirred at room temperature for 55 minutes. Then, the reaction mixture is treated in the same manner as in Example 1-8-(1) to give 400 mg of residue, which is purified by column chromatography (15 g of silica gel, benzene : ethyl acetate = 4 : 1) to give 283 mg of the compound 10(S)b as a foamy material (95 % yield).
- MS : m/z 773 (M+), m/z 741 (M+-CH3OH), 716 (M+-tBu).
- [α]D - 3.2 ± 0.6 ° (22.5 ° C, c = 0.786, CHCl3).
- IR : v max (CHCl3) 3425, 3075, 3005, 1704, 1591, 1112 cm-1.
- NMR : δ ppm (CDCl3) 0.81 (3H), 1.01 (9H, s), 1.04(9H, s), 3.01 (3H, s), 4.03(2H, m), 5.33(2H, m), 6.77(1 H, s), 7.1-7.8 (20H, m).
-
- To a solution of 5.81 g (6.39 mmol) of the keto-amide 5 (Example 1-4) dissolved in 100 ml of a mixture of dry dichloromethane and dry pyridine (1:1) are added 7.87g (64.42 mmol) of 4-dimethylaminopyridine and 3.51 g (32.44 mmol) of trimethylsilyl chloride in a nitrogen atmosphere and the mixture is stirred for two and half hours on an oil bath at 70 °C. After cooling, the reaction mixture is poured into iced water, and extracted 3 times with ethyl acetate. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 8.77 g of residue. The residue is refined by column chromatography (silica gel 200 g, benzene : ethyl acetate (30:1)) to provide 5.911 g of the compound 11 as an oil (94% yield).
-
- To a solution of 50 mg (0.055mmol) of the hydroxy-lactam 6 (Example 1-4) dissolved in 1 ml of a mixture of dry dichloromethane and dry pyridine (1:1) are added 68 mg (0.556 mmol) of 4-dimethylaminopyridine and 30 mg (0.277 mmol) of trimethylsilyl chloride in a nitrogen atmosphere and the mixture is stirred for 2 hrs on an oil bath at 70 °C. Then, the reaction mixture is treated in the same manner as in Example l-9-(1 ) to give 64 mg of residue, which is purified by column chromatography (3 g of silica gel; eluted with benzene : ethyl acetate = 30 : 1) to give 54 mg of the compound 11 (quantitative yield). MS : m/z 981 (M+), m/z 924 (M+-tBu).
- [α]D + 11.0 ± 1.0 ° (20 ° C, c = 0.510, CHCl3).
- IR : v max (CHCl3) 3072, 3004, 1682, 1615, 1591, 1507, 1113, 842 cm-1.
- NMR : δ ppm (CDCl3) -0.14 (9H, s), 0.79 (3H), 0.93 (9H, s), 1.05 (9H, s), 3.68 (3H, s), 3.73 (3H, s), 3.90 (1 H, m), 4.13 (1 H, m), 4.26 (1 H, d, J = 15Hz), 4.39 (1 H, d, J = 15Hz), 5.41 (2H, m), 6.36 (2H, m), 7.1-7.75 (21 H, m).
-
- To a solution of 2.02 g (2.06 mmol) of the trimethylsilyloxylactam 11 (Example 1-9) in 20 ml of dry ethyl ether are added 1.18 g (10.71 mmol) of thiophenol and 0.2 ml of 3N ethyl ether solution of hydrogen chloride in a nitrogen atmosphere, and the mixture is stirred at room temperature for 45 minutes. The reaction mixture is neutralized with powder sodium hydrogencarbonate and evaporated. The residue is purified by column chromatography (Lober column size B (two columns); eluted with cyclohexane : ethyl acetate = 5 : 1) to give 1.83 g of the compound 12a as a foamy material (89 % yield).
- MS : m/z 944 (M+-tBu), m/z 892 (M+-PhS).
- [a]o + 42.2 ± 1.6° (20°C, C=0.51, CHCl3).
- IR : v max (CHCl3) 3072, 3004, 1682, 1615, 1591, 1508, 1112 cm-1.
- NMR : δ ppm (CDCl3) 0.77 (3H), 0.92 (9H, s), 1.04 (9H, s), 3.71 (3H, s), 3.75 (3H, s), 4.05 (2H, m), 4.61 (1 H, d, J = 15Hz), 4.75 (1 H, d, J = 15Hz), 5.40 (2H, m), 6.43 (2H, m), 7.1-7.7 (26H, m).
-
- In an atmosphere of argon, 185 mg (0.185 mmol) of the phenylthio-lactam 12a (Example 1-10) is dissolved in 7 ml of dry chloroform and 1 ml (2 mmol) of 2M n-hexane solution of diethyl zinc is added thereto, and then the mixture is stirred in a tightly closed vessel on an oil bath at 80 ° C for 2 hours. After cooling, the reaction mixture is poured into iced water and a saturated aqueous solution of ammonium chloride is added. The mixture is extracted 3 times with dichloromethane and the extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 204 mg of residue, which is purified by column chromatography (Lober column size B; eluted with cyclohexane : ethyl acetate = 3 : 1) to give 109 mg of the compound 12d as an oil (64 % yield) and 57 mg of N-(2,4-dimethoxybenzyl)-2-aza-3-oxo-6-[-(3S)-3-tert-butyldiphenylsilyloxyoct-1-enyl]-7-tert-butyldiphenylsilyloxybicyclo[3.3.0]octane 12c as an oil (34.5 % yield).
- Compound 12d
- MS : m/z 922 (MH+), m/z 864 (M+-tBu).
- [α]D+ 7.5 ± 0.8° (20 ° C, C = 0.610, CHCl3).
- IR : v max (CHCl3) 3072, 3004, 1661, 1615, 1591, 1507, 1111 cm-1.
- NMR : δ ppm (CDCl3) 0.40 (3H, t, J=7Hz), 0.79 (3H), 0.94 (9H, s), 1.04 (9H, s), 3.68 (3H, s), 3.78 (3H, s), 3.80 (1 H, m), 4.15 (1 H, m), 4.22 (1 H, d, J = 15Hz), 4.38 (1 H, d, J =15Hz), 5.40 (2H, m), 6.40 (2H, m), 7.15-7.8 (21 H, m).
- Compound 12c
- MS : m/z 894 (MH+), m/z 836 (M+-tBu).
- [α]D - 29.7 ± 2.3 ° (20 ° C, c = 0.30, CHCl3).
- IR : v max (CHCl3) 3072, 3004, 1668, 1614, 1590, 1508, 1112 cm-1.
- NMR : δ ppm (CDCl3) 0.79 (3H), 1.01 (18H, s), 3.52 (1H, m), 3.67 (3H, s), 3.76 (3H, s), 3.96 (1H, d, J = 14.5Hz), 4.00 (2H, m), 4.74 (1 H, d, J = 14.5Hz), 5.27 (2H, m), 6.38 (2H, m), 7.05-7.8 (21 H, m).
-
In an atmosphere of argon, 905 mg (0.904 mmol) of the compound 12a (Example I-10) is dissolved in 30 ml of dry chloroform and 30 ml (60 mmol) of 2M n-hexane solution of dimethyl zinc is added thereto, and then the mixture is stirred in a tightly closed vessel on an oil bath at 80 ° C for 17 hours. After cooling, the reaction mixture is poured into iced water and a saturated aqueous solution of ammonium chloride is added. The mixture is extracted 3 times with dichloromethane and the extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 970 mg of residue, which is purified by column chromatography (Lober column size B; eluted with benzene : ethyl acetate = 15 : 1) to give 742 mg of the compound 12e as an oil (90.5 % yield). - MS : m/z 908 (MH+), m/z 850 (M+-tBu).
- [α]D - 7.2 ± 0.9 ° (20 ° C, c = 0.557, CHCl3).
- IR : v max (CHCl3) 3072, 3004, 1663, 1615, 1591, 1507, 1113 cm-1.
- NMR : 6 ppm (CDCl3) 0.79 (3H), 0.88 (3H, s), 0.95 (9H, s), 1.03 (9H, s), 3.70 (3H, s), 3.75 (3H, s), 3.82 (1 H, m), 4.12 (1 H, m), 4.35 (2H, s), 5.35 (2H, m), 6.40 (2H, m), 7.1-7.8 (21 H, m).
-
- In an atmosphere of argon, 3.19 g (32.5 mmol) of trimethylsilylacetylene is dissolved in 45 ml of dry tetrahydrofuran and the solution is cooled in an ice water bath and 18 ml (30.6 mmol) of 1.7 N n-hexane solution of n-butyl lithium is dropwise added in small portions thereto. The mixture is stirred at the same temperature for 30 minutes, then 0.68 M tetrahydrofuran solution of zinc chloride is added to adjust it to around neutral (added about 32 ml), and the mixture is stirred at the same temperature for additional 15 minutes. Subsequently, the reaction vessel is tightly closed and the mixture stirred on an oil bath at 60 ° C for 1 hour. The solvent is evaporated and to the residue is added a solution of 3.00 g (3.0 mmol) of the compound 12a (Example 1-10) in 100 ml of dry xylene. The mixture is stirred in a tightly closed vessel on an oil bath at 140 ° C for 30 minutes. After cooling, the reaction mixture is poured into a saturated aqueous solution of ammonium chloride and extracted 3 times with dichloromethane, and the extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 3.50 g of residue, which is purified by column chromatography (Lober column size C; eluted with benzene : ethyl acetate = 20 : 1) to give 2.49 g of the compound 12f as an oil (84 % yield).
- MS : m/z 989 (M+), m/z 932 (M+-tBu).
- [α]D - 19.2 ± 1.1 ° (20 ° C, c = 0.562, CHCl3).
- IR : v max (CHCl3) 3072, 3004, 2164, 1675, 1615, 1591, 1508, 1112, 844 cm-1.
- NMR : δ ppm (CDCl3) 0.03 (9H, s), 0.79 (3H), 0.97 (9H, s), 1.04 (9H, s), 3.70 (3H, s), 3.74 (3H, s), 4.00 (2H, m), 4.43 (1 H, d, J = 15Hz), 4.54 (1 H, d, J = 15Hz), 5.36 (2H, m), 6.33 (2H, m), 7.1-7.8 (21 H, m).
-
- To a solution of 1.743 g (15.53 mmol) of 1-trimethylsilylpropyne in 25 ml of dry tetrahydrofuran is dropwise added 7.6 ml (12.16 mmol) of 1.6 M ethyl ether solution of methyl lithium - lithium bromide complex in small portions in an atmosphere of argon, and the mixture is stirred at room temperature for 3 hours to become a white suspension. This suspension is cooled with ice water, and 0.69 M tetrahydrofuran solution of zinc chloride is added in order to adjust it to around neutral (added about 15 ml). The mixture is stirred at the same temperature for 15 minutes to become a solution, which is then stirred in a tightly closed state on an oil bath at 60 ° C for an hour, and then evaporated. To the residue is added a solution of 1.20 g (1.2 mmol) of the compound 12a (Example 1-10) in 50 ml of dry xylene and the mixture is stirred in a tightly closed vessel on an oil bath at 140 ° C for one and half hours. After cooling, the reaction mixture is poured into a saturated aqueous solution of ammonium chloride and extracted 3 times with dichloromethane, and the extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 1.61 g of residue, which is purified by column chromatography (Lober column size B (2 columns); eluted with benzene : ethyl acetate = 20 : 1) to give 887 mg of the compound 12h as an oil (79.5 % yield).
- MS : m/z 931 (M+), m/z 874 (M+-tBu).
- [α]D - 18.8 ± 1.1 ° (25 °C, C = 0.537, CHCl3).
- IR : v max(CHCl3) 3072, 3004, 1673, 1615, 1591, 1508, 1113 cm-1.
- NMR : 6 ppm (CDCl3) 0.79 (3H), 0.94 (9H, s), 1.03 (9H, s), 1.58 (3H, s), 3.71 (3H, s), 3.75 (3H, s), 4.05 (2H, m), 4.46 (2H, s), 5.36 (2H, m), 6.37 (2H, m), 7.15-7.75 (21 H, m).
-
- In an atmosphere of argon, 1.11 g (1.08 mmol) of phenylacetylene is dissolved in 2 ml of dry tetrahydrofuran, and the solution is cooled in an ice water bath, and then 0.64 ml (0.998 mmol) of 1.56 N n-hexane solution of n-butyl lithium is dropwise added thereto. The mixture is stirred at the same temperature for 35 minutes, then 0.68 M tetrahydrofuran solution of zinc chloride is added to adjust it to around neutral (added about 0.97 ml), and further, the mixture is stirred at the same temperature for 5 minutes. Then, the reaction mixture is stirred in a tightly closed state on an oil bath at 60 ° C for about 1 hour. The solvent is evaporated and to the residue is added a solution of 100 mg (0.10 mmol) of the compound 12a (Example I-10) in 5 ml of dry xylene. The mixture is stirred in a tightly closed vessel on an oil bath at 140 °C for 30 minutes. After cooling, the reaction mixture is poured into a saturated aqueous solution of ammonium chloride and extracted with dichloromethane twice, and the extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 126 mg of residue, which is purified by column chromatography (Lober column size A; eluted with benzene : ethyl acetate = 10 : 1) and thin layer chromatography (Merck, precoating plate, size 20 x 20, thickness 0.25 mm, 5 sheets; eluted with benzene : ethyl acetate = 15 : 1) to give 85 mg of the compound 12i as a foamy material(85 % yield),
- MS : m/z 993 (M+), m/z 936 (M+-tBu).
- [α]D- 51.3 ± 1.8° (24°C, C=0.518, CHCl3).
- IR : v max (CHCl3) 3072, 3004, 1674, 1615, 1591, 1508, 1113 cm-1.
- NMR : 6 ppm (CDCl3) 0.77 (3H), 0.97 (9H, s), 1.01 (9H, s), 3.67 (3H, s), 3.70 (3H, s), 3.85-4.25 (2H, m), 4.55(2H, s), 5.40 (2H, m), 6.35 (2H, m), 7.05-7.8 (26H, m).
-
- In 3 ml of a chloroform - water (19 : 1) mixture is dissolved 109 mg (0.118 mmol) of the N-benzyl-lactam 12d, and 55 mg (0.242 mmol) of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone is added thereto. The mixture is refluxed by heating for 1 hour under stirring, then additional 55 mg (0.242 mmol) of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone is added, and the mixture is refluxed by heating for additional 2 and half hours. After cooling, the reaction mixture is poured into water and extracted 3 times with dichloromethane, and the extract is washed with 1 N sodium thiosulfate aqueous solution and with water successively, dried over anhydrous magnesium sulfate and evaporated to give 138 mg of residue, which is purified by column chromatography (Lober column, size A (2 columns); eluted with benzene : ethyl acetate = 4 : 1) to give 58 mg of the compound 10(S)d as a foamy material (64 % yield).
-
- In the same manner as in Example I-11, 1.10 g of the phenylthio-lactam 10a is allowed to react with diethyl zinc to give foamy materials, that is, 548 mg of the compound 10(S)d (55 % yield), 190 mg of 2-aza-3-oxo-6-[(3S)-3-tert-butyldiphenylsilyloxyoct-1-enyl]-7-tert-butyldiphenylsilyloxybicyclo[3.3.0]octane 10(S)c - (20% yield), and 69 mg of the compound 8 (7 % yield). In addition, the compound 10 (S)c can also be prepared from the compound 12(S)c (Example I-11 ) on the reaction with 2, 3-dichloro-5, 6-dicyano-1, 4-benzoquinon in chloroform -water (19 : 1) mixture by refluxing under heating.
- Compound 10(S)d
- MS : m/z 771 (M+), m/z 714 (M+-tBu).
- [α]D - 15.2 ± 1.0 ° (25 ° C, c = 0.533, CHCl3).
- IR : v max (CHCl3) 3435, 3085, 3010, 1687, 1591, 1113 cm-1.
- NMR : δ ppm (CDCl3) 0.69 (3H, t, J =7Hz), 0.80 (3H), 1.01 (9H,s), 1.04 (9H, s), 3.82 (1 H, m), 4.12 (1H, m), 5.32 (2H, m), 6.66 (1 H, s), 7.1-7.8 (20H, m).
- Compound 10(S)c
- MS : m/z 743 (M+), m/z 686 (M+-tBu).
- IR : v max (CHCl3) 3440, 3080, 3005, 1688, 1591, 1112 cm-1.
- NMR : δ ppm (CDCl3) 0.80 (3H), 1.03 (18H, s), 3.83 (2H, m), 4.10 (1H, m), 5.27 (2H, m), 6.76 (1H, s), 7.2-7.8 (20H, m).
- Removal of the benzyl group carried out in the same manner as in Example I-16-(1) affords the compounds shown in Table 1.
-
-
-
- To a solution of 2.94 g (15.12 mmol) of 1,4-bis(trimethylsilyl)-1,3-butadiynein 25 ml of dry tetrahydrofuran is dropwise added 7.6 ml (12.16 mmol) of 1.6 M ethyl ether solution of methyl lithium - lithium bromide complex in small portions in an atmosphere of argon and the mixture is stirred at room temperature for 3 hours. After cooling in an ice water bath, the reaction mixture is adjusted to around neutral with 0.68 M tetrahydrofuran solution of zinc chloride (added about 15.5 ml). The mixture is stirred in a tightly closed vessel on an oil bath at 60 °C for 1 hour and evaporated. A solution of 1.20 g (1.2 mmol) of the compound 12a (Example 1-10) in 50 ml of dry xylene is added to the residue and the mixture is stirred in a tightly closed state on an oil bath at 140 °C for 2 hours. After cooling, the reaction mixture is poured into a saturated aqueous solution of ammonium chloride and extracted 3 times with dichloromethane. The extract is washed with water, dried over anhydrous magnesium sulfate and evaporated to give 1.894 g of a residue, which is purified by column chromatography (Lober column size B (2 columns); eluted with benzene : ethyl acetate = 30 : 1) to give 952 mg of the compound 12j as a foamy material (78.5 % yield). MS: m/z 1014(MH+), m/z 956(M+-tBu).
- [α]D - 71.4±2.2 ° (23 ° C, c = 0.510, CHCl3).
- IR: ν max(CHCl3) 3072, 3004, 2220, 2100, 1679, 1615, 1591, 1508, 1113, 845 cm-1.
- NMR: 6 ppm(CDCl3) 0.15(9H, s), 0.80(3H), 0.96(9H, s), 1.04(9H, s), 3.72(3H, s), 3.76(3H, s), 3.85-4.2(2H, m), 4.49(2H, s), 5.32(2H, m), 6.37(2H, m), 7.15-7.8(21 H, m).
-
- Removal of the benzyl group carried out in the same manner as in Example I-16-(1) using 2,3-dichloro-5,6-dicyano-1, 4-benzoquinon affords 563 mg of the compound 10(S)j as a foamy material in 69.5 % yield from 948 mg of N-benzyl-lactam 12j (Example 1-21).
- MS: m/z 806(M+-tBu).
- [α]D - 7.9±1.0 ° (25° C, c = 0.500, CHCl3).
- IR: ν max(CHCl3) 3428, 3072, 3004, 2224, 2100, 1698, 1590, 1112, 845 cm-1.
- NMR: δ ppm(CDCl3) 0.17(9H, s), 0.81 (3H), 1.00(9H, s), 1.03(9H, s), 4.00(2H, m), 5.23(2H, m), 6.40(1 H, s), 7.2-7.7(20H, m).
-
- In an atmosphere of nitrogen, 900 mg (1.164 mmol) of 1-methoxy-2-aza-3-oxo-6-[(3S)-3-tert-butyldiphenylsilyloxyloct-1-enyl]-7-tert-butyldiphenylsilyloxybicyclo[3.3.0]octane 10(S)b (Example 1-8) is dissolved in 45 ml of dry dichloromethane, 744 mg (7.50 mmol) of cyanotrimethylsilane and 58 mg (0.41 mmol) of boron trifluoride etherate are added thereto, and the mixture is stirred at room temperature for 4 hours. A dilute aqueous solution of sodium hydrogencarbonate is added to the reaction mixture, which is then extracted 3 times with dichloromethane. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 960 mg of residue, which is purified by column chromatography (Merck; Lober column1 size B; eluted with benzene : ethyl acetate = 10 : 1) to give 660 mg of the compound 10(S)m as a foamy material (74 % yield).
- MS: m/z 768(M+), m/z 711 (M+-tBu)
- 3428, 2240, 1713, 1591, 1113 cm-1.
- 0.81 (3H), 1.00 (9H,s), 1.03 (9H,s), 4.00 (2H,m), 5.07 (1 H,dd, J = 15.5, 6.5Hz), 5.33 (1 H,dd,J =15.5, 5.5Hz), 7.04 (1 H,s), 7.15-7.7 (20H,m).
-
- In an atmosphere of nitrogen, 689 mg of 1-trimethylsilylethynyl-2-aza-3-oxo-6-[(3S)-3-tert-butyldiphenylsilyloxyoct-1-enyl]-7-tert-butyldiphenylsilyloxybicyclo[3.3.0]octane 10(S)f [Example I-18-(2)] is dissolved in 20 ml of dry methanol, then 20 mg of anhydrous potassium carbonate is added thereto, and the mixture is stirred at room temperature for 3 hours and 50 minutes. Water is added to the reaction mixture which is then extracted 3 times with dichloromethane. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 630 mg of residue, which is purified by column chromatography (20 g of silica gel; eluted with benzene : ethyl acetate = 10 : 1) to give 618 mg of the compound 10(S)g as a foamy material (98 % yield).
- MS: m/z 767 (M+), m/z 710 (M+-tBu).
° (C=0.514, CHCI3). - 3432, 3312, 1698, 1590, 1112 cm-1.
- 0.81 (3H), 1.01 (9H,s), 1.03 (9H,s), 2.30 (1 H,s), 4.05 (2H,m), 5.28 (2H,m), 6.40 (1 H,s), 7.2-7.75 (20H,m).
-
- To a solution of 507 mg (Example 1-24) of the ethynyl-lactam 10(S)g in 50 ml of benzene are added 0.5 ml of quinoline and 25 mg of 5 % palladium-barium sulfate and the mixture is stirred in an atmosphere of hydrogen at ordinary temperature and atmospheric pressure for 55 minutes. The insoluble material is removed by filtration and the filtrate is evaporated. The residue is dissolved in ethyl acetate and the resulting mixture is successively washed with 1 N hydrochloric acid, water, dilute aqueous solution of sodium hydrogencarbonate, and water, dried over anhydrous magnesium sulfate, and evaporated to give 524 mg of residue, which is purified by column chromatography (Lober column, size B; eluted with benzene : ethyl acetate = 5 : 1) to give 466 mg of the compound 10(S)I as a foamy material (91.5 % yield).
- MS: m/z 769 (M+), m/z 712 (M+-tBu).
-
-23.1±1.2°(c=0.507, CHCl3). - 3432, 1694, 1590, 1111 cm-1.
- 0.80 (3H), 1.03 (18H,s), 3.8- 4.2 (2H,m), 4.85 (1 H,d,J = 10.5Hz), 4.91 (1 H,d,J = 17Hz), 5.29 (2H,m), 5.57 (1 H, dd,J = 10.5, 17Hz), 6.26 (1 H,s), 7.2~ 7.75 (20H,m).
-
- To a solution of 684 mg (0.89 mmol) of the cyano-lactam 10(S)m (Example 1-23) in 40 ml of dry benzene are added 2.84 g (35.85 mmol) of pyridine and 1.80 g (4.55 mmol) of Lawesson's Reagent in an atmosphere of nitrogen and the mixture is stirred on an oil bath at 70 ° C for 1 hour and 45 minutes. After cooling, the reaction mixture is directly purified by column chromatography (70 g of silica gel; eluted with benzene) to give 637 mg of the compound 13(S)m as a foamy material (91 % yield).
- MS: m/z 784 (M+), m/z 727 (M+-tBu).
- 3400, 2240, 1591, 1472, 1113 cm-1.
- 0.82 (3H), 1.03 (18H,s), 4.03 (2H,m), 5.05 (1 H,dd,J = 15.5, 6.5Hz), 5.32 (1 H,dd,J =15.5, 5.5Hz), 7.15-7.7 (20H,m), 8.24 (1 H,s).
-
- In the same manner as in Example 1-26, 419 mg of the ethenyllactam 10(S)I (Example 1-25) is allowed to react to give 423 mg of the compound 13(S)I as a foamy material (99 % yield).
- MS: m/z 785 (M+), m/z 728 (M+-tBu).
- D-11.8±1.0° (C=0.502, CHCl3).
- 3400, 1590, 1485, 1112 cm-1
- 0.80 (3H), 1.04 (18H,s), 3.8- 4.2 (2H,m), 4.90 (1 H,d,J =17.5Hz), 4.92 (1 H,d,J = 10Hz), 5.27 (2H,m), 5.56 (1H,dd,J =17.5, 10Hz), 7.2-7.75 (20H,m), 8.00 (1 H,s).
-
- In an atmosphere of nitrogen, 11.40 g (66.21 mmol) of (1S,5R, 6S,7R)-2-oxa-3-oxo-6-hydroxymethyl-7-hydroxybicyclo[3.3.0]octane 21 is dissolved in 140 ml of dry N,N-dimethylformamide and 28.32 g (231.7 mmol) of 4-dimethylaminopyridine and 45.49 g (165.5 mmol) of tert-butyldiphenyl silyl chloride are added to the above solution, and the mixture is allowed to stand at room temperature for 2 days. The reaction mixture is poured into iced water and extracted 3 times with ethyl acetate. The extract is washed with water, dried over anhydrous magnesium sulfate and evaporated. The residue is applied to column chromatography (100 g of silica gel; eluted with benzene - benzene : ethyl acetate = 20 : 1) to give 50.48 g of the crude product as a pale yellow oil, (which may be applied to the following reaction without further purification). A portion (about 240 mg) of the crude product 22 is purified by thin layer chromatography (Merck; precoated plate, size 20 x 20 cm, thickness 0.5 mm, 10 sheets; developed with n-hexane : ethyl acetate = 4 : 1) to give 179 mg of the compound 22 as a foamy material, of which portion is recrystallized from n-pentane to give crystals, mp. 79 - 81 ° C.
- MS:m/z 591 (M+-tBu),
-
-20.7±1.3° (C=0.483, CHCl3). - 1769, 1592, 1114, 1087 cm-1.
- 0.97 (9H,s), 1.02 (9H,s), 3.40 (2H,m), 4.10 (1 H,m), 4.78 (1 H,m), 7.15-7.75 (20H,m).
-
- In an atmosphere of nitrogen, a mixture of 50.24 g (66.21 mmol) of the lactone 22 (Example 1-28), 2.52 g (24.68 mmol) of 2-hydroxypyridine, and 44.2 g (264.2 mmol) of 2,4-dimethoxybenzylamine is stirred on an oil bath at 100 ° C for 3 hours and 30 minutes, and further, allowed to stand at room temperature overnight. A saturated aqueous solution of sodium chloride and dichloromethane are added to the reaction mixture. After acidified with 1 N hydrochloric acid, the mixture is extracted 3 times with dichloromethane. The extract is washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and evaporated to give 59.9 g of residue, which is purified by column chromatography (350 g of silica gel; eluted with benzene - benzene : ethyl acetate = 4 : 1) to give 50.18 g of the crude product 23 as an oil (93 % yield).
- A portion of the crude product (about 230 mg) is further purified by thin layer chromatography (Merck; precoated plate, size 20 cm x 20 cm, thickness 0.5 mm, 8 sheets; eluted with benzene : ethyl acetate = 4 :
- 1) to give 208 mg of the compound 23 as a foamy material.
- MS:m/z, 815 (M+), m/z 758 (M+-tBu).
- [a]82 +6.5±0.9° (C=0.520, CHCl3).
- 3504, 3452, 1656, 1617, 1592, 1509, 1114, 1037 cm-1.
- 0.92 (9H,s), 1.01 (9H,s), 3.41 (2H,m), 3.76 (6H,s), 4.11 (2H,m), 4.32 (2H,m), 6.11 (1H,m), 6.40 (2H,m), 7.1-7.75 (21 H,m).
-
- In an atmosphere of nitrogen, a solution of 19.4 g (152.8 mmol) of oxalyl chloride in 200 ml of dry dichloromethane is cooled to -60 ° C and a solution of 23.92 g (306.7 mmol) of dimethylsulfoxide in 100 ml of dry dichloromethane is added dropwise thereto over 25 minute period under stirring. The mixture is stirred at the same temperature for 5 minutes. A solution of 49.95 g (61.2 mmol) of the alcohol 23 (Example 1-29) and 30.88 g (305.8 mmol) of triethylamine in 300 ml of dry dichloromethane is added dropwise to the reaction mixture over a 1 hour and 10 minute period and the resulting mixture is further stirred at the same temperature for 50 minutes. After the temperature of the reaction mixture is brought to room temperature, iced water is added. The mixture is acidified with 1 N hydrochloric acid and extracted 3 times with dichloromethane. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 48.7 g of the crude product 24 as a foamy material (97.5 % yield). This may be applied to the following reaction without further purification. A portion of crude product 24 (about 200 mg) is purified by column chromatography (Lobar column, size A, 2 columns; eluted with benzene : ethyl acetate = 8 : 1) to give 172 mg of the compound 24 as a foamy material.
- MS:"'/Z 813 (M+), m/z 756 (M+-tBu).
-
D-27.9±1.4° (C=0.502, CHCl3). -
3452, 1741, 1670, 1617, 1592, 1509, 1114, 1038 cm-1. - 0.97 (9H,s), 1.01 (9H,s), 3.6- 3.95 (2H,m), 3.76 (6H,s), 4.15-4.45 (3H,m), 5.88 (1H,m), 6.40 (2H,m), 7.05-7.75 (21 H,m).
-
- In an atmosphere of nitrogen, 48.5 g (59.58 mmol) of the keto-amide 24 (Example 1-30) is dissolved in 360 ml of dry dichloromethane and dry pyridine (1 : 1) mixture and 29.12 g (238.3 mmol) of 4-dimethylaminopyridine and 12.95 g (119.2 mmol) of trimethylsilyl chloride are added thereto. The mixture is stirred on an oil bath at 70 ° C for 1 hour and 20 minutes. After cooling, the reaction mixture is poured into ice water and extracted 3 times with dichloromethane. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 75 g of a residue, which is purified by column chromatography (250 g of silica gel; eluted with benzene - benzene : ethyl acetate = 15 : 1) to give 49.1 g of the product 25 (93 % yield). A portion of the product 25 is recrystallized from ethyl ether - n-pentane to give crystals, mp. 113.5 - 115.5 ° C.
- MS:m/z 885 (M+), m/z 828 (M+-tBu).
-
+3.0±0.9° (C=0.500, CHCI3). 1683, 1617, 1592, 1509, 1114, 1086, 844 cm-1. - -0.15 (9H,s), 0.91 (9H,s), 1.01 (9H,s), 3.45-3.85 (2H,m), 3.69 (3H,s), 3.75 (3H,s), 3.9-4.2 (1H,m), 4.26 (1 H,d,J = 15Hz), 4.43 (1 H,d, J = 15Hz), 6.40 (2H,m), 7.05-7.7 (21 H,m).
-
- To a solution of 48.89 g (55.17 mmol) of the trimethylsilyloxy-lactam 25 (Example 1-31) in 500 ml of dry ethyl ether are added 34.33 g (311 mmol) of the thiophenol and 5 ml of 3 N ethyl ether solution of hydrogen chloride in an atmosphere of nitrogen and the mixture is stirred at room temperature for 1 hour and 35 minutes. The reaction mixture is neutralized with powdery sodium hydrogencarbonate and evaporated. The residue is applied to column chromatography (300 g of silica gel, eluted with benzene - ethyl acetate) to give 50 g of crystals, which are recrystallized from ethyl ether - n-pentane to give 40.57 g of the crystals 26a, mp. 133 - 135 ° C (81 % yield). A portion of the crystals are further recrystallized from ethyl ether - n-pentane to give the crystals 26a, mp. 134.5 - 136 ° C.
- MS:m/Z 848 (M+-tBu), m/Z 796 (M+-PhS).
-
+24.1±1.3° (C=0.507, CHCl3). 1682, 1617, 1592, 1509, 1114 cm-1. - 0.92 (9H,s), 1.01 (9H,s), 3.45 -3.9 (2H,m), 3.70 (3H,s), 3.76 (3H,s), 4.1-4.45 (1 H,m), 4.62 (1 H,d,J = 15Hz), 4.77 (1 H,d,J = 15Hz), 6.45 (2H,m), 7.05- 7.6 (26H,m).
-
- In an atmosphere of argon, a solution of 46.9 g (477 mmol) of the trimethylsilylacetylene in 420 ml of dry tetrahydrofuran is cooled with ice water and 281 ml (449 mmol) of 1.6 N n-hexane solution of n-butyl lithium is dropwise added thereto over 1 hour period under stirring. The mixture is stirred at the same temperature for 30 minutes, then 0.68 M tetrahydrofuran solution of zinc chloride (about 440 ml) is added to adjust it to around neutral, and the mixture is stirred in a tightly closed vessel on an oil bath at 60 ° C for 1 hour. The solvent is evaporated, then a solution of 40.1 g (44.31 mmol) of the phenylthio-lactam 26a - (Example 1-32) in 1100 ml of dry xylene is added to the residue and the mixture is stirred in a tightly closed state on an oil bath at 140 ° C for 30 minutes. After the reaction mixture is cooled, saturated aqueous solution of ammonium chloride is added and the mixture is extracted with ethyl acetate twice. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 45.2 g of residue, which is purified by column chromatography (1.5 kg of silica gel; eluted with cyclohexane : ethyl acetate = 5 : 1) to give 28.06 g of the crude product 26f as an oil (71 % yield). A portion of the crude product 26f - (134 mg) is further purified by column chromatography (Lobar column, size A, 2 columns; eluted with cyclohexane : ether acetate = 4 : 1) to give 128 mg of the foamy compound 26f.
- MS:m/z 893 (M+), m/z 836 (M+-tBu).
- [α]21 D -12.1±1.0° (C=0.513, CHCl3). IR:ν CHCI, max
- 2164, 1673, 1617, 1592, 1510, 1114, 845 cm-1.
-
0.0 (9H,s), 0.94 (9H,s), 0.98 (9H,s), 3.58 (2H,m), 3.67 (3H,s), 3.73 (3H,s), 4.08 (1 H,m), 4.42 (1 H,d, J=15Hz), 4.53 (1 H,d,J = 15Hz), 6.35 (2H,m), 7.15-7.65 (21 H,m). -
- To a solution of 39.42 g (349 mmol) of 1-trimethysilylpropyne in 400 ml of dry tetrahydrofuran is added dropwise 178 ml (281 mmol) of 1.58 M ethyl ether solution of methyl lithium - lithium bromide complex in small portions in an atmosphere of argon, and the mixture is stirred at room temperature for 3 hours to become a white suspension. This suspension is cooled with iced water, and 0.72 M tetrahydrofuran solution of zinc chloride is added to adjust it to around neutral (added about 342 ml). It becomes a solution, which is stirred in a tightly closed state on an oil bath at 60 ° C for 1 hour, and evaporated. To the residue is added a solution of 25.43 g (28.1 mmol) of the phenylthiolactam 26a (Example 1-32) in 900 ml of dry xylene and the mixture is stirred in a tightly closed state on an oil bath at 140 ° C for 1 hour. After the reaction mixture is cooled, saturated aqueous solution of ammonium chloride is added. The mixture is extracted with ethyl acetate twice and the extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 39.1 g of residue, which is purified by column chromatography (750 g of silica gel; eluted with toluene - toluene : ethyl acetate = 12 : 1) to give 17.44 g of the crude product 26h as a foamy material (74 % yield). A portion of the crude product (240 mg) is further purified by thin layer chromatography (Merck; precoated plate, size 20 cm x 20 cm, thickness 0.5 mm, 9 sheets; eluted with n-hexane : ethyl acetate = 3 : 1) to give 233 mg of the compound 26h as a foamy material.
- MS: m/z 835 (M+), m/z 778 (M+-tBu).
-
-7.1±0.9° (c=0.504, CHCl3). - 1675, 1615, 1592, 1510, 1114 cm-1.
0.92 (9H,s), 0.98 (9H,s), 1.56 (3H,s), 3.45-3.8 (2H,m), 3.70 (3H,s), 3.75 (3H,s), 3.95-4.25 (1H,m), 4.49 (2H,m), 6.38 (2H,m), 7.1- 7.7 (21H,m). -
- To a solution of 24.98 g (27.97 mmol) of the silyl ether 26f (Example 1-33) in 300 ml of dry tetrahydrofuran is added 200 ml (200 mmol) of 1 M tetrahydrofuran solution of tetra-n-butylammonium fluoride in an atmosphere of nitrogen and the mixture is stirred at room temperature for 1 hour and 30 minutes. Saturated aqueous solution of ammonium chloride is added to the reaction mixture, which is then extracted with ethyl acetate twice. The extract is washed with saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and evaporated to give 31.22 g of residue, which is dissolved in ethyl acetate. The solution is washed with dilute aqueous solution of sodium hydrogencarbonate and then with saturated aqueous solution of sodium chloride. The aqueous layer is extracted with ethyl acetate twice and the extract is washed with saturated aqueous solution of sodium chloride. The combined organic layer is dried over anhydrous magnesium sulfate and evaporated to give 26.9 g of residue, which is purified by column chromatography (270 g of alumina: eluted with benzene : ethyl acetate = 1 : 1 -ethyl acetate : methanol = 20 : 1 - ethyl acetate : methanol = 1 : 1) to give 9.09 g of the product 27g (94 % yield). A portion of the product 27g is recrystallized from dichloromethane - ethyl ether to give the compound 27g, mp. 159 -160 ° C.
- MS:m/z 345 (M+).
-
+29.4±1.4° (c = 0.487, CHCl3). - 3624, 3440, 3312, 1678, 1617, 1592, 1510, 1159, 1131, 1038 cm-1.
- 2.39 (1 H,s), 3.65 (2H,m), 3.75 (3H,s), 3.77 (3H,s), 4.08 (1 H,m), 4.43 (1 H,d,J = 15Hz), 4.62 (1 H,d,J = 15Hz), 6.42 (2H), 7.2 (1 H).
-
- Removal of silyl groups carried out in the same manner as in Example 1-35 using 17.14 g of the silyl ether 26h (Example 1-34) affords 6.70 g of the compound 27h, mp. 126 -127.5 ° C, (91 % yield).
- MS: m/z 359 (M+).
-
-2.7±0.8° (C=0.512, CHCl3). - 3620, 3548, 3444, 1676, 1616, 1592, 1510, 1159, 1130, 1040 cm-1.
- 1.68 (3H,s), 3.5-3.9 (2H,m), 3.77 (3H,s), 3.80 (3H,s), 4.1 (1 H,m), 4.45 (1 H,d,J = 15Hz), 4.57 (1 H,d,J = 15Hz), 6.43 (2H), 7.22 (1 H).
-
- To a solution 9.09 g (26.35 mmol) of the diol 27g (Example 1-35) in 100 ml of dry dichloromethane are added a solution of 6.50 g (53.2 mmol) of 4-dimethylaminopyridine and 4.49 g (29.77 mmol) of tert-butyldimethylsilyl chloride in 44 ml of dry dichloromethane in an atmosphere of nitrogen and the mixture is allowed to stand at room temperature overnight. Saturated aqueous solution of sodium chloride is added to the reaction mixture, which is extracted with dichloromethane 3 times. The extract is successively washed with 1 N hydrochloric acid, water, dilute aqueous solution of sodium hydrogencarbonate, and water, dried over anhydrous magnesium sulfate, and evaporated to give 12.08 g of residue, which is purified by column chromatography (150 g of silica gel; eluted with benzene - benzene : ethyl acetate = 20 : 1 - benzene : ethyl acetate = 2 : 1) to give 8.89 g of the compound 28g (73.5 % yield), which is recrystallized from acetone - n-hexane to give the crystals, mp. 112 - 113 ° C.
- MS:m/z 459 (M+).
- 3532, 3312, 1684, 1617, 1592, 1510, 1159, 1130, 1086, 1039, 839 cm-1.
- 0.06 (6H,s), 0.88 (9H,s), 2.39 (1 H,s), 3.7 (2H,m), 3.75 (3H,s), 3.79 (3H,s), 4.08 (1 H,m), 4.41 (1 H,d, J = 15Hz), 4.69 (1 H,d,J = 15Hz), 6.40 (2H, m), 7.25 (1 H).
-
- The silylation carried out in the same manner as in Example 1-37 using 6.54 g of the diol 27h (Example 1-36) affords 4.53 g of the compound 28h (52.5 % yield), mp. 125 - 128 ° C.
- MS: m/z 473 (M+).
-
+5.5±0.9° (C=0.507, CHCl3). - 3536, 1679, 1616, 1591, 1510, 1158, 1127, 1085, 1039, 837 cm-1.
- 0.06 (6H,s), 0.88 (9H,s), 1.70 (3H,s), 3.55-3.85 (2H,m), 3.74 (3H,s), 3.78 (3H,s), 4.03 (1 H, m), 4.43 (1 H,d, J = 15Hz), 4.61 (1 H,d,J = 15Hz), 6.43 (2H), 7.24 (1 H).
-
- To a solution of 8.71 g (18.97 mmol) of the alcohol 28g (Example 1-37) in 200 ml of dry dichloromethane are added 6.95 g (56.89 mmol) of 4- dimethylaminopyridine and 8.48 g (37.96 mmol) of p-phenylbenzoyl chloride in an atmosphere of nitrogen and the mixture is stirred at room temperature for 1 hour and 30 minutes. Iced water is added to the reaction mixture, which is extracted three times with dichloromethane. The extract is successively washed with 1 N hydrochloric acid, water, dilute aqueous solution of sodium hydrogencarbonate, and water, dried over anhydrous magnesium sulfate, and evaporated to give 12.74 g of residue, which is purified by column chromatography (150 g of silica gel; eluted with benzene : ethyl acetate = 50 : 1 - benzene : ethyl acetate = 10 : 1) to give 12.03 g of the crude product 29g (99 % yield). A portion (177 mg) of the crude product 29g is further purified by column chromatography (5.5 g of silica gel; benzene : ethyl acetate = 50 : 1 - benzene : ethyl acetate = 20 : 1) to give 170 mg of the compound 29g as a foamy material.
- MS:m/z 639 (M+), m/z 582 (M+-tBu).
-
+16.1±1.1 ° (C=0.510, CHCl3). - 3312, 1712, 1682, 1613, 1592, 1510, 1278, 1269, 1127, 1117, 837 cm-1.
- 0.06 (6H,s), 0.88 (9H,s), 2.32 (1 H,s), 3.6-3.8 (2H), 3.63 (3H,s), 3.73 (3H,s), 4.50 (1 H,d,J = 15Hz), 4.59 (1 H,d, J = 15Hz), 5.32 (1 H,m), 6.25 (2H,m), 7.3- 7.65 (6H,m), 7.63 (2H,d,J = 8Hz), 7.94 (2H,d,J = 8Hz).
-
- The esterification carried out in the same manner as in Example 1-39 using 4.53 g of the alcohol 28h - (Example 1-38) affords 5.73 g of the compound 29h as a foamy material (93 % yield).
- MS: m/z 653 (M+), m/z 596 (M+-tBu).
-
+12.2±1.0° (c=0.510, CHCl3). - 1714, 1679, 1613, 1592, 1509, 1279, 1269, 1125, 1116, 1104, 838 cm-1.
- 0.06 (6H,s), 0.90 (9H,s), 1.69 (3H,s), 3.6-3.8 (2H), 3.64 (3H,s), 3.76 (3H,s), 4.47 (1 H,d,J = 15Hz), 4.62 (1 H,d, J = 15Hz), 5.32 (1 H,m), 6.27 (2H,m), 7.25 -7.6 (6H,m), 7.64 (2H,d,J = 8Hz), 7.95 (2H,d,J = 8Hz).
-
To a solution of 11.86 g (18.56 mmol) of the benzyl-lactam 29g (Example 1-39) in 250 ml of acetonitrile - water mixture (9 : 1) is added 21 g (38.32 mmol) of ammonium cerium (IV) nitrate at room temperature under stirring. Every 20 minutes, additional amounts of ammonium cerium (IV) nitrate, that is, 4 g (7.3 mmol), 2 g (3.65 mmol), and 2 g (3.65 mmol) added respectively. The mixture is stirred for 1 hour and 25 minutes. Iced water is added to the reaction mixture, which is then neutralized with dilute aqueous solution of sodium hydrogencarbonate. The mixture is extracted with ethyl acetate twice and the extract is washed with saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and evaporated to give 11.20 g of residue, which is purified by column chromatography (120 g of silica gel; eluted with benzene : ethyl acetate = 2 : 1 - benzene : ethyl acetate = 1 : 1) to give 5.40 g of the product 30g - (77.5 % yield), which is recrystallized from acetone to give the crystals, mp. 201 - 203 ° C. - MS:m/z 375 (M+).
- 3424, 3276, 3192, 1722, 1681, 1611, 1268, 1112 cm-1.
- 2.65 (1 H,s), 3.68 (2H,m), 5.45 (1 H,m), 7.35-7.7 (5H,m), 7.66 (2H, d,J = 8Hz), 8.04 (2H,d,J = 8Hz).
-
- MS: m/z 389 (M+)
-
D +27.8±1.3° (C=0.511, CHCl3). 3628, 3432, 1703, 1612, 1280, 1115 cm-1. - 1.79 (3H,s), 3.70 (2H,m), 5.47 (1 H, m), 6.70 (1 H,s), 7.35-7.7 (5H,m), 7.65 (2H,d,J = 8Hz), 8.03 (2H,d,J = 8Hz).
-
- To a solution of 609 mg of the ethynyl-lactam 30g (Example 1-41) in 60 ml of methanol are added 0.6 ml of quinoline and 36 mg of 5 % palladium - barium sulfate. The mixture is stirred at ordinary temperature and atmosphric pressure in an atmosphere of hydrogen for 49 minutes. The reaction mixture is filtrated to remove the insoluble matter and the filtrate is evaporated. The residue is dissolved in ethyl acetate, which is successively washed with 1 N hydrochloric acid, water, dilute aqueous solution of sodium hydrogencarbonate, and saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and evaporated. The residue is purified by column chromatography (25 g of silica gel; ethyl acetate) to give 441 mg of the compound 301 (72.5 % yield). The product is recrystallized from dichloromethane -ethyl ether to give the crystals, mp. 121 - 122 ° C.
- MS: m/z 377 (M+).
-
-43.1±1.7° (C=0.50, CHCl3). - 3432, 1700, 1612, 1279, 1115 cm-1.
3.50-3.92 (2H,m), 5.11 (1 H,d, J =10Hz), 5.23 (1H,d,J=18Hz),5.45 (1 H, m), 5.96 (1H,dd,J=10, 18Hz), 6.59 (1 H,s), 7.35-7.75 (7H,m), 8.06 (2H,d, J = 8Hz). -
- A solution of 349 mg (2.75 mmol) of oxalyl chloride in 8 ml of dichloromethane is cooled to -60 ° C in an atmosphere of nitrogen, 1.63 ml of dichloromethane solution of dimethylsulfoxide (275 mg/ml; 448 mg of dimethylsulfoxide, 5.74 mmol) is added in small portions under stirring, and the mixture is stirred at the same temperature for 10 minutes. To the reaction mixture is added dropwise a solution of 500 mg (1.333 mmol) of the alcohol 30g (Example 1-41) in 50 ml of dry tetrahydrofuran - dry dichloromethane mixture (1 : 1) over 18 minute period. The mixture is stirred at the same temperature for additional 30 minutes and 573 mg (5.67 mmol) of triethylamine is added. The reaction mixture is warmed up to room temperature and acidified with 1 N hydrochloric acid, then water is added, and the mixture is extracted 3 times with dichloromethane. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 530 mg of residue.
- To a solution of 385 mg (1.735 mmol) of dimethyl(2-oxoheptyl)-phosphonate in 15 ml of dry tetrahydrofuran is added 58 mg (1.474 mmol) of 61 % sodium hydride in an atmosphere of nitrogen and the mixture is stirred at room temperature for 20 minutes. A solution of 530 mg of the above residue in 30 ml of tetrahydrofuran is dropwise added to the above mixture over 10 minute period and the mixture is stirred at room temperature for 25 minutes. Iced water is added to the reaction mixture, which is extracted with ethyl acetate twice. The extract is washed with saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and evaporated to give 820 mg of residue, which is applied to column chromatography (10 g of silica gel; toluene : ethyl acetate = 6 : 1) to give 570 mg of an oil. Further, this oil is purified by column chromatography (Lobar column, see B; eluted with toluene : ethyl acetate = 3 : 1) to give 449 mg of the product 31 g (72 % yield), which is recrystallized from acetone - n-hexane to give crystals, mp. 115 - 117 ° C.
- MS:m/z 469 (M+).
- [α]
-88.3±2.5° (C=0.509, CHCl3). - 3438, 3312, 1712, 1633, 1612, 1276, 1269, 1103 cm-1.
- 0.86 (3H), 2.57 (1 H,s), 5.43 (1 H,m), 6.25 (1H,d,J=16Hz), 6.76 (1 H, dd,J=16, 7Hz), 7.06 (1 H,s), 7.3-7.65 (5H,m), 7.63 (2H,d,J=8Hz), 8.01 (2H,d, J=8Hz).
-
-
- To a solution of 1.98 g (9.0 mmol) of 2,6-di-tert-butyl-4-methylphenol in 15 ml of dry toluene cooled in an ice water bath is added 6 ml (6.0 mmol) of 1.0 M toluene solution of aluminium diisobutyl hydride in small portions under stirring in an atmosphere of nitrogen and the mixture is stirred at the same temperature for 30 minutes and then cooled to -25 °C. To the resulting mixture is added dropwise a solution of 378 mg (0.806 mmol) of the enone 31 g (Example 1-44) in 20 ml of dry dichloromethane over 7 minute period and the mixture is stirred at the same temperature for 23 minutes. A saturated aqueous solution of ammonium chloride is added to the reaction mixture and the mixture is stirred at room temperature for 30 minutes. After the resulting precipitate is removed by filtration, the filtrate is extracted with ethyl acetate twice. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 3.20 g of residue, which is applied to column chromatography (20 g of silica gel; eluted with toluene - ethyl acetate) to give 376 mg of foamy material. This is further purified by column chromatography (Lober column, see B; eluted with toluene : ethyl acetate = 1 : 1) to give 212 mg of foamy material 32g (56 % yield) and 148 mg of foamy material 33g (39 % yield). The product 33g is crystallized from ethyl ether to give a sample of mp. 139 -141 ° C.
- 32g
- MS:m/z 471 (M+).
- [α]
-45.8±1.7° (C=0.500, CHCl3). 3608, 3432, 3312, 1711, 1612, 1278, 1111, 1102 cm-1. - 0.83 (3H), 2.53 (1H,s), 4.10 (1H,m), 5.36 (1H,m), 5.66 (2H,m), 7.04 (1H,s), 7.3-7.6 (5H,m), 7.63 (2H,d, J = 8Hz), 8.01 (2H,d,J = 8Hz).
- 33g
- MS:m/z 471 (M+).
-
59.3±2.0° (C=0.500, CHCl3). - 3608, 3432, 3312, 1710, 1612, 1277, 1111, 1102 cm-1.
- 0.80 (3H), 2.53 (1 H,s), 4.07 (1 H,m), 5.35 (1 H,m), 5.65 (2H,m), 7.03 (1 H,s), 7.3-7.6 (5H,m), 7.63 (2H,d, J = 8Hz), 8.01 (2H,d,J = 8Hz).
-
-
- To a solution of 187 mg of the ester 32g (Example I-55) in 4 ml of dry methanol is added 0.2 ml of 1 N methanol solution of sodium methoxide in an atmosphere of nitrogen and the mixture is stirred at room temperature for 2 hours and 10 minutes. Saturated aqueous solution of ammonium chloride is added to the reaction mixture, which is extracted with ethyl acetate twice. The extract is washed with saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and evaporated to give 208 mg of a residue, which is crystallized from ethyl ether to give 102 mg of the compound 34g (88.5 % yield). Recrystallization from ethyl ether gives a sample of mp. 187 - 188 ° C.
- MS : m/z 292 (MH+).
- [α]D + 10.9±1.0 (c=0.503, CHCl3:CH3OH = 1 : 1).
- 3328, 3216, 1683, 1082, 962 cm-1.
- 0.89 (3H), 2.71 (1 H,s), 4.0 (2H,m), 5.55 (2H,m).
-
-
- To a solution of 76 mg (0.261 mmol) of the alcohol 34g in 3 ml of dry N,N-dimethylformamide are added 290 mg (2.38 mmol) of 4-dimethylaminopyridine and 507 mg (1.85 mmol) of tert-buthyldiphenylsilyl chloride in an atmosphere of nitrogen and the mixture is allowed to stand at room temperature for 3 days. Ice water is poured into the reaction mixture, which is then extracted with ethyl acetate twice. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 632 mg of a residue, which is purified by column chromatography (Lobar column, size B; eluted with toluene : ethyl acetate = 6 : 1)to give 183 mg of the compound 10(S)g as a foamy material (91.5 % yield).
- The compound 10(S)g prepared in this example is comfirmed to be identical with the compound prepared in Example 1-24 by MS, [α]D, IR and proton NMR.
-
-
- To a solution of 466 mg of the ethynyl-lactam 10(S)g-b (Example 1-90) in 47 ml of benzene are added 0.47 ml of quinoline and 23 mg of 5 % palladium - barium sulfate and the mixture is stirred in an atmosphere of hydrogen at atmospheric pressure and ordinary temperature for 1 hour. The insoluble material is filtrated off and the filtrate is evaporated. The residue is dissolved in ethyl acetate and the solution is washed with 1 N hydrochloric acid, water, dilute aqueous solution of sodium hydrogencarbonate, and saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate, and evaporated to give 480 mg of residue, which is purified by column chromatography (Lober column, size B; eluted with toluene : ethyl acetate = 6 : 1) to give 409 mg of the compound 10(S)I-b as a foamy material (87.5 % yield).
- MS: m/z 783 (M+), m/z 726 (M+-tBu).
-
D-23.7±1.3° (C=0.510, CHCl3). - 3432, 1694, 1591, 1113 cm-1.
- 0.76 (6H,m), 1.02 (18H,s), 3.98 (2H,m), 4.76-5.73 (5H,m), 6.23 (1 H,s), 7.2-7.7 (20H,m).
-
-
- To a solution of 140 mg (0.182 mmol) of the lactam 10(S)g in 7 ml of dry benzene are added 587 mg (7.42 mmol) of pyridine and 370 mg (0.916 mmol) of Lawesson's Reagent in an atmosphere of nitrogen and the mixture is stirred on an oil bath at 70 ° C for 1 hour and 15 minutes. After cooling, the reaction mixture is directly purified by column chromatography (15 g of silica gel; eluted with benzene) to give 141 mg of the compound 13(S)g as a foamy material (98.5 % yield).
- MS:m/z 784 (MH+), m/z 726 (M+-tBu).
-
D-10.1±1.0° (C=0.514, CHCl3). - 3404, 3308, 1590, 1472, 1112 cm-1.
- 0.80 (3H), 1.01 (18H,s), 2.42 (1 H,s), 4.05 (2H,m), 5.27 (2H,m), 7.2- 7.75 (20H,m), 7.85 (1 H,s).
- Example 1-115 - 136 and 139 - 141
-
-
- To a solution of 300 mg (0.352 mmol) of the phenylthio-lactam 10(S)a (Example 1-7) in 20 ml of dry benzene is added 430 mg (1.064 mmol) of 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4- disulfide (Lawesson's Reagent) and the mixture is stirred on an oil bath at 50 ° C for 3 hours. After cooling, the reaction mixture is applied to column chromatography on silica gel (9 g; benzene) to give 305 mg of a residue, which further is purified by column chromatography (Lober column, size B; eluted with cyclohexane : ethyl acetate = 30 : 1) to give 270 mg of the compound 13(S)a as a foamy material (88 % yield).
- MS : m/z 758 (M+-PhS).
- [α]D - 27.3 ± 0.7 ° (23 ° C, c = 1.005, CHCl3).
- IR : ν max (CHCl3) 3400, 3075, 3005, 1589, 1470, 1112 cm-1.
- NMR : 6 ppm (CDCl3) 0.80 (3H), 1.01 (9H, s), 1.05 (9H, s), 4.07 (2H, m), 5.34 (2H, m), 7.1-7.8 (25H, m), 8.28 (1 H, s).
-
- A solution of 270 mg (0.311 mmol) of the phenylthio-lactam 13(S)a (Example F-1-(1)) in 8 ml dry N,N-dimethylformamide is cooled in an ice water bath and 14 mg (0.344 mmol) of 59 % sodium hydride is added thereto and the mixture is stirred for 1 hour in an atmosphere of nitrogen. Subsequently, 79 mg (0.405 mmol) of ethyl 4-bromobutyrate is added to the reaction mixture and the mixture is stirred at the same temperature for 40 minutes. The reaction mixture is poured into ice water and extracted 3 times with ethyl acetate. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 333 mg of a residue, which is purified by column chromatography (Lober column, size B; eluted with cyclohexane : ethyl acetate = 25 : 1) to give 264 mg of the compound 15(S)a as an oil (86 % yield).
- MS : m/z 936 (M+-OC2H5) , m/z 924 (M+-tBu), m/z 872 (M+-PhS).
- [α]D - 18.1 ± 1.6 ° (23 ° C, C = 0.375, CHCl3).
- IR : ν max (CHCl3) 3075, 3005, 1730, 1590, 1572, 1112 cm-1.
- NMR : δ ppm (CDCl3) 0.81 (3H), 1.00 (9H, s), 1.05 (9H, s), 1.25 (3H, t, J=7Hz), 3.13 (2H, m), 4.03 (2H, m), 4.13 (2H, q, J = 7Hz), 5.33 (2H, m), 7.1-7.8 (25H, m).
-
- To a solution of 303 mg (0.392 mmol) of the methoxy-lactam 10(S)b (Example 1-8) in 15 ml of dry benzene are added 1.27 g (16.07 mmol) of pyridine and 792 mg (1.96 mmol) of Lawesson's Reagent in an atmosphere of nitrogen and the mixture is stirred on an oil bath at 55 ° C for five and half hours. After cooling, the reaction mixture is directly purified by column chromatography (30 g of silica gel; eluted with benzene-benzene : ethyl acetate = 30 : 1 - dichloromethane) to give 213 mg of the compound 13(S)b as a foamy material (69 % yield) and 36 mg of 1-mercapto-2-aza-3-thioxo-6-[(3S)-3-tert-butyldiphenylsilyloxyoct-1-enyl]-7-tert-butyldiphenylsilyloxybicyclo[3.3.0]octane 14 as a foamy material (12 % yield).
- Compound 13(S)b
- MS : m/z 789 (M+), m/z 758 (M+-OCH3), m/z 732 (M+-tBu).
- [α]D 0.0 ° (23 ° C, c = 0.664, CHCl3).
- IR : v max (CHCl3) 3400, 3075, 3005, 1591, 1472, 1111 cm-1.
- NMR : δ ppm (CDCl3) 0.81 (3H), 1.01 (9H, s), 1.03(9H, s), 3.03 (3H, s), 4.01 (2H, m), 5.28 (2H, m), 7.1-7.8 (20H, m), 8.22 (1 H, s).
- Compound 14
- MS : m/z 757 (M+-H2S), m/z 734 (M+-tBu).
- IR : ν max (CHCl3) 3400, 3080, 3005, 1590, 1471, 1111 cm-1.
- NMR : δ ppm (CDCl3) 0.81 (3H), 1.02 (9H, s), 1.04 (9H, s), 4.04 (2H, m), 5.27 (2H, m), 7.1-7.7 (20H, m), 8.32 (1 H, s).
- [α]D - 21.8 ± 0.8 ° (22.5 ° C, c = 0.748, CHCl3).
-
- In the same manner as in Example F-1-(2), 254 mg of the methoxy-thiolactam 13(S)b (Example F-2-(1)) is alkylated to give 262 mg of the compound 15(S)b as an oil (90 % yield) and 19 mg of ethyl 4-[7-tert-butyldiphenylsilyloxy-6-[(3S)-3-tert-butyldiphenylsilyloxy-1-octenyl]-1-methoxy-3-thioxo-2-azabicyclo[3.3.0]-oct-2-yl]butanoate 16(S)b as an oil (6.5 % yield).
- Compound 15(S)b
- MS : m/z 904(MH+), m/z 872(M+-OCH3), m/z 858(M+-OC2H5), m/z 846(M+-tBu).
- [α]D + 21.6 ± 1.1 ° (23°C, c=0.541, CHCl3).
- IR : ν max (CHCl3) 3075, 3005, 1729, 1590, 1582, 1111 cm-1.
- NMR : δ ppm (CDCl3) 0.81 (3H), 1.00 (9H, s), 1.03 (9H, s), 1.23 (3H, t, J = 7Hz), 2.99 (3H, s), 3.07 (2H, m), 3.95 (2H, m), 4.11 (2H, q, J = 7Hz), 5.28 (2H, m), 7.1-7.8 (20H, m).
- Compound 16b
- MS : m/z 904(MH+), m/z 872(M+-OCH3), m/z 858(M+-OC2H5), m/z 846(M+-tBu).
- [α]D - 6.1 ± 2.3 ° (23 ° C, C = 0.147, CHCl3).
- IR : ν max (CHCl3) 3080, 1730, 1592, 1472, 1112 cm-1.
- NMR : δ ppm (CDCl3) 0.79 (3H), 1.00 (9H, s), 1.03 (9H, s), 1.24 (3H, t, J=7Hz), 2.84 (3H, m), 3.45 (2H , m), 3.98 (2H, m), 4.15(2H, q, J=7Hz), 5.27 (2H, m), 7.1-7.7 (20H, m).
-
-
- In an atmosphere of nitrogen, 1.1 ml (1.1 mmol) of 1 M tetrahydrofuran solution of tetra-n-butylammonium fluoride is added to a solution of 264 mg (0.269 mmol) of the silyl ether 15(S)a (Example F-1-(2)) in 8 ml of dry tetrahydrofuran and the mixture is stirred at room temperature for 21 hours. The reaction mixture is poured into a saturated aqueous solution of sodium chloride and extracted 3 times with ethyl acetate, and the extract is washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and evaporated to give 270 mg of a residue, which is purified by thin layer chromatography (Merck; precoated plate; size 20 x 20, thickness 0.5 mm; 13 plates; developed with benzene : ethyl acetate = 1 : 4) to give 118 mg of the compound 17(S)a as an oil (87 % yield)
- MS : m/z 506 (MH+), m/z 460 (M+-OC2Hs), m/s 396 (M+-SPh).
- [α]D - 24.7 ± 0.6 ° (24 ° C, c = 1.016, CHCl3).
- IR : ν max (CHCl3) 3605, 3405, 1728, 1570, 1074, 971 cm-1.
- NMR : 6 ppm (CDCl3) 0.85 (3H), 1.25 (3H, t, J=7Hz), 3.13 (2H, t, J=7Hz), 3.98 (2H, m), 4.13 (2H, q, J = 7Hz), 5.45 (2H, m), 7.1-7.6 (5H, m).
- Removal of silyl groups, of which results are shown in Table 14, is carried out in the same manner as in
-
-
- In an atmosphere of nitrogen, 0.3 ml (0.3 mmol) of 1 N methanol solution of sodium methoxide is added to a solution of 150 mg (0.356 mmol) of the ethyl ester 17(S)g (Fxample F-12) in 3 ml of dry methanol and the mixture is stirred at room temperature for 1 hour and 40 minutes. The reaction mixture is poured into a saturated aqueous solution of ammonium chloride and then methanol is evaporated. The residue is poured into water and extracted 3 times with ethyl acetate. The extract is washed with water, dried over anhydrous magnesium sulfate and evaporated to give 150 mg of a residue. The residue is purified by column chromatography (Lobar column, size A (2 columns); eluted with benzene : acetone = 4 : 1) to give 137 mg of the compound 18(S)g as an oil (94.5 % yield).
- MS : m/z 407 (M+), m/z 376 (M+-OCH3).
- [α]D + 47.8 ± 1.7 (23.5 ° C, C = 0.513, CHCl3).
- IR : v max (CHCl3) 3604, 3424, 3312, 1733, 1579, 1083, 1052, 971 cm-1.
- NMR : δ ppm (CDCl3) 0.87 (3H), 2.46 (1 H, s), 3.13 (2H, m), 3.67 (3H, s), 3.75-4.2 (2H, m), 5.52 (2H, m).
-
- In an atmosphere of nitrogen, 0.70 ml (0.070 mmol) of 0.1 N aqueous solution of sodium hydroxide and 0.3 ml of water are added to a solution of 30.0 mg (0.0719 mmol) of the ethyl ester 17(S)g (Example F-12) and the mixture is allowed to stand at room temperature for 2 days. The reaction mixture is evaporated under reduced pressure and the residue is washed well with diethyl ether. Insoluble material is dissolved in methanol and evaporated again, and the residue is washed well with diethyl ether. This operation is repeated again, and the residue is dried to give 25 mg of the compound 19(S)g as a hygroscopic foamy material.
- IR : v max (KBr) 3380, 3290, 1575, 1408, 1086 cm-1.
- NMR : 6 ppm (D20-TMS external standard) 1.35 (3H), 4.53 (2H, m), 6.03 (2H, m).
-
- In ethyl acetate is suspended the sodium salt of carboxylic acid 19(S)g (Fxample F-16-(1)) prepared from 29.3 mg (0.0695 mmol) of the ethyl ester 17(S)g (Example F-12) and then a buffer of about pH 4.5 [which is prepared by mixing an aqueous solution of disodium citrate (prepared from 21 g of citric acid (C6H8O7· H20) and 200 ml of aqueous solution of sodium hydroxide) and 1/10 N hydrochloric acid in the ratio 5.65 : 4.35] and an aqueous solution of sodium chloride are added to the suspension. After the mixture is shaken, the ethyl acetate layer is separated. The aqueous layer is extracted with ethyl acetate again. The combined organic layer is washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and evaporated to give 24 mg of the compound 20(S)g as an oil.
- IR : v max (CHCl3) 3400 (br.), 3300, 1708, 1578, 1080 cm-1.
- NMR : 6 ppm (CDCl3 + D20) 0.87 (3H), 2.50 (1 H, s), 4.01 (2H, m), 5.52 (2H, m).
-
- The 4-trimethylsilyl-1,3-butadiynyl-lactam 10(S)j (454 mg; Example 1-22) is allowed to react in the same manner as in Example F-2-(1) to give 445 mg of the compound 13(S)j as a foamy material (96 % yield). MS: m/z 822(M+-tBu).
- [α]D - 34.9±1.5 ° (23.5 ° C, c = 0.504, CHCl3).
- IR: ν max(CHCl3) 3400, 3072, 2200, 2104, 1590, 1472, 1112, 843 cm-1.
- NMR: δ ppm(CDCl3) 0.16(9H, s), 0.81(3H), 1.00(9H, s), 1.02(9H, s), 4.03(2H, m), 5.25(2H, m), 7.2-7.75(20H, m), 7.96(1 H, s).
-
- The alkylation of 402 mg of the 4-trimethylsilyl-1,3-butadiynyl-thiolactam 13(S)j (Example F-17-(1)) is carried out in the same manner as in Example F-1-(2) to afford 403 mg of the compound 15(S)k as an oil (95.5 % yield).
- MS: m/z 864(M+-tBu).
- [α]D- 14.1±1.1 ° (23°C, c=0.514, CHCl3).
- IR: ν max(CHCl3) 3312, 3072, 2228, 1730, 1590, 1577, 1112 cm-1.
- NMR: δ ppm(CDCl3) 0.82(3H), 1.00(9H, s), 1.03 (9H, s), 1.25(3H, t, J=7Hz), 2.13(1H, s), 3.13 (2H, t, J = 7Hz), 3.75-4.15(2H, m), 4.14(2H, q J=7Hz), 5.37(2H, m), 7.15-7.75(20H, m).
-
- Removal of silyl groups carried out in the same manner as in Example F-8 using 346 mg the silyl ether 15(S)k (Example F-17-(2)) affords 136 mg of the compound 17(S)k as an oil (81.5 % yield)
- MS: m/z 445(M+), m/z 400(M+-OC2H5).
- [α]D - 19.6±1.2 ° (23 ° C, c = 0.509, CHCl3).
- IR: ν max(CHCl3) 3604, 3412, 3312, 2228, 1727, 1578, 1085, 971 cm-1.
- NMR: δ ppm(CDCl3) 0.87(3H), 1.24(3H, t, J=7Hz), 2.18(1 H, s), 3.10 (2H, m), 3.75-4.15(2H, m), 4.11(2H, q, J = 7Hz), 5.49(2H, m).
-
- In an atmosphere of nitrogen, a solution of 590 mg (0.752 mmol) of the cyano-thiolactam 13(S)m - (Example 1-26) in 15 ml of dry N,N-dimethylformamide is cooled in an ice water bath, then 37 mg (0.91 mmol) of 59 % sodium hydride is added thereto, and the mixture is stirred for 2 hours and 50 minutes. Subsequently, 191 mg (0.978 mmol) of 4-bromobutyric acid ethyl ester is added and the mixture is stirred at the same temperature for 40 minutes. The reaction mixture is poured into ice water and extracted with ethyl acetate twice. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 737 mg of residue, which is purified by column chromatography (Lobar column, size B, 2 columns; eluted with benzene : ethyl acetate = 100 : 1) to give 640 mg of the compound 15(S)m as an oil (94.5 % yield).
- MS:m/z 899 (MH+), m/z 853 (M+-OCH2CH3), m/z 841 (M+-tBu).
-
+ 10.2±1.0 ° (C = 0.506, CHCl3). - 2236, 1730, 1591, 1575, 1113 cm-1.
- 0.81 (3H), 1.00 (9H,s), 1.02 (9H,s), 1.24 (3H,t,J = 7Hz), 3.10 (2H,m), 3.75-4.15 (2H,m), 4.12 (2H,q, J = 7Hz), 5.20 (2H,m), 7.15-7.75 (20H,m).
-
- In the same manner as in Example F-19, 383 mg of the ethenyl-thiolactam 13(S)I (Example 1-27) is alkylated to give 402 mg of the compound 15(S)I as an oil (91.5 % yield).
- MS:m/z 899 (M+), m/z 854 (M+-OCH2CH3), m/z 842 (M+-tBu).
-
+5.0±0.9° (c=0.504, CHCl3). - 1729, 1638, 1588, 1112 cm-1.
- 0.81 (3H), 1.00 (9H,s), 1.04 (9H,s), 1.24 (3H,t,J = 7Hz), 3.12 (2H,m), 3.79 (1H,m), 3.95-4.2 (1H,m), 4.11 (2H,q,J = 7Hz), 4.6-4.85 (2H,m), 5.30 (2H,m), 5.46-5.8 (1 H,m), 7.2-7.75 (20H,m).
-
- To a solution of 535 mg (0.596 mmol) of the silyl ether 15(S)m (Example F-19) in 15 ml of dry tetrahydrofuran is added 3.6 ml (3.6 mmol) of 1 M tetrahydrofuran solution of tetra-n-butylammonium fluoride in an atmosphere of nitrogen and the mixture is stirred at room temperature for 5 hours. A saturated aqueous solution of ammonium chloride is added to the reaction mixture, which is then extracted with ethyl acetate twice. The extract is washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and evaporated to give 593 mg of residue, which is purified by column chromatography (30 g of alumina; eluted with benzene : ethyl acetate = 1 : 1 - ethyl acetate : methanol = 1 : 1) to give 230 mg of an oily material. Further purification by column chromatography (Lober column, size B; eluted with benzene : acetone = 3 : 1) affords 209 mg of the compound 17(S)m as an oil (83 % yield).
- MS:m/z 422 (M+), m/z 377 (M+-OCH2CH3).
-
+65.4±2.1 ° (C=0.510, CHCl3). - 3608, 3420, 2240, 1731 , 1575, 1089, 1075, 972 cm-1.
- 0.88 (3H), 1.26 (3H,t,J = 7Hz), 3.13 (2H,m), 4.0 (2H,m), 4.14 (2H,q, J = 7Hz), 5.52 (2H, m).
-
- Removal of silyl groups carried out in the same manner as in Example F-21 affords 145 mg of the oily compound 17(S)I (85.5 % yield) from 360 mg of the silyl ether 15(S)I (Example F-20).
- MS:m/z 423 (M+), m/z 378 (M+-OCH2CH3).
-
+48.5±1.7° (c=0.513, CHCl3). - 3604, 3424, 1729, 1639, 1585, 1079, 971 cm-1.
- 0.88 (3H), 1.24 (3H,t ,J=7Hz), 3.12 (2H,t, J=7Hz), 3.7-4.2 (2H,m), 4.11 (2H,q, J=7Hz), 4.8-5.1 (2H, m), 5.50 (2H, m), 5.8-6.1 (1 H, m).
-
- A solution of 126 mg (0.161 mmol) of the thiolactam 13(S)g (Example 1-114) in 5 ml of dry N,N-dimethylformamide is cooled in an ice water bath, then 8 mg (0.203 mmol) of 61 % sodium hydride is added in an atmosphere of nitrogen thereto, and the mixture is stirred for 2 hours. Then 44 mg (0.224 mmol) of ethyl 4-bromobutyrate is added and the mixture is stirred at the same temperature for 35 minutes. Ice water is added to the reaction mixture, which is then extracted with ethyl acetate twice. The extract is washed with water, dried over anhydrous magnesium sulfate, and evaporated to give 167 mg of residue, which is purified by column chromatography (Lober column, size B; eluted with benzene : ethyl acetate = 80 : 1) to give 134 mg of the compound 15(S)g as an oil (93 % yield).
- MS:m/z 898 (MH+), m/Z 852 (M+-OCH2CH3), m/Z 840 (M+-tBu).
- [a]
+6.1±0.8° (C=0.589, CHCl3). - 3312, 1730, 1589, 1580, 1112 cm-1.
- 0.81 (3H), 1.00 (9H,s), 1.03 (9H,s), 1.23 (3H,t,J=7Hz), 2.29 (1H,s), 3.11 (2H,t,J=7Hz), 3.97 (2H,m), 4.11 (2H,q,J=7Hz), 5.28 (2H,m), 7.15-7.75 (20H,m).
-
- Preparation of ethyl 4-[1-ethynyl-7-hydroxy-6-[(3S)-3-hydroxy-1-octenyl]-2-azabicyclo[3.3.0]oct-2-en-3-yl]-thiobutanoate 17(S)g
-
- To a solution of 254 mg (0.283 mmol) of the silyl ether 15(S)g (Example 1-23) in 8 ml of dry tetrahydrofuran is added 1.7 ml (1.7 mmol) of 1 M tetrahydrofuran solution of tetra-n-butyl ammonium fluoride in an atmosphere of nitrogen and the mixture is allowed to stand at room temperature overnight. Saturated aqueous solution of ammonium chloride is added to the reaction mixture, which is then extracted with ethyl acetate twice. The extract is washed with saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, and evaporated to give 297 mg of a residue, which is applied to column chromatography (15 g of alumina; eluted with benzene : ethyl acetate = 1 : 1 - ethyl acetate : methanol = 1 : 1) to give 117 mg of an oily product. Futher purification by column chromatography (Lober column, size A, 2 columns; eluted with benzene : ethyl acetate = 2 : 3 - ethyl acetate) affords 99 mg of the compound 17(S)g as an oil (83 % yield).
- MS:m/z 421 (M+), m/z 376 (M+-OCH2CH3).
- [a]82 +45.4±1.2° (C=0.715, CHCl3).
- 3604, 3408, 3312, 1729, 1579, 1084, 1049, 971 cm-1.
- 0.88 (3H), 1.25 (3H,t,J = 7Hz), 2.45 (1 H,s), 3.13 (2H,m), 3.8-4.25 (2H,m), 4.14 (2H,q,J = 7Hz), 5.53 (2H,m).
-
-
- To a solution of 57 mg (0.131 mmol) of the ethyl ester 17(S)g-e (Example F-53) in 2 ml of methanol are added 1.27 ml (0.127 mmol) of 0.1 N aqueous solution of sodium hydroxide and 0.6 ml of water, and the mixture is allowed to stand for 2 days. The reaction mixture is evaporated under reduced pressure and the residue is washed well with diethyl ether. The insoluble material is dissolved in methanol and the mixture is evaporated again. The residue is washed with diethyl ether. This operation is repeated and the residue is dried to give 47 mg of the compound 19(S)g-e as a foamy material.
- 3400, 3300, 1573, 1407, 1088 cm-1.
- (External Standard) 4.1-4.7 (2H,m), 6.03 (2H, m).
-
-
- 3400, 1573, 1405, 1085 cm-1.
- The compounds of the present invention are chemically stable analogues of prostacyclin (PG12) which act as agonists to PG12 receptors. The compounds of the present invention strongly inhibit platelet agglutination as does PG12 so that they are expected to be useful as antithrombotic drugs for the improvement of peripheral circulatory insufficiency, extracorporeal circulation such as artificial dialysis or ischemic disease, and the like. Besides, having an antiulcer activity, the compounds of the present invention may be used as antiulcer drugs.
- The inhibitory activity of representative compounds of the present invention against platelet agglutination is shown in the following in vitro test.
- Mature male rabbits (NIBS-JW, RABITON Institute Inc., weighing 2.2 - 2.7 kg) were used. Under sodium pentobarbital anesthesia (Somnopentyl, Pitman Movre, about 25 mg/Kg, i. v. ), blood was withdrawn from the carotid artery by cannulation into centrifuge tubes containing 1/10 vol of a 3.8 % sodium citrate solution. (The total volume in each tube was adjusted to 8 ml.) The blood in a tube was gentyl mixed by turning and centrifuged for 10 minutes at 210 g at 20 ° C to give platelet rich plasma (PRP). The remaining blood was further centrifuged at 3,000 rpm (about 1,900 g) for 10 minutes at 20 ° C to give platelet-poor plasma (PPP).
- PRP was diluted with PPP to prepare a blood sample whose platelet number was 50 - 55 x 104/µl. The sample was then subjected to a platelet agglutination test.
- The platelet agglutination was examined by the method of Born [Born, G.V.R., Nature, 194, 927-929 (1962)], using a Type AUTO RAM-61 aggregometer, (Rika Denki Co., Ltd., Tokyo). A volume of 400 µl of PRP, whose platelet number was adjusted to 50 - 55x104/µl, was placed in a measuring cuvette and set in the aggregometer. PRP was warmed at 37 ° C for 1 minute with stirring at 1,200 rpm, and then a solution of the test compound [dimethylsulfoxide solution (2µl) of the compound + saline (48ul); in case of prostaglandin 12 (PG12) and prostagladin E1 (PG E1), a solution of each compound (50µl) in Tris buffer] was added thereto. Exactly 2 minutes later, 50 µl of ADP (Pharracia, USA; final concentration: 30µM) or collagen (Hormon Chemie, Munich,FRG; final concentration: 20µg/ml) or arachidonic acid (sodium salt, Sigma, final concentration (500 µM)) was added as the platelet agglutinating agent, and the change in light transmission caused by platelet agglutination was recorded.
- The light transmissions of PRP and PPP were taken as 0 % and 100 % agglutination, respectively, and the maximum light transmission after addition of an agglutinating agent was made to the maximum agglutination. The inhibition rate of the platelet agglutination was expressed as the percentage of the maximum agglutination by a test compound to that by a control (Vehicle added group).
- The results of the test are shown in Table 19.
-
- The compounds of the present invention strongly inhibit the platelet agglutination induced by arachidonic acid, collagen and ADP. The compounds of the present invention act as agonist to PG12 receptors and strongly inhibit the platelet agglutination or aggregation. Therefore, clinical application of the compounds having such pharmacological action can be expected, that is, the compounds can be used for extracorporeal circulation, e.g., artificial dialysis, pump-oxygenator; prevention of thrombosis caused after operation; or treatment or prevention of peripheral circulatory insufficiency or ischemic disease, e.g., vibration disease, Buerger disease, arteriosclerosis obliteration, plumonary embolism, plumonary hypertension, angina pectoris, acute myocardial infarction, cerebral thrombosis, cerebral embolism or cerebral infarction.
- For oral administration, the compounds are formulated into dosage forms such as tablets, capsules, pills, granules, fine subtilaes, solutions, or emulsions and for parenteral administration, such as suppositories or injections, e.g., intravenous, intramusucular or subcutaneous injection. When the pharmaceutical preparations of the compounds are prepared, adequated carriers and fillers are selected from conventionally used carriers and fillers.
- The compounds of the present invention may be orally administered to the adult in a daily dose of about 0.1 mg - 500mg.
Claims (31)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT87104669T ATE97404T1 (en) | 1986-03-31 | 1987-03-30 | PROSTACYCLINE (PGI2) ANALOGUES. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7493286 | 1986-03-31 | ||
| JP74932/86 | 1986-03-31 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP0240890A2 EP0240890A2 (en) | 1987-10-14 |
| EP0240890A3 EP0240890A3 (en) | 1989-05-10 |
| EP0240890B1 true EP0240890B1 (en) | 1993-11-18 |
Family
ID=13561619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP87104669A Expired - Lifetime EP0240890B1 (en) | 1986-03-31 | 1987-03-30 | Prostacyclin (PGI2) analogues |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US4820836A (en) |
| EP (1) | EP0240890B1 (en) |
| JP (1) | JPH07121907B2 (en) |
| AT (1) | ATE97404T1 (en) |
| CA (1) | CA1284642C (en) |
| DE (2) | DE3788149T2 (en) |
| ES (1) | ES2008067T3 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227157B1 (en) * | 2001-07-30 | 2010-09-28 | Chinoin Gyogyszer Es Vegyeszet | Production of beraprost ester by selective oxidation |
| US20070243632A1 (en) * | 2003-07-08 | 2007-10-18 | Coller Barry S | Methods for measuring platelet reactivity of patients that have received drug eluting stents |
| US7790362B2 (en) | 2003-07-08 | 2010-09-07 | Accumetrics, Inc. | Controlled platelet activation to monitor therapy of ADP antagonists |
| US7595169B2 (en) * | 2005-04-27 | 2009-09-29 | Accumetrics, Inc. | Method for determining percent platelet aggregation |
| KR20100017576A (en) * | 2007-05-03 | 2010-02-16 | 아큐메트릭스, 인크. | Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists |
| RU2472791C2 (en) | 2008-08-27 | 2013-01-20 | КалсиМедика Инк. | Intracellular calcium modulating compounds |
| US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3006865A1 (en) * | 1980-02-23 | 1981-09-10 | Hoechst Ag, 6000 Frankfurt | HETERO-IMINO-PROSTACYCLINE |
| US4496742A (en) * | 1981-10-13 | 1985-01-29 | The Upjohn Company | Analogs of 5,6-dihydro PGI2 |
| US4588823A (en) * | 1982-02-16 | 1986-05-13 | The Upjohn Company | 9-substituted carbacyclin analogs |
| US4487960A (en) * | 1982-04-19 | 1984-12-11 | The Upjohn Company | 9-Substituted carbacyclin analogs |
-
1987
- 1987-03-11 CA CA000531708A patent/CA1284642C/en not_active Expired - Fee Related
- 1987-03-13 US US07/025,807 patent/US4820836A/en not_active Expired - Fee Related
- 1987-03-20 JP JP62066817A patent/JPH07121907B2/en not_active Expired - Fee Related
- 1987-03-30 ES ES87104669T patent/ES2008067T3/en not_active Expired - Lifetime
- 1987-03-30 DE DE87104669T patent/DE3788149T2/en not_active Expired - Fee Related
- 1987-03-30 EP EP87104669A patent/EP0240890B1/en not_active Expired - Lifetime
- 1987-03-30 AT AT87104669T patent/ATE97404T1/en not_active IP Right Cessation
- 1987-03-30 DE DE198787104669T patent/DE240890T1/en active Pending
-
1988
- 1988-08-01 US US07/226,844 patent/US4855449A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US4855449A (en) | 1989-08-08 |
| JPH07121907B2 (en) | 1995-12-25 |
| DE3788149T2 (en) | 1994-04-07 |
| EP0240890A3 (en) | 1989-05-10 |
| DE3788149D1 (en) | 1993-12-23 |
| ES2008067A4 (en) | 1989-07-16 |
| US4820836A (en) | 1989-04-11 |
| DE240890T1 (en) | 1988-04-28 |
| CA1284642C (en) | 1991-06-04 |
| ATE97404T1 (en) | 1993-12-15 |
| EP0240890A2 (en) | 1987-10-14 |
| JPS6366168A (en) | 1988-03-24 |
| ES2008067T3 (en) | 1994-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100598660B1 (en) | 5-thia-ω-substituted phenyl-prostaglandin E derivatives, a preparation method thereof and a medicament containing the same as an active ingredient | |
| FR2466446A1 (en) | BICYCLO-ALCANONES, INTERMEDIATES FOR THE PREPARATION OF PGI2 9-DESOXY-9A-METHYLENE ISOSTERS | |
| EP0240890B1 (en) | Prostacyclin (PGI2) analogues | |
| US4169895A (en) | Antisecretory 16,16-dimethyl-17-oxaprostaglandins | |
| EP0051284B1 (en) | Novel thiaprostaglandin e1 derivatives, process for production thereof, and pharmaceuticals containing these compounds | |
| KR900009006B1 (en) | Process for preparation mevalolactone and derivatives | |
| CH624934A5 (en) | ||
| EP0338796B1 (en) | 2-substituted-2-cyclopentenones | |
| JPH0141142B2 (en) | ||
| US4681951A (en) | Bicyclo(3.3.0)octene derivatives | |
| US4100192A (en) | Inter-phenylene-PG amides | |
| US4622422A (en) | Cyclohexanealkanoic acids | |
| JPH037666B2 (en) | ||
| KR920010641B1 (en) | Anti-inflammatory benzoxazolone | |
| US4906663A (en) | 6-fluoroprostaglandins | |
| JP2503073B2 (en) | 2-Substituted-2-cyclopentenones and osteogenic promoters or anticancer agents containing the same | |
| EP0553352B1 (en) | Novel prostaglandin i2 derivatives | |
| US4092349A (en) | 11-Desoxy-15-thiaprostaglandins | |
| US4342868A (en) | 2-Descarboxy-2-(tetrazol-5-yl)-16,16-dimethyl-17-(2-furyl)-ω-trisnorprostaglandin E2 | |
| JP4386581B2 (en) | Process for producing purified prostaglandin derivatives | |
| JP2571250B2 (en) | Prostaglandin compounds | |
| FI60557B (en) | EFFECTIVE EFFECTIVE EFFECTIVE 9-OXO-PROSTANSYRADERIVAT | |
| EP0112633A2 (en) | Novel 5-thiaprostaglandin, process for production thereof, and pharmaceutical use thereof | |
| EP0276124B1 (en) | Prostaglandin derivatives, their preparation and their therapeutic use | |
| KR810000412B1 (en) | Process for the preparation of new prostaglandines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
| ITCL | It: translation for ep claims filed |
Representative=s name: JACOBACCI CASETTA & PERANI S.P.A. |
|
| TCNL | Nl: translation of patent claims filed | ||
| TCAT | At: translation of patent claims filed | ||
| EL | Fr: translation of claims filed | ||
| DET | De: translation of patent claims | ||
| PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
| AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SHIONOGI & CO., LTD. |
|
| 17P | Request for examination filed |
Effective date: 19890517 |
|
| 17Q | First examination report despatched |
Effective date: 19901025 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
| REF | Corresponds to: |
Ref document number: 97404 Country of ref document: AT Date of ref document: 19931215 Kind code of ref document: T |
|
| ITF | It: translation for a ep patent filed | ||
| REF | Corresponds to: |
Ref document number: 3788149 Country of ref document: DE Date of ref document: 19931223 |
|
| ET | Fr: translation filed | ||
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3010439 |
|
| EPTA | Lu: last paid annual fee | ||
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed | ||
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2008067 Country of ref document: ES Kind code of ref document: T3 |
|
| EAL | Se: european patent in force in sweden |
Ref document number: 87104669.4 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19960312 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19960318 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19960321 Year of fee payment: 10 Ref country code: BE Payment date: 19960321 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19960325 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19960328 Year of fee payment: 10 Ref country code: CH Payment date: 19960328 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 19960329 Year of fee payment: 10 Ref country code: ES Payment date: 19960329 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19960501 Year of fee payment: 10 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19960530 Year of fee payment: 10 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970330 Ref country code: GB Effective date: 19970330 Ref country code: AT Effective date: 19970330 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19970331 Ref country code: LI Effective date: 19970331 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19970331 Ref country code: CH Effective date: 19970331 Ref country code: BE Effective date: 19970331 |
|
| BERE | Be: lapsed |
Owner name: SHIONOGI & CO. LTD Effective date: 19970331 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 19970930 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19971001 |
|
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: MM2A Free format text: 3010439 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 19970330 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19971128 |
|
| NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19971001 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19971202 |
|
| EUG | Se: european patent has lapsed |
Ref document number: 87104669.4 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 19990301 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050330 |